Christie M Ballantyne

List of Publications by Year
in descending order

1,028	89,772	385 134	515 267
papers	citations	h-index	g-index

1095	1095	1095	70033
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease. New England Journal of Medicine, 2017, 377, 1119-1131.	13.9	6,227
2	Biological, clinical and population relevance of 95 loci for blood lipids. Nature, 2010, 466, 707-713.	13.7	3,249
3	From Vulnerable Plaque to Vulnerable Patient. Circulation, 2003, 108, 1664-1672.	1.6	2,308
4	Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia. New England Journal of Medicine, 2019, 380, 11-22.	13.9	2,153
5	Effect of Very High-Intensity Statin Therapy on Regression of Coronary Atherosclerosis. JAMA - Journal of the American Medical Association, 2006, 295, 1556.	3.8	1,759
6	Effects of Dalcetrapib in Patients with a Recent Acute Coronary Syndrome. New England Journal of Medicine, 2012, 367, 2089-2099.	13.9	1,754
7	From Vulnerable Plaque to Vulnerable Patient. Circulation, 2003, 108, 1772-1778.	1.6	1,562
8	Triglycerides and Cardiovascular Disease. Circulation, 2011, 123, 2292-2333.	1.6	1,511
9	Efficacy and Safety of Evolocumab in Reducing Lipids and Cardiovascular Events. New England Journal of Medicine, 2015, 372, 1500-1509.	13.9	1,352
10	Circulating Adhesion Molecules VCAM-1, ICAM-1, and E-selectin in Carotid Atherosclerosis and Incident Coronary Heart Disease Cases. Circulation, 1997, 96, 4219-4225.	1.6	1,133
11	Criteria for Evaluation of Novel Markers of Cardiovascular Risk. Circulation, 2009, 119, 2408-2416.	1.6	998
12	The Metabolic Syndrome and 11-Year Risk of Incident Cardiovascular Disease in the Atherosclerosis Risk in Communities Study. Diabetes Care, 2005, 28, 385-390.	4.3	988
13	Effect of interleukin-1Î² inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial. Lancet, The, 2017, 390, 1833-1842.	6.3	948
14	Loss-of-Function Mutations inAPOC3,Triglycerides, and Coronary Disease. New England Journal of Medicine, 2014, 371, 22-31.	13.9	936
15	Low-Grade Systemic Inflammation and the Development of Type 2 Diabetes: The Atherosclerosis Risk in Communities Study. Diabetes, 2003, 52, 1799-1805.	0.3	908
16	Effect of Evolocumab on Progression of Coronary Disease in Statin-Treated Patients. JAMA - Journal of the American Medical Association, 2016, 316, 2373.	3.8	813
17	Carotid Intima-Media Thickness and Presence or Absence of Plaque Improves Prediction of Coronary Heart Disease Risk. Journal of the American College of Cardiology, 2010, 55, 1600-1607.	1.2	794
18	Effect of Two Intensive Statin Regimens on Progression of Coronary Disease. New England Journal of Medicine, 2011, 365, 2078-2087.	13.9	731

#	Article	IF	Citations
19	Cardiac Troponin T Measured by a Highly Sensitive Assay Predicts Coronary Heart Disease, Heart Failure, and Mortality in the Atherosclerosis Risk in Communities Study. Circulation, 2011, 123, 1367-1376.	1.6	655
20	Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial. Lancet, The, 2018, 391, 319-328.	6.3	628
21	Effect of Ezetimibe Coadministered With Atorvastatin in 628 Patients With Primary Hypercholesterolemia. Circulation, 2003, 107, 2409-2415.	1.6	627
22	A 52-Week Placebo-Controlled Trial of Evolocumab in Hyperlipidemia. New England Journal of Medicine, 2014, 370, 1809-1819.	13.9	607
23	Intraluminal crawling of neutrophils to emigration sites: a molecularly distinct process from adhesion in the recruitment cascade. Journal of Experimental Medicine, 2006, 203, 2569-2575.	4.2	599
24	Lipoprotein-Associated Phospholipase A2, High-Sensitivity C-Reactive Protein, and Risk for Incident Coronary Heart Disease in Middle-Aged Men and Women in the Atherosclerosis Risk in Communities (ARIC) Study. Circulation, 2004, 109, 837-842.	1.6	598
25	T-Cell Accumulation and Regulated on Activation, Normal T Cell Expressed and Secreted Upregulation in Adipose Tissue in Obesity. Circulation, 2007, 115, 1029-1038.	1.6	577
26	Platelet Glycoprotein Ibî± Is a Counterreceptor for the Leukocyte Integrin Mac-1 (Cd11b/Cd18). Journal of Experimental Medicine, 2000, 192, 193-204.	4.2	558
27	Lipoprotein-associated phospholipase A2 and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies. Lancet, The, 2010, 375, 1536-1544.	6.3	544
28	Effect of High-Dose Omega-3 Fatty Acids vs Corn Oil on Major Adverse Cardiovascular Events in Patients at High Cardiovascular Risk. JAMA - Journal of the American Medical Association, 2020, 324, 2268.	3.8	540
29	Safety and Efficacy of Bempedoic Acid to Reduce LDL Cholesterol. New England Journal of Medicine, 2019, 380, 1022-1032.	13.9	529
30	Familial Hypercholesterolemia: Screening, diagnosis and management of pediatric and adult patients. Journal of Clinical Lipidology, 2011, 5, 133-140.	0.6	483
31	Safety and efficacy of dalcetrapib on atherosclerotic disease using novel non-invasive multimodality imaging (dal-PLAQUE): a randomised clinical trial. Lancet, The, 2011, 378, 1547-1559.	6.3	479
32	Exome-wide association study of plasma lipids in >300,000 individuals. Nature Genetics, 2017, 49, 1758-1766.	9.4	470
33	Meta-Analysis of Genome-Wide Association Studies in >80 000 Subjects Identifies Multiple Loci for C-Reactive Protein Levels. Circulation, 2011, 123, 731-738.	1.6	461
34	Metabolic Inflammation and Insulin Resistance in Obesity. Circulation Research, 2020, 126, 1549-1564.	2.0	438
35	Skeletal muscle inflammation and insulin resistance in obesity. Journal of Clinical Investigation, 2017, 127, 43-54.	3.9	436
36	Efficacy and Tolerability of Evolocumab vs Ezetimibe in Patients With Muscle-Related Statin Intolerance. JAMA - Journal of the American Medical Association, 2016, 315, 1580.	3.8	420

#	Article	IF	Citations
37	Novel Loci for Adiponectin Levels and Their Influence on Type 2 Diabetes and Metabolic Traits: A Multi-Ethnic Meta-Analysis of 45,891 Individuals. PLoS Genetics, 2012, 8, e1002607.	1.5	419
38	Familial Hypercholesterolemia: Screening, diagnosis and management of pediatric and adult patients. Journal of Clinical Lipidology, 2011, 5, S1-S8.	0.6	406
39	National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines: Emerging Biomarkers for Primary Prevention of Cardiovascular Disease. Clinical Chemistry, 2009, 55, 378-384.	1.5	405
40	Risk for Myopathy With Statin Therapy in High-Risk Patients. Archives of Internal Medicine, 2003, 163, 553.	4.3	404
41	Identifying Individuals at High Risk for Diabetes: The Atherosclerosis Risk in Communities study. Diabetes Care, 2005, 28, 2013-2018.	4.3	401
42	Influence of Low High-Density Lipoprotein Cholesterol and Elevated Triglyceride on Coronary Heart Disease Events and Response to Simvastatin Therapy in 4S. Circulation, 2001, 104, 3046-3051.	1.6	390
43	Clinical Genetic Testing for FamilialÂHypercholesterolemia. Journal of the American College of Cardiology, 2018, 72, 662-680.	1.2	387
44	Inactivating Mutations in NPC1L1 and Protection from Coronary Heart Disease. New England Journal of Medicine, 2014, 371, 2072-2082.	13.9	386
45	Small Dense Low-Density Lipoprotein-Cholesterol Concentrations Predict Risk for Coronary Heart Disease. Arteriosclerosis, Thrombosis, and Vascular Biology, 2014, 34, 1069-1077.	1.1	386
46	Modulation of the interleukin-6 signalling pathway and incidence rates of atherosclerotic events and all-cause mortality: analyses from the Canakinumab Anti-Inflammatory Thrombosis Outcomes Study (CANTOS). European Heart Journal, 2018, 39, 3499-3507.	1.0	375
47	Efficacy and tolerability of adding prescription Omega-3 fatty acids 4 g/d to Simvastatin 40 mg/d in hypertriglyceridemic patients: An 8-week, randomized, double-blind, placebo-controlled study. Clinical Therapeutics, 2007, 29, 1354-1367.	1.1	371
48	2016 ACC Expert Consensus Decision Pathway on the Role of Non-Statin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk. Journal of the American College of Cardiology, 2016, 68, 92-125.	1.2	371
49	Lipid-Related Markers and Cardiovascular Disease Prediction. JAMA - Journal of the American Medical Association, 2012, 307, 2499-506.	3.8	352
50	A novel pathway of HMGB1-mediated inflammatory cell recruitment that requires Mac-1-integrin. EMBO Journal, 2007, 26, 1129-1139.	3.5	344
51	Comparison of the Instructional Efficacy of Internet-Based CME With Live Interactive CME Workshops. JAMA - Journal of the American Medical Association, 2005, 294, 1043.	3.8	335
52	Genome Analyses of >200,000 Individuals Identify 58 Loci for Chronic Inflammation and Highlight Pathways that Link Inflammation and Complex Disorders. American Journal of Human Genetics, 2018, 103, 691-706.	2.6	326
53	An Assessment of Incremental Coronary Risk Prediction Using C-Reactive Protein and Other Novel Risk Markers. Archives of Internal Medicine, 2006, 166, 1368.	4.3	323
54	Effects of Fluvastatin on Coronary Atherosclerosis in Patients With Mild to Moderate Cholesterol Elevations (Lipoprotein and Coronary Atherosclerosis Study [LCAS]). American Journal of Cardiology, 1997, 80, 278-286.	0.7	317

#	Article	IF	Citations
55	Adiponectin and the Development of Type 2 Diabetes: The Atherosclerosis Risk in Communities Study. Diabetes, 2004, 53, 2473-2478.	0.3	315
56	2017 Focused Update of the 2016ÂACCÂExpert Consensus Decision Pathway on the Role of Non-Statin Therapies for LDL-Cholesterol Lowering inÂthe Management of Atherosclerotic Cardiovascular Disease Risk. Journal of the American College of Cardiology, 2017, 70, 1785-1822.	1.2	313
57	Eicosapentaenoic Acid Ethyl Ester (AMR101) Therapy in Patients With Very High Triglyceride Levels (from the Multi-center, plAcebo-controlled, Randomized, double-blINd, 12-week study with an) Tj ETQq1 1 0.784314 rgBT /Overlock 10	4.7	307
58	Low-density lipoproteins and risk for coronary artery disease. American Journal of Cardiology, 1998, 82, 3-12.	0.7	303
59	Age- and Sex-Dependent Upper Reference Limits for the High-Sensitivity Cardiac Troponin T Assay. Journal of the American College of Cardiology, 2014, 63, 1441-1448.	1.2	303
60	Efficacy and safety of bempedoic acid added to ezetimibe in statin-intolerant patients with hypercholesterolemia: A randomized, placebo-controlled study. Atherosclerosis, 2018, 277, 195-203.	0.4	298
61	Efficacy and Safety of Eicosapentaenoic Acid Ethyl Ester (AMR101) Therapy in Statin-Treated Patients With Persistent High Triglycerides (from the ANCHOR Study). American Journal of Cardiology, 2012, 110, 984-992.	0.7	295
62	Familial Hypercholesterolemias: Prevalence, genetics, diagnosis and screening recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. Journal of Clinical Lipidology, 2011, 5, S9-S17.	0.6	292
63	Plasma Lipid Profile and Incident Ischemic Stroke. Stroke, 2003, 34, 623-631.	1.0	279
64	Del-1, an Endogenous Leukocyte-Endothelial Adhesion Inhibitor, Limits Inflammatory Cell Recruitment. Science, 2008, 322, 1101-1104.	6.0	271
65	The ACC/AHA 2013 guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular disease risk in adults: the good the bad and the uncertain: a comparison with ESC/EAS guidelines for the management of dyslipidaemias 2011. European Heart Journal, 2014, 35, 960-968.	1.0	270
66	Diastolic Blood Pressure, Subclinical Myocardial Damage, and Cardiac Events. Journal of the American College of Cardiology, 2016, 68, 1713-1722.	1.2	269
67	IL-10 Is Induced in the Reperfused Myocardium and May Modulate the Reaction to Injury. Journal of Immunology, 2000, 165, 2798-2808.	0.4	261
68	Results of the National Cholesterol Education (NCEP) Program Evaluation Project Utilizing Novel E-Technology (NEPTUNE) II Survey and Implications for Treatment Under the Recent NCEP Writing Group Recommendations. American Journal of Cardiology, 2005, 96, 556-563.	0.7	257
69	Levels of Soluble Cell Adhesion Molecules in Patients With Dyslipidemia. Circulation, 1996, 93, 1334-1338.	1.6	256
70	Adiponectin, Inflammation, and the Expression of the Metabolic Syndrome in Obese Individuals: The Impact of Rapid Weight Loss through Caloric Restriction. Journal of Clinical Endocrinology and Metabolism, 2004, 89, 2697-2703.	1.8	255
71	Effects of sirolimus on plasma lipids, lipoprotein levels, and fatty acid metabolism in renal transplant patients. Journal of Lipid Research, 2002, 43, 1170-1180.	2.0	253
72	Development and Validation of a Patient Self-assessment Score for Diabetes Risk. Annals of Internal Medicine, 2009, 151, 775.	2.0	253

#	Article	IF	Citations
73	Lipoprotein-Associated Phospholipase A2, High-Sensitivity C-Reactive Protein, and Risk for Incident Ischemic Stroke in Middle-aged Men and Women in the Atherosclerosis Risk in Communities (ARIC) Study. Archives of Internal Medicine, 2005, 165, 2479.	4.3	244
74	Associations Between Lipoprotein(a) Levels and Cardiovascular Outcomes in Black and White Subjects. Circulation, 2012, 125, 241-249.	1.6	239
75	Dose-comparison study of the combination of ezetimibe and simvastatin (Vytorin) versus atorvastatin in patients with hypercholesterolemia: The Vytorin Versus Atorvastatin (VYVA) Study. American Heart Journal, 2005, 149, 464-473.	1.2	237
76	Clinical utility of inflammatory markers and advanced lipoprotein testing: Advice from an expert panel of lipid specialists. Journal of Clinical Lipidology, 2011, 5, 338-367.	0.6	235
77	Large-scale genomic studies reveal central role of ABO in sP-selectin and sICAM-1 levels. Human Molecular Genetics, 2010, 19, 1863-1872.	1.4	233
78	Large-Scale Gene-Centric Meta-analysis across 32 Studies Identifies Multiple Lipid Loci. American Journal of Human Genetics, 2012, 91, 823-838.	2.6	227
79	Accuracy of the Atherosclerotic Cardiovascular Risk Equation inÂaÂLargeÂContemporary, MultiethnicÂPopulation. Journal of the American College of Cardiology, 2016, 67, 2118-2130.	1.2	227
80	Bempedoic acid plus ezetimibe fixed-dose combination in patients with hypercholesterolemia and high CVD risk treated with maximally tolerated statin therapy. European Journal of Preventive Cardiology, 2020, 27, 593-603.	0.8	224
81	Endothelial lipase is a major genetic determinant for high-density lipoprotein concentration, structure, and metabolism. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 2748-2753.	3.3	218
82	Pharmacogenetic meta-analysis of genome-wide association studies of LDL cholesterol response to statins. Nature Communications, 2014, 5, 5068.	5.8	216
83	Effects of the high-density lipoprotein mimetic agent CER-001 on coronary atherosclerosis in patients with acute coronary syndromes: a randomized trial. European Heart Journal, 2014, 35, 3277-3286.	1.0	214
84	Decreased neointimal formation in Mac-1â€"/â€" mice reveals a role for inflammation in vascular repair after angioplasty. Journal of Clinical Investigation, 2000, 105, 293-300.	3.9	213
85	Effects of Icosapent Ethyl on TotalÂIschemic Events. Journal of the American College of Cardiology, 2019, 73, 2791-2802.	1.2	208
86	The Effect of Darapladib on Plasma Lipoprotein-Associated Phospholipase A2 Activity and Cardiovascular Biomarkers in Patients With Stable Coronary Heart Disease or Coronary Heart Disease Risk Equivalent. Journal of the American College of Cardiology, 2008, 51, 1632-1641.	1.2	207
87	Lipid lowering with PCSK9 inhibitors. Nature Reviews Cardiology, 2014, 11, 563-575.	6.1	207
88	Effects of Cyclosporine Therapy on Plasma Lipoprotein Levels. JAMA - Journal of the American Medical Association, 1989, 262, 53.	3.8	205
89	Functional Role of CD11c ⁺ Monocytes in Atherogenesis Associated With Hypercholesterolemia. Circulation, 2009, 119, 2708-2717.	1.6	200
90	Soluble Cell Adhesion Molecules in Hypertriglyceridemia and Potential Significance on Monocyte Adhesion. Arteriosclerosis, Thrombosis, and Vascular Biology, 1998, 18, 723-731.	1.1	196

#	Article	IF	Citations
91	Whole-Exome Sequencing Identifies Rare and Low-Frequency Coding Variants Associated with LDL Cholesterol. American Journal of Human Genetics, 2014, 94, 233-245.	2.6	193
92	The ARIC (Atherosclerosis Risk In Communities) Study. Journal of the American College of Cardiology, 2021, 77, 2939-2959.	1.2	192
93	Insensitivity of noninvasive tests to detect coronary artery vasculopathy after heart transplant. American Journal of Cardiology, 1991, 67, 243-247.	0.7	191
94	Influence of Low HDL on Progression of Coronary Artery Disease and Response to Fluvastatin Therapy. Circulation, 1999, 99, 736-743.	1.6	191
95	Meta-analysis of genome-wide association studies from the CHARGE consortium identifies common variants associated with carotid intima media thickness and plaque. Nature Genetics, 2011, 43, 940-947.	9.4	191
96	Effect of Rosuvastatin Therapy on Coronary Artery Stenoses Assessed by Quantitative Coronary Angiography. Circulation, 2008, 117, 2458-2466.	1.6	186
97	Prediction of Incident Heart Failure in General Practice. Circulation: Heart Failure, 2012, 5, 422-429.	1.6	185
98	Efficacy and safety of ezetimibe co-administered with simvastatin compared with atorvastatin in adults with hypercholesterolemia. American Journal of Cardiology, 2004, 93, 1487-1494.	0.7	184
99	Rationale and design of the dal-OUTCOMES trial: Efficacy and safety of dalcetrapib in patients with recent acute coronary syndrome. American Heart Journal, 2009, 158, 896-901.e3.	1.2	184
100	Control of leukocyte rolling velocity in TNF-Î±â€“induced inflammation by LFA-1 and Mac-1. Blood, 2002, 99, 336-341.	0.6	180
101	Association of blood lactate with type 2 diabetes: the Atherosclerosis Risk in Communities Carotid MRI Study. International Journal of Epidemiology, 2010, 39, 1647-1655.	0.9	176
102	Expression, activation, and function of integrin Î±MÎ²2 (Mac-1) on neutrophil-derived microparticles. Blood, 2008, 112, 2327-2335.	0.6	174
103	Diabetes Mellitus, Prediabetes, and Incidence of Subclinical Myocardial Damage. Circulation, 2014, 130, 1374-1382.	1.6	174
104	Stem Cell Factor Induction Is Associated With Mast Cell Accumulation After Canine Myocardial Ischemia and Reperfusion. Circulation, 1998, 98, 687-698.	1.6	170
105	Treatment Gaps in Adults With Heterozygous Familial Hypercholesterolemia in the United States. Circulation: Cardiovascular Genetics, 2016, 9, 240-249.	5.1	170
106	Cytokines and the Microcirculation in Ischemia and Reperfusion. Journal of Molecular and Cellular Cardiology, 1998, 30, 2567-2576.	0.9	168
107	Efficacy and Safety of Rosuvastatin 40 mg Alone or in Combination With Ezetimibe in Patients at High Risk of Cardiovascular Disease (Results from the EXPLORER Study). American Journal of Cardiology, 2007, 99, 673-680.	0.7	168
108	Racial Differences in Glycemic Markers: A Cross-sectional Analysis of Community-Based Data. Annals of Internal Medicine, 2011, 154, 303.	2.0	168

#	Article	IF	Citations
109	Achieving and maintaining national cholesterol education program low-density lipoprotein cholesterol goals with five statins. American Journal of Medicine, 2001, 111, 185-191.	0.6	166
110	Effects of Laropiprant on Nicotinic Acid-Induced Flushing in Patients With Dyslipidemiaâ€â€A list of study investigators appears in the Appendix.. American Journal of Cardiology, 2008, 101, 625-630.	0.7	164
111	Multiplexed Analysis of Biomarkers Related to Obesity and the Metabolic Syndrome in Human Plasma, Using the Luminex-100 System. Clinical Chemistry, 2005, 51, 1102-1109.	1.5	163
112	Correlation of serum triglyceride and its reduction by Ï‰-3 fatty acids with lipid transfer activity and the neutral lipid compositions of high-density and low-density lipoproteins. Atherosclerosis, 1999, 143, 285-297.	0.4	161
113	Efficacy and Safety of a Novel Oral Inducer of Apolipoprotein A-I Synthesis in Statin-Treated Patients With Stable Coronary Artery Disease. Journal of the American College of Cardiology, 2011, 57, 1111-1119.	1.2	161
114	Reduction of Cardiovascular Events by Simvastatin in Nondiabetic Coronary Heart Disease Patients With and Without the Metabolic Syndrome: Subgroup analyses of the Scandinavian Simvastatin Survival Study (4S). Diabetes Care, 2004, 27, 1735-1740.	4.3	159
115	Natriuretic peptides and integrated risk assessment for cardiovascular disease: an individual-participant-data meta-analysis. Lancet Diabetes and Endocrinology,the, 2016, 4, 840-849.	5.5	159
116	Correlation of non-high-density lipoprotein cholesterol with apolipoprotein B: effect of 5 hydroxymethylglutaryl coenzyme A reductase inhibitors on non-high-density lipoprotein cholesterol levels. American Journal of Cardiology, 2001, 88, 265-269.	0.7	157
117	Prevalence of coronary heart disease and carotid arterial thickening in patients with the metabolic syndrome (The ARIC Study). American Journal of Cardiology, 2004, 94, 1249-1254.	0.7	156
118	High-Sensitivity Troponin I and Incident Coronary Events, Stroke, Heart Failure Hospitalization, and Mortality in the ARIC Study. Circulation, 2019, 139, 2642-2653.	1.6	155
119	Rationale and design of <scp>REDUCEâ€IT</scp>: Reduction of Cardiovascular Events with Icosapent Ethylâ€"Intervention Trial. Clinical Cardiology, 2017, 40, 138-148.	0.7	154
120	Results of Bococizumab, A Monoclonal Antibody Against Proprotein Convertase Subtilisin/Kexin Type 9, from a Randomized, Placebo-Controlled, Dose-Ranging Study in Statin-Treated Subjects With Hypercholesterolemia. American Journal of Cardiology, 2015, 115, 1212-1221.	0.7	153
121	Assessment of omegaâ€3 carboxylic acids in statinâ€treated patients with high levels of triglycerides and low levels of highâ€density lipoprotein cholesterol: Rationale and design of the STRENGTH trial. Clinical Cardiology, 2018, 41, 1281-1288.	0.7	151
122	Novel Markers of Kidney Function as Predictors of ESRD, Cardiovascular Disease, and Mortality in the General Population. American Journal of Kidney Diseases, 2012, 59, 653-662.	2.1	150
123	Efficacy and Safety of a Novel Dual Modulator of Adenosine Triphosphate-Citrate Lyase and Adenosine Monophosphate-Activated Protein Kinase in Patients With Hypercholesterolemia. Journal of the American College of Cardiology, 2013, 62, 1154-1162.	1.2	150
124	Common carotid artery intima-media thickness is as good as carotid intima-media thickness of all carotid artery segments in improving prediction of coronary heart disease risk in the Atherosclerosis Risk in Communities (ARIC) study. European Heart Journal, 2012, 33, 183-190.	1.0	149
125	Obesity and Subtypes of Incident Cardiovascular Disease. Journal of the American Heart Association, 2016, 5, .	1.6	149
126	Low-Density Lipoprotein in Hypercholesterolemic Human Plasma Induces Vascular Endothelial Cell Apoptosis by Inhibiting Fibroblast Growth Factor 2 Transcription. Circulation, 2003, 107, 2102-2108.	1.6	147

#	Article	IF	Citations
127	Induction of Monocyte Chemoattractant Protein-1 in the Small Veins of the Ischemic and Reperfused Canine Myocardium. Circulation, 1997, 95, 693-700.	1.6	147
128	A Common PCSK9Haplotype, Encompassing the E670G Coding Single Nucleotide Polymorphism, Is a Novel Genetic Marker for Plasma Low-Density Lipoprotein Cholesterol Levels and Severity of Coronary Atherosclerosis. Journal of the American College of Cardiology, 2005, 45, 1611-1619.	1.2	146
129	sRAGE and Risk of Diabetes, Cardiovascular Disease, and Death. Diabetes, 2013, 62, 2116-2121.	0.3	146
130	Dynamic incorporation of multiple in silico functional annotations empowers rare variant association analysis of large whole-genome sequencing studies at scale. Nature Genetics, 2020, 52, 969-983.	9.4	146
131	2021 ACC Expert Consensus Decision Pathway on the Management of ASCVD Risk Reduction in Patients With Persistent Hypertriglyceridemia. Journal of the American College of Cardiology, 2021, 78, 960-993.	1.2	146
132	Troponin T, N-Terminal Proâ€"B-Type Natriuretic Peptide, and Incidence of Stroke. Stroke, 2013, 44, 961-967.	1.0	145
133	B-type natriuretic peptide and C-reactive protein in the prediction of atrial fibrillation risk: the CHARGE-AF Consortium of community-based cohort studies. Europace, 2014, 16, 1426-1433.	0.7	144
134	Fasting Plasma Free Fatty Acids and Risk of Type 2 Diabetes: The Atherosclerosis Risk in Communities study. Diabetes Care, 2004, 27, 77-82.	4.3	142
135	Plasma MCP-1 level and risk for peripheral arterial disease and incident coronary heart disease: Atherosclerosis Risk in Communities study. Atherosclerosis, 2005, 183, 301-307.	0.4	139
136	CD11c/CD18 Expression Is Upregulated on Blood Monocytes During Hypertriglyceridemia and Enhances Adhesion to Vascular Cell Adhesion Molecule-1. Arteriosclerosis, Thrombosis, and Vascular Biology, 2011, 31, 160-166.	1.1	139
137	Long-term effects of maximally intensive statin therapy on changes in coronary atheroma composition: insights from SATURN. European Heart Journal Cardiovascular Imaging, 2014, 15, 380-388.	0.5	139
138	Sex-Specific Association of Sleep Apnea Severity With Subclinical Myocardial Injury, Ventricular Hypertrophy, and Heart Failure Risk in a Community-Dwelling Cohort. Circulation, 2015, 132, 1329-1337.	1.6	137
139	A Variant of p22 ^{phox} , Involved in Generation of Reactive Oxygen Species in the Vessel Wall, Is Associated With Progression of Coronary Atherosclerosis. Circulation Research, 2000, 86, 391-395.	2.0	134
140	Gender Disparities in Evidence-Based Statin Therapy in Patients With Cardiovascular Disease. American Journal of Cardiology, 2015, 115, 21-26.	0.7	134
141	Comparative effects of rosuvastatin and atorvastatin across their dose ranges in patients with hypercholesterolemia and without active arterial disease. American Journal of Cardiology, 2003, 91, 33-41.	0.7	131
142	Using the Whole Cohort in the Analysis of Case-Cohort Data. American Journal of Epidemiology, 2009, 169, 1398-1405.	1.6	130
143	Effect of Infusion of High-Density Lipoprotein Mimetic Containing Recombinant Apolipoprotein A-I Milano on Coronary Disease in Patients With an Acute Coronary Syndrome in the MILANO-PILOT Trial. JAMA Cardiology, 2018, 3, 806.	3.0	129
144	Hyperlipidemia after heart transplantation: Report of a 6-year experience, with treatment recommendations. Journal of the American College of Cardiology, 1992, 19, 1315-1321.	1.2	125

#	Article	IF	Citations
145	Markers of inflammation and their clinical significance. Atherosclerosis Supplements, 2005, 6, 21-29.	1.2	125
146	Remnant-Like Particle Cholesterol, Low-Density Lipoprotein Triglycerides, and Incident Cardiovascular Disease. Journal of the American College of Cardiology, 2018, 72, 156-169.	1.2	124
147	The Use of Sex-Specific Factors in the Assessment of Womenâ€™s Cardiovascular Risk. Circulation, 2020, 141, 592-599.	1.6	124
148	CD11c Expression in Adipose Tissue and Blood and Its Role in Diet-Induced Obesity. Arteriosclerosis, Thrombosis, and Vascular Biology, 2010, 30, 186-192.	1.1	123
149	Blood Lipid Levels, Lipid-Lowering Medications, and the Incidence of Atrial Fibrillation. Circulation: Arrhythmia and Electrophysiology, 2012, 5, 155-162.	2.1	123
150	Effect of omega-3 fatty acids on cardiovascular outcomes: A systematic review and meta-analysis. EClinicalMedicine, 2021, 38, 100997.	3.2	121
151	Residual Cardiovascular Risk at Low LDL: Remnants, Lipoprotein(a), and Inflammation. Clinical Chemistry, 2021, 67, 143-153.	1.5	120
152	Icosapent Ethyl, a Pure Ethyl Ester of Eicosapentaenoic Acid: Effects on Circulating Markers of Inflammation from the MARINE and ANCHOR Studies. American Journal of Cardiovascular Drugs, 2013, 13, 37-46.	1.0	119
153	Treatment with ETC-1002 alone and in combination with ezetimibe lowers LDL cholesterol in hypercholesterolemic patients with or without statin intolerance. Journal of Clinical Lipidology, 2016, 10, 556-567.	0.6	119
154	Apolipoprotein E Polymorphisms Predict Low Density Lipoprotein Cholesterol Levels and Carotid Artery Wall Thickness but Not Incident Coronary Heart Disease in 12,491 ARIC Study Participants. American Journal of Epidemiology, 2006, 164, 342-348.	1.6	116
155	Chronic Hyperglycemia and Subclinical Myocardial Injury. Journal of the American College of Cardiology, 2012, 59, 484-489.	1.2	116
156	Mendelian Randomization Studies Do Not Support a Causal Role for Reduced Circulating Adiponectin Levels in Insulin Resistance and Type 2 Diabetes. Diabetes, 2013, 62, 3589-3598.	0.3	116
157	EFFECT OF SIROLIMUS ON THE METABOLISM OF ApoB100- CONTAINING LIPOPROTEINS IN RENAL TRANSPLANT PATIENTS1. Transplantation, 2001, 72, 1244-1250.	0.5	114
158	Mac-1, but Not LFA-1, Uses Intercellular Adhesion Molecule-1 to Mediate Slow Leukocyte Rolling in TNF-Î±-Induced Inflammation. Journal of Immunology, 2003, 171, 6105-6111.	0.4	113
159	Duffy antigen receptor for chemokines (Darc) polymorphism regulates circulating concentrations of monocyte chemoattractant protein-1 and other inflammatory mediators. Blood, 2010, 115, 5289-5299.	0.6	113
160	Statins, plasma cholesterol, and risk of Parkinson's disease: A prospective study. Movement Disorders, 2015, 30, 552-559.	2.2	113
161	Improved Horvitzâ€“Thompson Estimation of Model Parameters from Two-phase Stratified Samples: Applications in Epidemiology. Statistics in Biosciences, 2009, 1, 32-49.	0.6	112
162	Trans-Ethnic Fine-Mapping of Lipid Loci Identifies Population-Specific Signals and Allelic Heterogeneity That Increases the Trait Variance Explained. PLoS Genetics, 2013, 9, e1003379.	1.5	112

#	Article	IF	Citations
163	Multi-ancestry genome-wide geneâ€“smoking interaction study of 387,272 individuals identifies new loci associated with serum lipids. Nature Genetics, 2019, 51, 636-648.	9.4	112
164	A Prospective Study of Plasma Ferritin Level and Incident Diabetes: The Atherosclerosis Risk in Communities (ARIC) Study. American Journal of Epidemiology, 2007, 165, 1047-1054.	1.6	110
165	Eotaxin and Obesity. Journal of Clinical Endocrinology and Metabolism, 2006, 91, 256-261.	1.8	109
166	C-Reactive Protein, but not Low-Density Lipoprotein Cholesterol Levels, Associate With Coronary Atheroma Regression and Cardiovascular Events After Maximally Intensive Statin Therapy. Circulation, 2013, 128, 2395-2403.	1.6	109
167	Six-Year Change in High-Sensitivity Cardiac Troponin T and Risk of Subsequent Coronary Heart Disease, Heart Failure, and Death. JAMA Cardiology, 2016, 1, 519.	3.0	109
168	Efficacy and safety of volanesorsen in patients with multifactorial chylomicronaemia (COMPASS): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Diabetes and Endocrinology,the, 2021, 9, 264-275.	5.5	109
169	Nontraditional Markers of Glycemia. Diabetes Care, 2011, 34, 960-967.	4.3	108
170	Current and future aims of lipid-lowering therapy: changing paradigms and lessons from the heart protection study on standards of efficacyand safety. American Journal of Cardiology, 2003, 92, 3-9.	0.7	105
171	Novel Polymorphisms in Promoter Region of ATP Binding Cassette Transporter Gene and Plasma Lipids, Severity, Progression, and Regression of Coronary Atherosclerosis and Response to Therapy. Circulation Research, 2001, 88, 969-973.	2.0	104
172	Follow-up lipid tests and physician visits are associated with improved adherence to statin therapy. Pharmacoeconomics, 2004, 22, 13-23.	1.7	104
173	REDUCE-IT USA. Circulation, 2020, 141, 367-375.	1.6	104
174	Carotid Arterial Wall Characteristics Are Associated With Incident Ischemic Stroke But Not Coronary Heart Disease in the Atherosclerosis Risk in Communities (ARIC) Study. Stroke, 2012, 43, 103-108.	1.0	103
175	Association of Isolated Diastolic Hypertension as Defined by the 2017 ACC/AHA Blood Pressure Guideline With Incident Cardiovascular Outcomes. JAMA - Journal of the American Medical Association, 2020, 323, 329.	3.8	103
176	The Virulence Function of Streptococcus pneumoniae Surface Protein A Involves Inhibition of Complement Activation and Impairment of Complement Receptor-Mediated Protection. Journal of Immunology, 2004, 173, 7506-7512.	0.4	102
177	Effects of sirolimus on plasma lipids, lipoprotein levels, and fatty acid metabolism in renal transplant patients. Journal of Lipid Research, 2002, 43, 1170-80.	2.0	102
178	A COmparative study with rosuvastatin in subjects with METabolic Syndrome: results of the COMETS studyâ€. European Heart Journal, 2005, 26, 2664-2672.	1.0	101
179	Lipid-altering efficacy of the ezetimibe/simvastatin single tablet versus rosuvastatin in hypercholesterolemic patients. Current Medical Research and Opinion, 2006, 22, 2041-2053.	0.9	101
180	Association of Clonal Hematopoiesis With Incident HeartÂFailure. Journal of the American College of Cardiology, 2021, 78, 42-52.	1.2	101

#	Article	IF	Citations
181	Effects of diet-induced obesity on inflammation and remodeling after myocardial infarction. American Journal of Physiology - Heart and Circulatory Physiology, 2006, 291, H2504-H2514.	1.5	99
182	Statin Therapy Alters the Relationship Between Apolipoprotein B and Low-Density Lipoprotein Cholesterol and Nonâ€"High-Density Lipoprotein Cholesterol Targets in High-Risk Patients. Journal of the American College of Cardiology, 2008, 52, 626-632.	1.2	99
183	Role of Î±4Integrin and VCAM-1 in CD18-Independent Neutrophil Migration Across Mouse Cardiac Endothelium. Circulation Research, 2002, 90, 562-569.	2.0	98
184	Midlife systemic inflammatory markers are associated with late-life brain volume. Neurology, 2017, 89, 2262-2270.	1.5	97
185	N-Terminal Pro-Brain Natriuretic Peptide and Heart Failure Risk Among Individuals With and Without Obesity. Circulation, 2016, 133, 631-638.	1.6	96
186	Use of Guideline-Recommended Risk Reduction Strategies Among Patients With Diabetes and Atherosclerotic Cardiovascular Disease. Circulation, 2019, 140, 618-620.	1.6	96
187	Endothelial Domes Encapsulate Adherent Neutrophils and Minimize Increases in Vascular Permeability in Paracellular and Transcellular Emigration. PLoS ONE, 2008, 3, e1649.	1.1	96
188	Effect of Evolocumab on CoronaryÂPlaque Composition. Journal of the American College of Cardiology, 2018, 72, 2012-2021.	1.2	95
189	Efficacy and Tolerability of Fluvastatin XL 80 mg Alone, Ezetimibe Alone, and the Combination of Fluvastatin XL 80 mg With Ezetimibe in Patients With a History of Muscle-Related Side Effects With Other Statins. American Journal of Cardiology, 2008, 101, 490-496.	0.7	94
190	High-Molecular-Weight Adiponectin and the Risk of Type 2 Diabetes in the ARIC Study. Journal of Clinical Endocrinology and Metabolism, 2010, 95, 5097-5104.	1.8	94
191	A 1-Year Lifestyle Intervention for Weight Loss in Individuals With Type 2 Diabetes Reduces High C-Reactive Protein Levels and Identifies Metabolic Predictors of Change. Diabetes Care, 2010, 33, 2297-2303.	4.3	92
192	Circulating Biomarkers and Abdominal Aortic Aneurysm Incidence. Circulation, 2015, 132, 578-585.	1.6	92
193	Effect of ETC-1002 on Serum Low-Density Lipoprotein Cholesterol in Hypercholesterolemic Patients Receiving Statin Therapy. American Journal of Cardiology, 2016, 117, 1928-1933.	0.7	92
194	Apolipoprotein E genotypes and response of plasma lipids and progressionâ€"regression of coronary atherosclerosis to lipid-lowering drug therapy. Journal of the American College of Cardiology, 2000, 36, 1572-1578.	1.2	91
195	Impact of Adding a Single Allele in the 9p21 Locus to Traditional Risk Factors on Reclassification of Coronary Heart Disease Risk and Implications for Lipid-Modifying Therapy in the Atherosclerosis Risk in Communities Study. Circulation: Cardiovascular Genetics, 2009, 2, 279-285.	5.1	91
196	Pharmacological strategies for lowering LDL cholesterol: statins and beyond. Nature Reviews Cardiology, 2011, 8, 253-265.	6.1	90
197	New therapeutic principles in dyslipidaemia: focus on LDL and Lp(a) lowering drugs. European Heart Journal, 2013, 34, 1783-1789.	1.0	90
198	Eight genetic loci associated with variation in lipoprotein-associated phospholipase A2 mass and activity and coronary heart disease: meta-analysis of genome-wide association studies from five community-based studies. European Heart Journal, 2012, 33, 238-251.	1.0	89

#	Article	IF	Citations
199	Chronic inflammation role in the obesity-diabetes association: a case-cohort study. Diabetology and Metabolic Syndrome, 2013, 5, 31.	1.2	88
200	Adoption of the 2013 American College of Cardiology/American Heart Association Cholesterol Management Guideline in Cardiology Practices Nationwide. JAMA Cardiology, 2017, 2, 361.	3.0	88
201	Clonal Hematopoiesis Is Associated With Higher Risk of Stroke. Stroke, 2022, 53, 788-797.	1.0	88
202	Achieving LDL cholesterol, non-HDL cholesterol, and apolipoprotein B target levels in high-risk patients: Measuring Effective Reductions in Cholesterol Using Rosuvastatin therapY (MERCURY) II. American Heart Journal, 2006, 151, 975.e1-975.e9.	1.2	87
203	Comparison of the Safety and Efficacy of a Combination Tablet of Niacin Extended Release and Simvastatin vs Simvastatin Monotherapy in Patients With Increased Nonâ€“HDL Cholesterol (from the) Tj ETQq1 1 0.784314 rgBT /Ov	0.7	87
204	Comparison by Meta-Analysis of Mortality After Isolated Coronary Artery Bypass Grafting in Women Versus Men. American Journal of Cardiology, 2013, 112, 309-317.	0.7	87
205	Ten things to know about ten cardiovascular disease risk factors. American Journal of Preventive Cardiology, 2021, 5, 100149.	1.3	87
206	Coronary atheroma volume and cardiovascular events during maximally intensive statin therapy. European Heart Journal, 2013, 34, 3182-3190.	1.0	86
207	NH 2 -Terminal Proâ€“Brain Natriuretic Peptide and Risk of Diabetes. Diabetes, 2013, 62, 3189-3193.	0.3	86
208	Use of Lipid-Lowering Therapies Over 2 Years in GOULD, a Registry of Patients With Atherosclerotic Cardiovascular Disease in the US. JAMA Cardiology, 2021, 6, 1060.	3.0	86
209	Multiancestry Genome-Wide Association Study of Lipid Levels Incorporating Gene-Alcohol Interactions. American Journal of Epidemiology, 2019, 188, 1033-1054.	1.6	85
210	Manifestations of Inflammatory Arthritis Are Critically Dependent on LFA-1. Journal of Immunology, 2005, 174, 3668-3675.	0.4	84
211	High-Sensitivity Cardiac Troponin T and Risk of Hypertension. Circulation, 2015, 132, 825-833.	1.6	84
212	Relations between lipoprotein(a) concentrations, LPA genetic variants, and the risk of mortality in patients with established coronary heart disease: a molecular and genetic association study. Lancet Diabetes and Endocrinology,the, 2017, 5, 534-543.	5.5	84
213	Association of midlife lipids with 20â€year cognitive change: A cohort study. Alzheimer's and Dementia, 2018, 14, 167-177.	0.4	84
214	Conditional Risk Factors for Atherosclerosis. Mayo Clinic Proceedings, 2005, 80, 219-230.	1.4	83
215	Pre-Morbid Body Mass Index and MortalityÂAfter Incident Heart Failure. Journal of the American College of Cardiology, 2014, 64, 2743-2749.	1.2	83
216	Midlife Systemic Inflammation, Late-Life White Matter Integrity, and Cerebral Small Vessel Disease. Stroke, 2017, 48, 3196-3202.	1.0	83

#	Article	IF	Citations
217	Nine-year trends in achievement of risk factor goals in the US and European outpatients with cardiovascular disease. American Heart Journal, 2008, 156, 719-727.	1.2	82
218	Troponin T and N-Terminal Proâ€“B-Type Natriuretic Peptide: A Biomarker Approach to Predict Heart Failure Riskâ€”The Atherosclerosis Risk in Communities Study. Clinical Chemistry, 2013, 59, 1802-1810.	1.5	82
219	Effect of the BET Protein Inhibitor, RVX-208, on Progression of Coronary Atherosclerosis: Results of the Phase 2b, Randomized, Double-Blind, Multicenter, ASSURE Trial. American Journal of Cardiovascular Drugs, 2016, 16, 55-65.	1.0	82
220	Cardiometabolic Risk in Impaired Fasting Glucose and Impaired Glucose Tolerance: The Atherosclerosis Risk in Communities Study. Diabetes Care, 2007, 30, 325-331.	4.3	81
221	Obesity, Subclinical Myocardial Injury, and Incident Heart Failure. JACC: Heart Failure, 2014, 2, 600-607.	1.9	81
222	Integrin engagement regulates monocyte differentiation through the forkhead transcription factor Foxp1. Journal of Clinical Investigation, 2004, 114, 408-418.	3.9	81
223	Longitudinal impact of physical activity on lipid profiles in middle-aged adults: the Atherosclerosis Risk in Communities Study. Journal of Lipid Research, 2009, 50, 1685-1691.	2.0	80
224	Pooled Analyses of Effects on C-Reactive Protein and Low Density Lipoprotein Cholesterol in Placebo-Controlled Trials of Ezetimibe Monotherapy or Ezetimibe Added to Baseline Statin Therapy. American Journal of Cardiology, 2009, 103, 369-374.	0.7	80
225	Combined Association of Albuminuria and Cystatin Câ€“Based Estimated GFR With Mortality, Coronary Heart Disease, and Heart Failure Outcomes: The Atherosclerosis Risk in Communities (ARIC) Study. American Journal of Kidney Diseases, 2012, 60, 207-216.	2.1	80
226	ApoA-I Induction as a Potential Cardioprotective Strategy: Rationale for the SUSTAIN and ASSURE Studies. Cardiovascular Drugs and Therapy, 2012, 26, 181-187.	1.3	80
227	Six-year change in high-sensitivity C-reactive protein and risk of diabetes, cardiovascular disease, and mortality. American Heart Journal, 2015, 170, 380-389.e4.	1.2	80
228	Lipids and CVD management: towards a global consensus. European Heart Journal, 2005, 26, 2224-2231.	1.0	79
229	Lipoprotein-Associated Phospholipase A ₂ and High-Sensitivity C-Reactive Protein Improve the Stratification of Ischemic Stroke Risk in the Atherosclerosis Risk in Communities (ARIC) Study. Stroke, 2009, 40, 376-381.	1.0	79
230	Reduction in First and Total Ischemic Events With Icosapent Ethyl Across Baseline Triglyceride Tertiles. Journal of the American College of Cardiology, 2019, 74, 1159-1161.	1.2	79
231	The Differential Roles of LFA-1 and Mac-1 in Host Defense Against Systemic Infection with Streptococcus pneumoniae. Journal of Immunology, 2001, 166, 7362-7369.	0.4	78
232	Loss of LFA-1, but not Mac-1, Protects MRL/MpJ-Faslpr Mice from Autoimmune Disease. American Journal of Pathology, 2004, 165, 609-616.	1.9	78
233	Attenuated adipose tissue and skeletal muscle inflammation in obese mice with combined CD4+ and CD8+ T cell deficiency. Atherosclerosis, 2014, 233, 419-428.	0.4	78
234	Bempedoic Acid (ETC-1002): an Investigational Inhibitor of ATP Citrate Lyase. Current Atherosclerosis Reports, 2016, 18, 61.	2.0	78

#	Article	IF	Citations
235	Circulating Monocyte Chemoattractant Protein-1 and Risk of Stroke. Circulation Research, 2019, 125, 773-782.	2.0	78
236	Apolipoprotein C-III reduction in subjects with moderate hypertriglyceridaemia and at high cardiovascular risk. European Heart Journal, 2022, 43, 1401-1412.	1.0	78
237	Interactions between angiotensin-I converting enzyme insertion/deletion polymorphism and response of plasma lipids and coronary atherosclerosis to treatment with fluvastatin. Journal of the American College of Cardiology, 2000, 35, 89-95.	1.2	77
238	Deficiency of CD11b or CD11d Results in Reduced Staphylococcal Enterotoxin-Induced T Cell Response and T Cell Phenotypic Changes. Journal of Immunology, 2004, 173, 297-306.	0.4	77
239	Association of Variation at the ABO Locus With Circulating Levels of Soluble Intercellular Adhesion Molecule-1, Soluble P-selectin, and Soluble E-selectin. Circulation: Cardiovascular Genetics, 2011, 4, 681-686.	5.1	77
240	Sleep Apnea Is Associated with Subclinical Myocardial Injury in the Community. The ARIC-SHHS Study. American Journal of Respiratory and Critical Care Medicine, 2013, 188, 1460-1465.	2.5	77
241	Myocardial infarction and remodeling in mice: effect of reperfusion. American Journal of Physiology - Heart and Circulatory Physiology, 1999, 277, H660-H668.	1.5	76
242	In-Hospital Initiation of Lipid-Lowering Therapy for Patients With Coronary Heart Disease. Circulation, 2001, 103, 2768-2770.	1.6	76
243	Rationale and design of the familial hypercholesterolemia foundation CAscade SCreening for Awareness and DEtection of Familial Hypercholesterolemia registry. American Heart Journal, 2014, 167, 342-349.e17.	1.2	76
244	Multimodality Strategy for Cardiovascular Risk Assessment. Circulation, 2017, 135, 2119-2132.	1.6	75
245	Sources of Variability in Measurements of Cardiac Troponin T in a Community-Based Sample: The Atherosclerosis Risk in Communities Study. Clinical Chemistry, 2011, 57, 891-897.	1.5	74
246	Association of C-Reactive Protein and Microalbuminuria (from the National Health and Nutrition) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 3	0.7	73
247	Icosapent ethyl, a pure EPA omega-3 fatty acid: Effects on lipoprotein particle concentration and size in patients with very high triglyceride levels (the MARINE study). Journal of Clinical Lipidology, 2012, 6, 565-572.	0.6	73
248	Troponin T, B-type natriuretic peptide, C-reactive protein, and cause-specific mortality. Annals of Epidemiology, 2013, 23, 66-73.	0.9	72
249	Efficacy and tolerability of fluvastatin extended-release delivery system: a pooled analysis. Clinical Therapeutics, 2001, 23, 177-192.	1.1	71
250	Combination Therapy with Statins and Omega-3 Fatty Acids. American Journal of Cardiology, 2006, 98, 34-38.	0.7	71
251	Preoperative statin therapy is not associated with a decrease in the incidence of postoperative atrial fibrillation in patients undergoing cardiac surgery. American Heart Journal, 2008, 155, 541-546.	1.2	71
252	Foamy Monocytes Form Early and Contribute to Nascent Atherosclerosis in Mice With Hypercholesterolemia. Arteriosclerosis, Thrombosis, and Vascular Biology, 2015, 35, 1787-1797.	1.1	71

#	Article	IF	Citations
253	Recalibration of Blood Analytes over 25 Years in the Atherosclerosis Risk in Communities Study: Impact of Recalibration on Chronic Kidney Disease Prevalence and Incidence. Clinical Chemistry, 2015, 61, 938-947.	1.5	71
254	Role of Bempedoic Acid in Clinical Practice. Cardiovascular Drugs and Therapy, 2021, 35, 853-864.	1.3	71
255	Impact of Evidence-Based "Clinical Judgment" on the Number of American Adults Requiring Lipid-Lowering Therapy Based on Updated NHANES III Data. Archives of Internal Medicine, 2000, 160, 1361.	4.3	70
256	FDG-PET Imaging for Oxidized LDL in StableÂAtherosclerotic Disease: A Phase II Study ofÂSafety, Tolerability, and Anti-Inflammatory Activity. JACC: Cardiovascular Imaging, 2015, 8, 493-494.	2.3	70
257	Bempedoic acid safety analysis: Pooled data from four phase 3 clinical trials. Journal of Clinical Lipidology, 2020, 14, 649-659.e6.	0.6	70
258	Maximizing the Cost-effectiveness of Lipid-Lowering Therapy. Archives of Internal Medicine, 1998, 158, 1977.	4.3	69
259	Effect on high-density lipoprotein cholesterol of maximum dose simvastatin and atorvastatin in patients with hypercholesterolemia: Results of the Comparative HDL Efficacy and Safety Study (CHESS). American Heart Journal, 2003, 146, 862-869.	1.2	69
260	A genetic risk score based on direct associations with coronary heart disease improves coronary heart disease risk prediction in the Atherosclerosis Risk in Communities (ARIC), but not in the Rotterdam and Framingham Offspring, Studies. Atherosclerosis, 2012, 223, 421-426.	0.4	69
261	Large-scale plasma proteomic analysis identifies proteins and pathways associated with dementia risk. Nature Aging, 2021, 1, 473-489.	5.3	69
262	Lipid measurements in the management of cardiovascular diseases: Practical recommendations a scientific statement from the national lipid association writing group. Journal of Clinical Lipidology, 2021, 15, 629-648.	0.6	69
263	Association of Lipoprotein(a) With Risk of Recurrent Ischemic Events Following Acute Coronary Syndrome. JAMA Cardiology, 2018, 3, 164.	3.0	68
264	Critical role of integrin CD11c in splenic dendritic cell capture of missing-self CD47 cells to induce adaptive immunity. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, 6786-6791.	3.3	68
265	Relationship of Alcohol Consumption and Type of Alcoholic Beverage Consumed With Plasma Lipid Levels: Differences Between Whites and African Americans of the ARIC Study. Annals of Epidemiology, 2008, 18, 101-107.	0.9	66
266	Mechanism of chronic obstructive uropathy: Increased expression of apoptosis-promoting molecules. Kidney International, 2000, 58, 1481-1491.	2.6	65
267	Metabolomic Pattern Predicts Incident Coronary Heart Disease. Arteriosclerosis, Thrombosis, and Vascular Biology, 2019, 39, 1475-1482.	1.1	65
268	Integrin engagement regulates monocyte differentiation through the forkhead transcription factor Foxp1. Journal of Clinical Investigation, 2004, 114, 408-418.	3.9	65
269	Effects of prescription omega-3-acid ethyl esters on lipoprotein particle concentrations, apolipoproteins AI and CIII, and lipoprotein-associated phospholipase A2 mass in statin-treated subjects with hypertriglyceridemia. Journal of Clinical Lipidology, 2009, 3, 332-340.	0.6	64
270	Health disparities among adult patients with a phenotypic diagnosis of familial hypercholesterolemia in the CASCADE-FHâ„¢ patient registry. Atherosclerosis, 2017, 267, 19-26.	0.4	64

#	Article	IF	Citations
271	Role of early reperfusion in the induction of adhesion molecules and cytokines in previously ischemic myocardium. Molecular and Cellular Biochemistry, 1995, 147, 5-12.	1.4	63
272	Primary Prevention of Coronary Heart Disease. Journal of Clinical Endocrinology and Metabolism, 2000, 85, 2089-2092.	1.8	63
273	Frequency and Practice-Level Variation in Inappropriate Aspirin Use for the Primary Prevention of Cardiovascular Disease. Journal of the American College of Cardiology, 2015, 65, 111-121.	1.2	63
274	The effect of BMS-582949, a P38 mitogen-activated protein kinase (P38 MAPK) inhibitor on arterial inflammation: A multicenter FDG-PET trial. Atherosclerosis, 2015, 240, 490-496.	0.4	63
275	Genetically determined NLRP3 inflammasome activation associates with systemic inflammation and cardiovascular mortality. European Heart Journal, 2021, 42, 1742-1756.	1.0	63
276	Increases in Lung Tissue Expression of Intercellular Adhesion Molecule-1 Are Associated with Hyperoxic Lung Injury and Inflammation in Mice. American Journal of Respiratory Cell and Molecular Biology, 1993, 9, 393-400.	1.4	62
277	Comparison of Effects of Ezetimibe/Simvastatin Versus Simvastatin Versus Atorvastatin in Reducing C-Reactive Protein and Low-Density Lipoprotein Cholesterol Levels. American Journal of Cardiology, 2007, 99, 1706-1713.e1.	0.7	62
278	Lipid-Altering Efficacy and Safety of Ezetimibe/Simvastatin Versus Atorvastatin in Patients With Hypercholesterolemia and the Metabolic Syndrome (from the VYMET Study). American Journal of Cardiology, 2009, 103, 1694-1702.	0.7	62
279	Multi-ancestry sleep-by-SNP interaction analysis in 126,926 individuals reveals lipid loci stratified by sleep duration. Nature Communications, 2019, 10, 5121.	5.8	62
280	Soluble Adhesion Molecules and the Search for Biomarkers for Atherosclerosis. Circulation, 2002, 106, 766-767.	1.6	61
281	Factors underlying regression of coronary atheroma with potent statin therapy. European Heart Journal, 2013, 34, 1818-1825.	1.0	61
282	Provider understanding of the 2013 ACC/AHA cholesterol guideline. Journal of Clinical Lipidology, 2016, 10, 497-504.e4.	0.6	61
283	Reproducibility and Variability of Protein Analytes Measured Using a Multiplexed Modified Aptamer Assay. journal of applied laboratory medicine, The, 2019, 4, 30-39.	0.6	61
284	Glutathione-S-transferase genotypes, smoking, and their association with markers of inflammation, hemostasis, and endothelial function: the atherosclerosis risk in communities (ARIC) study. Atherosclerosis, 2003, 171, 265-272.	0.4	60
285	Adiposopathy: why do adiposity and obesity cause metabolic disease?. Future Lipidology, 2006, 1, 389-420.	0.5	60
286	Associations between HDL-cholesterol and polymorphisms in hepatic lipase and lipoprotein lipase genes are modified by dietary fat intake in African American and White adults. Atherosclerosis, 2007, 194, e131-e140.	0.4	60
287	Efficacy and Safety of ABT-335 (Fenofibric Acid) in Combination With Atorvastatin in Patients With Mixed Dyslipidemia. American Journal of Cardiology, 2009, 103, 515-522.	0.7	60
288	Effects of icosapent ethyl on lipid and inflammatory parameters in patients with diabetes mellitus-2, residual elevated triglycerides (200â€“500Âmg/dL), and on statin therapy at LDL-C goal: the ANCHOR study. Cardiovascular Diabetology, 2013, 12, 100.	2.7	60

#	Article	IF	Citations
289	Evaluation of the efficacy, safety and glycaemic effects of evolocumab (<scp>AMG</scp> 145) in hypercholesterolaemic patients stratified by glycaemic status and metabolic syndrome. Diabetes, Obesity and Metabolism, 2017, 19, 98-107.	2.2	60
290	Cardiovascular Biomarkers and Subclinical Brain Disease in the Atherosclerosis Risk in Communities Study. Stroke, 2013, 44, 1803-1808.	1.0	59
291	Effects of Fenofibric Acid on Carotid Intima-Media Thickness in Patients With Mixed Dyslipidemia on Atorvastatin Therapy. Arteriosclerosis, Thrombosis, and Vascular Biology, 2014, 34, 1298-1306.	1.1	59
292	High-sensitivity cardiac troponin T and the risk of incident atrial fibrillation: The Atherosclerosis Risk in Communities (ARIC) study. American Heart Journal, 2015, 169, 31-38.e3.	1.2	59
293	The association of mid-to late-life systemic inflammation with white matter structure in older adults: The Atherosclerosis Risk in Communities Study. Neurobiology of Aging, 2018, 68, 26-33.	1.5	59
294	Effect of Moderate Alcohol Consumption on Hypertriglyceridemia. Archives of Internal Medicine, 1999, 159, 981.	4.3	58
295	Comparative effectiveness of outpatient cardiovascular disease and diabetes care delivery between advanced practice providers and physician providers in primary care: Implications for care under the Affordable Care Act. American Heart Journal, 2016, 181, 74-82.	1.2	58
296	B vitamin status and inflammatory markers. Atherosclerosis, 2003, 169, 169-174.	0.4	57
297	Cardiac and Kidney Markers for Cardiovascular Prediction in Individuals With Chronic Kidney Disease. Arteriosclerosis, Thrombosis, and Vascular Biology, 2014, 34, 1770-1777.	1.1	57
298	US physician practices for diagnosing familial hypercholesterolemia: data from the CASCADE-FH registry. Journal of Clinical Lipidology, 2016, 10, 1223-1229.	0.6	57
299	Estimation of Eligibility for Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors and Associated Costs Based on the FOURIER Trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition) Tj ETQq1 1 0.784314 rgBT /Ov	1.1	57
300	Causal Role of Alcohol Consumption in an Improved Lipid Profile: The Atherosclerosis Risk in Communities (ARIC) Study. PLoS ONE, 2016, 11, e0148765.	1.1	57
301	Role of lipid and lipoprotein profiles in risk assessment and therapy. American Heart Journal, 2003, 146, 227-233.	1.2	56
302	Correlates of Carotid Plaque Presence and Composition as Measured by MRI. Circulation: Cardiovascular Imaging, 2009, 2, 314-322.	1.3	56
303	The Upregulation of Integrin Î±DÎ²2 (CD11d/CD18) on Inflammatory Macrophages Promotes Macrophage Retention in Vascular Lesions and Development of Atherosclerosis. Journal of Immunology, 2017, 198, 4855-4867.	0.4	56
304	Short-Term Global Cardiovascular Disease RiskÂPrediction in Older Adults. Journal of the American College of Cardiology, 2018, 71, 2527-2536.	1.2	56
305	Myocardial Extracellular Volume Fraction Adds Prognostic Information Beyond Myocardial Replacement Fibrosis. Circulation: Cardiovascular Imaging, 2019, 12, e009535.	1.3	56
306	Development and Validation of Machine Learningâ€“Based Race-Specific Models to Predict 10-Year Risk of Heart Failure: A Multicohort Analysis. Circulation, 2021, 143, 2370-2383.	1.6	56

#	Article	IF	Citations
307	Regulation of ICAM-1 and IL-6 in Myocardial Ischemia: Effect of Reperfusion a. Annals of the New York Academy of Sciences, 1994, 723, 258-270.	1.8	55
308	A prospective study of paraoxonase gene Q/R192 polymorphism and severity, progression and regression of coronary atherosclerosis, plasma lipid levels, clinical events and response to fluvastatin. Atherosclerosis, 2001, 154, 633-640.	0.4	55
309	Tracking regression and progression of atherosclerosis in human carotid arteries using high-resolution magnetic resonance imaging. Magnetic Resonance Imaging, 2004, 22, 1249-1258.	1.0	55
310	Relationship between circulating levels of RANTES (regulated on activation, normal T-cell expressed,) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5 Carotid MRI Study. European Heart Journal, 2011, 32, 459-468.	1.0	55
311	Clinical trial endpoints: angiograms, events, and plaque instability. American Journal of Cardiology, 1998, 82, 5M-11M.	0.7	54
312	Interaction Between Soluble Thrombomodulin and Intercellular Adhesion Molecule-1 in Predicting Risk of Coronary Heart Disease. Circulation, 2003, 107, 1729-1732.	1.6	54
313	Management of Lp(a). Journal of Clinical Lipidology, 2010, 4, 240-247.	0.6	54
314	Sex-Related Differences of Coronary Atherosclerosis Regression Following Maximally Intensive Statin Therapy. JACC: Cardiovascular Imaging, 2014, 7, 1013-1022.	2.3	54
315	Ideal Cardiovascular Health During Adult Life and Cardiovascular Structure and Function Among the Elderly. Circulation, 2015, 132, 1979-1989.	1.6	54
316	Provider Type and Quality of Outpatient Cardiovascular Disease Care. Journal of the American College of Cardiology, 2015, 66, 1803-1812.	1.2	54
317	Combination therapy for combined dyslipidemia. American Journal of Cardiology, 2002, 90, 21-29.	0.7	53
318	Combination of Niacin and Fenofibrate with Lifestyle Changes Improves Dyslipidemia and Hypoadiponectinemia in HIV Patients on Antiretroviral Therapy: Results of â€œHeart Positive,â€•a Randomized, Controlled Trial. Journal of Clinical Endocrinology and Metabolism, 2011, 96, 2236-2247.	1.8	53
319	Lactate and Risk of Incident Diabetes in a Case-Cohort of the Atherosclerosis Risk in Communities (ARIC) Study. PLoS ONE, 2013, 8, e55113.	1.1	53
320	Is Highâ€•Intensity Statin Therapy Associated With Lower Statin Adherence Compared With Lowâ€•to Moderateâ€•Intensity Statin Therapy? Implications of the 2013 American College ofÂCardiology/American Heart Association Cholesterol Management Guidelines. Clinical Cardiology, 2014, 37, 653-659.	0.7	53
321	Racial Differences in Circulating Natriuretic Peptide Levels: The Atherosclerosis Risk in Communities Study. Journal of the American Heart Association, 2015, 4, .	1.6	53
322	Plasma galectin-3 levels are associated with the risk of incident chronic kidney disease. Kidney International, 2018, 93, 252-259.	2.6	53
323	Effectiveness and tolerability of ezetimibe add-on therapy to a bile acid resin-based regimen for hypercholesterolemia. American Journal of Cardiology, 2004, 94, 795-797.	0.7	52
324	Regulation of LFA-1â€“dependent inflammatory cell recruitment by Cbl-b and 14-3-3 proteins. Blood, 2008, 111, 3607-3614.	0.6	52

#	Article	IF	Citations
325	Association of gender with morbidity and mortality after isolated coronary artery bypass grafting. A propensity score matched analysis. International Journal of Cardiology, 2013, 167, 180-184.	0.8	52
326	Patients with severe chronic kidney disease benefit from early revascularization after acute coronary syndrome. International Journal of Cardiology, 2013, 168, 3741-3746.	0.8	52
327	Essential Role of CD11a in CD8 ⁺ T-Cell Accumulation and Activation in Adipose Tissue. Arteriosclerosis, Thrombosis, and Vascular Biology, 2014, 34, 34-43.	1.1	52
328	Review of Clinical Practice Guidelines for the Management of LDL-Related Risk. Journal of the American College of Cardiology, 2014, 64, 196-206.	1.2	52
329	Mortality Implications of Prediabetes and Diabetes in Older Adults. Diabetes Care, 2020, 43, 382-388.	4.3	52
330	Association Between Achieved Ï‰-3 Fatty Acid Levels and Major Adverse Cardiovascular Outcomes in Patients With High Cardiovascular Risk. JAMA Cardiology, 2021, 6, 910.	3.0	52
331	Effect of dalcetrapib plus pravastatin on lipoprotein metabolism and high-density lipoprotein composition and function in dyslipidemic patients: Results of a phase IIb dose-ranging study. American Heart Journal, 2012, 163, 515-521.e3.	1.2	51
332	Lifestyle intervention and/or statins for the reduction of Câ€reactive protein in type 2 diabetes: From the look AHEAD study. Obesity, 2013, 21, 944-950.	1.5	51
333	Effects of PPAR??, ?? and ?? haplotypes on plasma levels of lipids, severity and progression of coronary atherosclerosis and response to statin therapy in the lipoprotein coronary atherosclerosis study. Pharmacogenetics and Genomics, 2004, 14, 61-71.	5.7	50
334	Increased risk of incident stroke associated with the cyclooxygenase 2 (COX-2) Gâ^'765C polymorphism in African-Americans: The Atherosclerosis Risk in Communities Study. Atherosclerosis, 2008, 196, 926-930.	0.4	50
335	ACCF/AHA/ACP 2009 Competence and Training Statement: A Curriculum on Prevention of Cardiovascular Disease. Journal of the American College of Cardiology, 2009, 54, 1336-1363.	1.2	50
336	Frequency and correlates of treatment intensification for elevated cholesterol levels in patients with cardiovascular disease. American Heart Journal, 2011, 162, 725-732.e1.	1.2	50
337	White Blood Cell Count, C-Reactive Protein, and Incident Heart Failure in the Atherosclerosis Risk in Communities (ARIC) Study. Annals of Epidemiology, 2011, 21, 739-748.	0.9	50
338	High-Intensity Statin Therapy Alters the Natural History of Diabetic Coronary Atherosclerosis: Insights From SATURN. Diabetes Care, 2014, 37, 3114-3120.	4.3	50
339	Practical Approaches for Whole-Genome Sequence Analysis of Heart- and Blood-Related Traits. American Journal of Human Genetics, 2017, 100, 205-215.	2.6	50
340	Orthostatic Hypotension and Risk of Clinical and Subclinical Cardiovascular Disease in Middleâ€Aged Adults. Journal of the American Heart Association, 2018, 7, .	1.6	50
341	Biomarker-Based Risk Prediction of Incident HeartÂFailure in Pre-Diabetes andÂDiabetes. JACC: Heart Failure, 2021, 9, 215-223.	1.9	50
342	Clinical Implications of JUPITER (Justification for the Use of statins in Prevention: an Intervention) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 6 2009, 54, 2388-2395.	1.2	49

#	Article	IF	Citations
343	Incorporation of Biomarkers Into Risk Assessment for Allocation of Antihypertensive Medication According to the 2017 ACC/AHA High Blood Pressure Guideline. Circulation, 2019, 140, 2076-2088.	1.6	49
344	Associations Between High-Density Lipoprotein Particles and Ischemic Events by Vascular Domain, Sex, and Ethnicity. Circulation, 2020, 142, 657-669.	1.6	49
345	Utilization Rates of SGLT2 Inhibitors and GLP-1 Receptor Agonists and Their Facility-Level Variation Among Patients With Atherosclerotic Cardiovascular Disease and Type 2 Diabetes: Insights From the Department of Veterans Affairs. Diabetes Care, 2022, 45, 372-380.	4.3	49
346	Effects of lipid lowering therapy on progression of coronary and carotid artery disease. Current Opinion in Lipidology, 1997, 8, 354-361.	1.2	48
347	The LFA-1 Adhesion Molecule Is Required for Protective Immunity during PulmonaryMycobacterium tuberculosisInfection. Journal of Immunology, 2006, 176, 4914-4922.	0.4	48
348	Peroxisome proliferatorâ€“activated receptor Î± genetic variation interacts with nâˆ’6 and long-chain nâˆ’3 fatty acid intake to affect total cholesterol and LDL-cholesterol concentrations in the Atherosclerosis Risk in Communities Study. American Journal of Clinical Nutrition, 2008, 87, 1926-1931.	2.2	48
349	Lipoprotein(a) and Family History Predict Cardiovascular Disease Risk. Journal of the American College of Cardiology, 2020, 76, 781-793.	1.2	48
350	Plateletâ€“monocyte complex formation: effect of blocking PSGL-1 alone, and in combination with Î±IIbÎ²3 and Î±MÎ²2, in coronary stenting. Thrombosis Research, 2003, 111, 171-177.	0.8	47
351	Assessing Risk Prediction Models Using Individual Participant Data From Multiple Studies. American Journal of Epidemiology, 2014, 179, 621-632.	1.6	47
352	Metabolic Factors, Adipose Tissue, and Plasminogen Activator Inhibitor-1 Levels in Type 2 Diabetes. Arteriosclerosis, Thrombosis, and Vascular Biology, 2011, 31, 1689-1695.	1.1	46
353	Ceruloplasmin and Heart Failure in the Atherosclerosis Risk in Communities Study. Circulation: Heart Failure, 2013, 6, 936-943.	1.6	46
354	Natriuretic Peptide and High-Sensitivity Troponin for Cardiovascular Risk Prediction in Diabetes: The Atherosclerosis Risk in Communities (ARIC) Study. Diabetes Care, 2016, 39, 677-685.	4.3	46
355	Endothelial LRP1 regulates metabolic responses by acting as a co-activator of PPARÎ³. Nature Communications, 2017, 8, 14960.	5.8	46
356	Statin prescription rates and their facility-level variation in patients with peripheral artery disease and ischemic cerebrovascular disease: Insights from the Department of Veterans Affairs. Vascular Medicine, 2018, 23, 232-240.	0.8	46
357	Six-Year Changes in Physical Activity and the Risk of Incident Heart Failure. Circulation, 2018, 137, 2142-2151.	1.6	46
358	High-sensitivity cardiac troponin and natriuretic peptide with risk of lower-extremity peripheral artery disease: the Atherosclerosis Risk in Communities (ARIC) Study. European Heart Journal, 2018, 39, 2412-2419.	1.0	46
359	Reduction in Revascularization With Icosapent Ethyl. Circulation, 2021, 143, 33-44.	1.6	46
360	Racial and Geographic Disparities in Internet Use in the U.S. Among Patients With Hypertension or Diabetes: Implications for Telehealth in the Era of COVID-19. Diabetes Care, 2021, 44, e15-e17.	4.3	46

#	Article	IF	Citations
361	Multi-Ethnic Analysis of Lipid-Associated Loci: The NHLBI CARe Project. PLoS ONE, 2012, 7, e36473.	1.1	46
362	Biological Surrogates for Enhancing Cardiovascular Risk Prediction in Type 2 Diabetes Mellitus. American Journal of Cardiology, 2007, 99, 80-88.	0.7	45
363	Genetic determinants of plasma von Willebrand factor antigen levels: a target gene SNP and haplotype analysis of ARIC cohort. Blood, 2011, 117, 5224-5230.	0.6	45
364	Impact of PCSK9 inhibition on coronary atheroma progression: Rationale and design of Global Assessment of Plaque Regression with a PCSK9 Antibody as Measured by Intravascular Ultrasound (GLAGOV). American Heart Journal, 2016, 176, 83-92.	1.2	45
365	Practice-Level Variation inÂStatin Use Among Patients With Diabetes. Journal of the American College of Cardiology, 2016, 68, 1368-1369.	1.2	45
366	P-selectin Thr715Pro polymorphism predicts P-selectin levels but not risk of incident coronary heart disease or ischemic stroke in a cohort of 14595 participants: The Atherosclerosis Risk In Communities Study. Atherosclerosis, 2006, 186, 74-79.	0.4	44
367	Variants in the APOA5 gene region and the response to combination therapy with statins and fenofibric acid in a randomized clinical trial of individuals with mixed dyslipidemia. Atherosclerosis, 2011, 219, 737-742.	0.4	44
368	Frequency and Practice-Level Variation in Inappropriate and Nonrecommended Prasugrel Prescribing. Journal of the American College of Cardiology, 2014, 63, 2876-2877.	1.2	44
369	Lipoprotein(a) levels and risk of cardiovascular disease events in individuals with diabetes mellitus or prediabetes: The Atherosclerosis Risk in Communities study. Atherosclerosis, 2019, 282, 52-56.	0.4	44
370	Nucleotide sequence of the cDNA for murine intercellular adhesion molecul-1 (ICAM-1). Nucleic Acids Research, 1989, 17, 5853-5853.	6.5	43
371	Lipoprotein(a) and apolipoprotein changes after cardiac transplantation. Journal of the American College of Cardiology, 1991, 18, 926-930.	1.2	43
372	Statin use and risks of death or fatal rejection in the Heart Transplant Lipid Registry. American Journal of Cardiology, 2005, 95, 367-372.	0.7	43
373	Candidate genetic analysis of plasma high-density lipoprotein-cholesterol and severity of coronary atherosclerosis. BMC Medical Genetics, 2009, 10, 111.	2.1	43
374	Institutional, provider, and patient correlates of low-density lipoprotein and nonâ€“high-density lipoprotein cholesterol goal attainment according to the Adult Treatment Panel III guidelines. American Heart Journal, 2011, 161, 1140-1146.	1.2	43
375	Impact of statins on progression of atherosclerosis: rationale and design of SATURN (Study of) Tj ETQq1 1 0.784314 rgBT /Overlock 1 Current Medical Research and Opinion, 2011, 27, 1119-1129.	0.9	43
376	Elevated Plasma SPARC Levels Are Associated with Insulin Resistance, Dyslipidemia, and Inflammation in Gestational Diabetes Mellitus. PLoS ONE, 2013, 8, e81615.	1.1	43
377	Plasma Lactate and Incident Hypertension in the Atherosclerosis Risk in Communities Study. American Journal of Hypertension, 2015, 28, 216-224.	1.0	43
378	Statin Use and Its Facilityâ€Level Variation in Patients With Diabetes: Insight From the Veterans Affairs National Database. Clinical Cardiology, 2016, 39, 185-191.	0.7	43

#	Article	IF	Citations
379	Variation in Lipid-Lowering Therapy Use in Patients With Low-Density Lipoprotein Cholesterol â‰¥190 mg/dL. Circulation: Cardiovascular Quality and Outcomes, 2018, 11, e004652.	0.9	43
380	LPL polymorphism predicts stroke risk in men. Genetic Epidemiology, 2002, 22, 233-242.	0.6	42
381	Effects of SREBF-1a and SCAP polymorphisms on plasma levels of lipids, severity, progression and regression of coronary atherosclerosis and response to therapy with fluvastatin. Journal of Molecular Medicine, 2002, 80, 737-744.	1.7	42
382	CD11a Regulates Effector CD8 T Cell Differentiation and Central Memory Development in Response to Infection with Listeria monocytogenes. Infection and Immunity, 2013, 81, 1140-1151.	1.0	42
383	BNP and obesity in acute decompensated heart failure with preserved vs. reduced ejection fraction: The Atherosclerosis Risk in Communities Surveillance Study. International Journal of Cardiology, 2017, 233, 61-66.	0.8	42
384	An NPPB Promoter Polymorphism Associated With Elevated Nâ€Terminal proâ€“Bâ€Type Natriuretic Peptide and Lower Blood Pressure, Hypertension, and Mortality. Journal of the American Heart Association, 2017, 6, .	1.6	42
385	Cardiac Allograft Survival in Mice Deficient in Intercellular Adhesion Moleculeâ€“1. Circulation, 1995, 92, 82-87.	1.6	42
386	Preoperative Statin Therapy Decreases Risk of Postoperative Renal Insufficiency. Cardiovascular Therapeutics, 2010, 28, 80-86.	1.1	41
387	Antiatherosclerotic Effects of Long-Term Maximally Intensive Statin Therapy After Acute Coronary Syndrome. Arteriosclerosis, Thrombosis, and Vascular Biology, 2014, 34, 2465-2472.	1.1	41
388	Galectin-3 and incidence of atrial fibrillation: The Atherosclerosis Risk in Communities (ARIC) study. American Heart Journal, 2017, 192, 19-25.	1.2	41
389	Association of Resting Heart Rate and Temporal Changes in Heart Rate With Outcomes in Participants of the Atherosclerosis Risk in Communities Study. JAMA Cardiology, 2018, 3, 200.	3.0	41
390	Comparative effects of simvastatin and atorvastatin in hypercholesterolemic patients with characteristics of metabolic syndrome. Clinical Therapeutics, 2003, 25, 1670-1686.	1.1	40
391	Association of apolipoprotein A1 and B with kidney function and chronic kidney disease in two multiethnic population samples. Nephrology Dialysis Transplantation, 2012, 27, 2839-2847.	0.4	40
392	Programmable Bio-NanoChip Technology for the Diagnosis of Cardiovascular Disease at the Point of Care. Methodist DeBakey Cardiovascular Journal, 2021, 8, 6.	0.5	40
393	Efficacy, safety and effect on biomarkers related to cholesterol and lipoprotein metabolism of rosuvastatin 10 or 20Âmg plus ezetimibe 10Âmg vs. simvastatin 40 or 80Âmg plus ezetimibe 10Âmg in high-risk patients: Results of the GRAVITY randomized study. Atherosclerosis, 2014, 232, 86-93.	0.4	40
394	Safety and efficacy of mipomersen in patients with heterozygous familial hypercholesterolemia. Atherosclerosis, 2019, 280, 109-117.	0.4	40
395	Gene-Centric Meta-Analysis of Lipid Traits in African, East Asian and Hispanic Populations. PLoS ONE, 2012, 7, e50198.	1.1	40
396	Usefulness of Single Nucleotide Polymorphism in Chromosome 4q25 to Predict In-Hospital and Long-Term Development of Atrial Fibrillation and Survival in Patients Undergoing Coronary Artery Bypass Grafting. American Journal of Cardiology, 2011, 107, 1504-1509.	0.7	39

#	Article	IF	Citations
397	Icosapent ethyl (eicosapentaenoic acid ethyl ester): Effects on remnant-like particle cholesterol from the MARINE and ANCHOR studies. Atherosclerosis, 2016, 253, 81-87.	0.4	39
398	Risk Factor Optimization and Guideline-Directed Medical Therapy in US Veterans With Peripheral Arterial and Ischemic Cerebrovascular Disease Compared to Veterans With Coronary Heart Disease. American Journal of Cardiology, 2016, 118, 1144-1149.	0.7	39
399	Postprandial Monocyte Activation in Individuals With Metabolic Syndrome. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 4195-4204.	1.8	39
400	Associations of Lipoprotein(a) Levels With Incident Atrial Fibrillation and Ischemic Stroke: The ARIC (Atherosclerosis Risk in Communities) Study. Journal of the American Heart Association, 2017, 6, .	1.6	39
401	Bempedoic Acid (ETC-1002). Cardiology Clinics, 2018, 36, 257-264.	0.9	39
402	Preventive Cardiology as a Subspecialty of Cardiovascular Medicine. Journal of the American College of Cardiology, 2019, 74, 1926-1942.	1.2	39
403	Sex Hormones and Incident Heart Failure in Men and Postmenopausal Women: The Atherosclerosis Risk in Communities Study. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e3798-e3807.	1.8	39
404	Icosapent Ethyl Reduces Ischemic Events in Patients With a History of Previous Coronary Artery Bypass Grafting: REDUCE-IT CABG. Circulation, 2021, 144, 1845-1855.	1.6	39
405	Efficacy of rosuvastatin 10 mg in patients with the metabolic syndrome. American Journal of Cardiology, 2003, 91, 25-27.	0.7	38
406	Association of Circulating Matrix Metalloproteinases With Carotid Artery Characteristics. Arteriosclerosis, Thrombosis, and Vascular Biology, 2010, 30, 1034-1042.	1.1	38
407	Relation of cholesterol and lipoprotein parameters with carotid artery plaque characteristics: The Atherosclerosis Risk in Communities (ARIC) carotid MRI study. Atherosclerosis, 2011, 219, 596-602.	0.4	38
408	Novel Risk Factors and the Prediction of Type 2 Diabetes in the Atherosclerosis Risk in Communities (ARIC) Study. Diabetes Care, 2013, 36, 70-76.	4.3	38
409	Soluble receptor for advanced glycation end products and the risk for incident heart failure: The Atherosclerosis Risk in Communities Study. American Heart Journal, 2015, 170, 961-967.	1.2	38
410	Influence of cigarette smoking on cardiac biomarkers: the Atherosclerosis Risk in Communities (<scp>ARIC</scp>) Study. European Journal of Heart Failure, 2016, 18, 629-637.	2.9	38
411	Effects of Icosapent Ethyl (Eicosapentaenoic Acid Ethyl Ester) on Atherogenic Lipid/Lipoprotein, Apolipoprotein, and Inflammatory Parameters in Patients With Elevated High-Sensitivity C-Reactive Protein (from the ANCHOR Study). American Journal of Cardiology, 2019, 124, 696-701.	0.7	38
412	Association Between Circulating Troponin Concentrations, Left Ventricular Systolic and Diastolic Functions, and Incident Heart Failure in Older Adults. JAMA Cardiology, 2019, 4, 997.	3.0	38
413	Association of Cardiac Injury and Malignant Left Ventricular Hypertrophy With Risk of Heart Failure in African Americans. JAMA Cardiology, 2019, 4, 51.	3.0	38
414	Triglycerides and ASCVD Risk Reduction: Recent Insights and Future Directions. Current Atherosclerosis Reports, 2020, 22, 25.	2.0	38

#	Article	IF	Citations
415	Comparison of the efficacy and safety of a combination tablet of niacin extended-release and simvastatin with simvastatin 80 mg monotherapy: the SEACOAST II (high-dose) study. Journal of Clinical Lipidology, 2008, 2, 79-90.	0.6	37
416	High-sensitivity cardiac troponin T and cognitive function and dementia risk: the atherosclerosis risk in communities study. European Heart Journal, 2014, 35, 1817-1824.	1.0	37
417	Effects of icosapent ethyl on lipoprotein particle concentration and size in statin-treated patients with persistent high triglycerides (the ANCHOR Study). Journal of Clinical Lipidology, 2015, 9, 377-383.	0.6	37
418	The association of liver enzymes with biomarkers of subclinical myocardial damage and structural heart disease. Journal of Hepatology, 2015, 62, 841-847.	1.8	37
419	Icosapent ethyl: Eicosapentaenoic acid concentration and triglyceride-lowering effects across clinical studies. Prostaglandins and Other Lipid Mediators, 2016, 125, 57-64.	1.0	37
420	Recreational substance use among patients with premature atherosclerotic cardiovascular disease. Heart, 2021, 107, 650-656.	1.2	37
421	Characterization of the murine Icam-1 gene. Genomics, 1992, 14, 1076-1080.	1.3	36
422	Long-Term, Randomized Clinical Trial of Two Diets in the Metabolic Syndrome and Type 2 Diabetes. Diabetes Care, 2003, 26, 2481-2482.	4.3	36
423	Detection of Undiagnosed Diabetes and Other Hyperglycemia States: The Atherosclerosis Risk in Communities Study. Diabetes Care, 2003, 26, 1338-1343.	4.3	36
424	Combined Association of Creatinine, Albuminuria, and Cystatin C with All-Cause Mortality and Cardiovascular and Kidney Outcomes. Clinical Journal of the American Society of Nephrology: CJASN, 2013, 8, 434-442.	2.2	36
425	The Impact of Rapid Weight Loss on Oxidative Stress Markers and the Expression of the Metabolic Syndrome in Obese Individuals. Journal of Obesity, 2013, 2013, 1-10.	1.1	36
426	Patterns and determinants of temporal change in high-sensitivity cardiac troponin-T: The Atherosclerosis Risk in Communities Cohort Study. International Journal of Cardiology, 2015, 187, 651-657.	0.8	36
427	Benefits of Icosapent Ethyl Across the Range of Kidney Function in Patients With Established Cardiovascular Disease or Diabetes: REDUCE-IT RENAL. Circulation, 2021, 144, 1750-1759.	1.6	36
428	Mendelian randomization supports bidirectional causality between telomere length and clonal hematopoiesis of indeterminate potential. Science Advances, 2022, 8, eabl6579.	4.7	36
429	Prevention of Cardiovascular Events and Mortality With Icosapent Ethyl in Patients With PriorÂMyocardial Infarction. Journal of the American College of Cardiology, 2022, 79, 1660-1671.	1.2	36
430	Existing and emerging strategies to lower Lipoprotein(a). Atherosclerosis, 2022, 349, 110-122.	0.4	36
431	Lipoprotein lipase gene mutations, plasma lipid levels, progression/regression of coronary atherosclerosis, response to therapy, and future clinical events. Atherosclerosis, 1999, 144, 435-442.	0.4	35
432	Prevalence of Metabolic Syndrome and Associated Risk Factors in Asian Indians. Journal of Immigrant and Minority Health, 2008, 10, 313-323.	0.8	35

#	Article	IF	Citations
433	Outcomes of Preoperative Angiotensin-Converting Enzyme Inhibitor Therapy in Patients Undergoing Isolated Coronary Artery Bypass Grafting. American Journal of Cardiology, 2012, 110, 919-923.	0.7	35
434	High-Sensitivity Troponin T and Cardiovascular Events in Systolic Blood Pressure Categories. Hypertension, 2015, 65, 78-84.	1.3	35
435	Icosapent ethyl (eicosapentaenoic acid ethyl ester): Effects on plasma apolipoprotein C-III levels in patients from the MARINE and ANCHOR studies. Journal of Clinical Lipidology, 2016, 10, 635-645.e1.	0.6	35
436	Lipoprotein(a) and coronary atheroma progression rates during long-term high-intensity statin therapy: Insights from SATURN. Atherosclerosis, 2017, 263, 137-144.	0.4	35
437	Association of Circulating Monocyte Chemoattractant Proteinâ€“1 Levels With Cardiovascular Mortality. JAMA Cardiology, 2021, 6, 587.	3.0	35
438	A prospective study of genetic markers of susceptibility to infection and inflammation, and the severity, progression, and regression of coronary atherosclerosis and its response to therapy. Journal of Molecular Medicine, 2000, 78, 562-568.	1.7	34
439	The 9p21 susceptibility locus for coronary artery disease and the severity of coronary atherosclerosis. BMC Cardiovascular Disorders, 2009, 9, 3.	0.7	34
440	Prognostic Significance of High-Sensitivity Cardiac Troponin T Concentrations between the Limit of Blank and Limit of Detection in Community-Dwelling Adults: A Metaanalysis. Clinical Chemistry, 2015, 61, 1524-1531.	1.5	34
441	Access to Nonstatin Lipid-Lowering Therapies in Patients at High Risk of Atherosclerotic Cardiovascular Disease. Circulation, 2017, 135, 2204-2206.	1.6	34
442	Genome-Wide Association Study Evaluating Lipoprotein-Associated Phospholipase A ₂ Mass and Activity at Baseline and After Rosuvastatin Therapy. Circulation: Cardiovascular Genetics, 2012, 5, 676-685.	5.1	33
443	Adiponectin and the mediation of HDL-cholesterol change with improved lifestyle: the Look AHEAD Study. Journal of Lipid Research, 2012, 53, 2726-2733.	2.0	33
444	The Association of Plasma Lactate With Incident Cardiovascular Outcomes. American Journal of Epidemiology, 2013, 178, 401-409.	1.6	33
445	Cardiac ScoreCard: A diagnostic multivariate index assay system for predicting a spectrum of cardiovascular disease. Expert Systems With Applications, 2016, 54, 136-147.	4.4	33
446	Evaluation of Aspirin and Statin Therapy Use and Adherence in Patients With Premature Atherosclerotic Cardiovascular Disease. JAMA Network Open, 2020, 3, e2011051.	2.8	33
447	Age-Stratified Sex Disparities in Care and Outcomes in Patients With ST-Elevation Myocardial Infarction. American Journal of Medicine, 2020, 133, 1293-1301.e1.	0.6	33
448	Racial Differences in Malignant Left Ventricular Hypertrophy and Incidence of Heart Failure. Circulation, 2020, 141, 957-967.	1.6	33
449	Pro-apoptotic low-density lipoprotein subfractions in type II diabetes. Atherosclerosis, 2007, 193, 283-291.	0.4	32
450	Association of plasma levels of soluble receptor for advanced glycation end products and risk of kidney disease: the Atherosclerosis Risk in Communities study. Nephrology Dialysis Transplantation, 2015, 30, 77-83.	0.4	32

#	Article	IF	Citations
451	Comparison of <scp>PCSK9</scp> Inhibitor Evolocumab vs Ezetimibe in Statinâ€Intolerant Patients: Design of the Goal Achievement After Utilizing an Antiâ€<scp>PCSK9</scp> Antibody in Statinâ€Intolerant Subjects 3 (<scp>GAUSS</scp>â€3) Trial. Clinical Cardiology, 2016, 39, 137-144.	0.7	32
452	Comparative effects of cholesteryl ester transfer protein inhibition, statin or ezetimibe on lipid factors: The ACCENTUATE trial. Atherosclerosis, 2017, 261, 12-18.	0.4	32
453	Genome-wide association study of circulating interleukin 6 levels identifies novel loci. Human Molecular Genetics, 2021, 30, 393-409.	1.4	32
454	Long-Term Safety and Efficacy of Bempedoic Acid in Patients With Atherosclerotic Cardiovascular Disease and/or Heterozygous Familial Hypercholesterolemia (from the CLEAR Harmony Open-Label) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5	3.7	32
455	Low-density lipoprotein metabolism in cerebrotendinous xanthomatosis. Metabolism: Clinical and Experimental, 1987, 36, 270-276.	1.5	31
456	Kinetics of CD11b/CD18 Up-Regulation During Infection with the Agent of Human Granulocytic Ehrlichiosis in Mice. Laboratory Investigation, 2002, 82, 303-311.	1.7	31
457	Cardiometabolic risk assessment: An approach to the prevention of cardiovascular disease and diabetes mellitus. Clinical Cornerstone, 2005, 7, 7-16.	1.0	31
458	L5, the most electronegative subfraction of plasma LDL, induces endothelial vascular cell adhesion molecule 1 and CXC chemokines, which mediate mononuclear leukocyte adhesion. Atherosclerosis, 2007, 192, 56-66.	0.4	31
459	Increased Myocardial Susceptibility to Repetitive Ischemia With Highâ€fat dietâ€induced Obesit. Obesity, 2008, 16, 2593-2600.	1.5	31
460	Isolated Coronary Artery Bypass Grafting in Obese Individuals - A Propensity Matched Analysis of Outcomes -. Circulation Journal, 2011, 75, 1378-1385.	0.7	31
461	The Effect of Lipid Modification on Peripheral Artery Disease after Endovascular Intervention Trial (ELIMIT). Atherosclerosis, 2013, 231, 371-377.	0.4	31
462	Elevated High-Sensitivity C-Reactive Protein as a Risk Marker of the Attenuated Relationship Between Serum Cholesterol and Cardiovascular Events at Older Age. American Journal of Epidemiology, 2013, 178, 1076-1084.	1.6	31
463	Large multiethnic Candidate Gene Study for C-reactive protein levels: identification of a novel association at CD36 in African Americans. Human Genetics, 2014, 133, 985-995.	1.8	31
464	The Association of Socioeconomic Status With Subclinical Myocardial Damage, Incident Cardiovascular Events, and Mortality in the ARIC Study. American Journal of Epidemiology, 2016, 183, 452-461.	1.6	31
465	Temporal Trends in E-Cigarette Use Among U.S. Adults: Behavioral Risk Factor Surveillance System, 2016 to 2018. American Journal of Medicine, 2020, 133, e508-e511.	0.6	31
466	Association of NT-ProBNP, Blood Pressure, and Cardiovascular Events. Journal of the American College of Cardiology, 2021, 77, 559-571.	1.2	31
467	Leukocyte CD11b expression is not essential for the development of atherosclerosis in mice. Journal of Lipid Research, 2000, 41, 1060-1066.	2.0	31
468	A proteomic surrogate for cardiovascular outcomes that is sensitive to multiple mechanisms of change in risk. Science Translational Medicine, 2022, 14, eabj9625.	5.8	31

#	Article	IF	Citations
469	Measurement of Cholesterol. Circulation, 2004, 110, e296-7.	1.6	30
470	Effect of niacin ER/lovastatin on claudication symptoms in patients with peripheral artery disease. Vascular Medicine, 2010, 15, 171-179.	0.8	30
471	Safety of extended-release niacin/laropiprant in patients with dyslipidemia. Journal of Clinical Lipidology, 2010, 4, 105-112.e1.	0.6	30
472	Barriers to Non-HDL Cholesterol Goal Attainment by Providers. American Journal of Medicine, 2011, 124, 876-880.e2.	0.6	30
473	Differential effect of weight loss with low-fat diet or high-fat diet restriction on inflammation in the liver and adipose tissue of mice with diet-induced obesity. Atherosclerosis, 2011, 219, 100-108.	0.4	30
474	Relation of Lipid Gene Scores to Longitudinal Trends in Lipid Levels and Incidence of Abnormal Lipid Levels Among Individuals of European Ancestry. Circulation: Cardiovascular Genetics, 2012, 5, 73-80.	5.1	30
475	Do Genetic Modifiers of High-Density Lipoprotein Cholesterol and Triglyceride Levels Also Modify Their Response to a Lifestyle Intervention in the Setting of Obesity and Type-2 Diabetes Mellitus?. Circulation: Cardiovascular Genetics, 2013, 6, 391-399.	5.1	30
476	Dual Role of the Leukocyte Integrin Î±MÎ²2in Angiogenesis. Journal of Immunology, 2014, 193, 4712-4721.	0.4	30
477	N-Terminal Pro-Brain Natriuretic Peptide (NT-proBNP) and Risk of Hypertension in the Atherosclerosis Risk in Communities (ARIC) Study. American Journal of Hypertension, 2015, 28, 1262-1266.	1.0	30
478	Development of Chagas Cardiac Manifestations Among Texas Blood Donors. American Journal of Cardiology, 2015, 115, 113-117.	0.7	30
479	Health Care Resource Utilization for Outpatient Cardiovascular Disease and Diabetes Care Delivery Among Advanced Practice Providers and Physician Providers in Primary Care. Population Health Management, 2018, 21, 209-216.	0.8	30
480	A colitogenic memory CD4+ T cell population mediates gastrointestinal graft-versus-host disease. Journal of Clinical Investigation, 2016, 126, 3541-3555.	3.9	30
481	Use of Denaturing HPLC to Provide Efficient Detection of Mutations Causing Familial Hypercholesterolemia. Clinical Chemistry, 2002, 48, 1913-1918.	1.5	29
482	Association of Lactate With Blood Pressure Before and After Rapid Weight Loss. American Journal of Hypertension, 2008, 21, 1337-1342.	1.0	29
483	Association of the Complement Factor H Y402H Polymorphism With Cardiovascular Disease Is Dependent Upon Hypertension Status: The ARIC Study. American Journal of Hypertension, 2008, 21, 533-538.	1.0	29
484	What's the deal with niacin development: is laropiprant add-on therapy a winning strategy to beat a straight flush?. Current Opinion in Lipidology, 2009, 20, 467-476.	1.2	29
485	The association of lipoprotein(a) with incident heart failure hospitalization: Atherosclerosis Risk in Communities study. Atherosclerosis, 2017, 262, 131-137.	0.4	29
486	Lipoprotein(a) and ethnicities. Atherosclerosis, 2022, 349, 42-52.	0.4	29

#	Article	IF	Citations
487	Extended-Release Niacin/Laropiprant: Reducing Niacin-Induced Flushing to Better Realize the Benefit of Niacin in Improving Cardiovascular Risk Factors. Cardiology Clinics, 2008, 26, 547-560.	0.9	28
488	Transcription Factor 7-Like 2 (TCF7L2) Polymorphism and Context-Specific Risk of Type 2 Diabetes in African American and Caucasian Adults: The Atherosclerosis Risk in Communities Study. Diabetes, 2009, 58, 285-289.	0.3	28
489	Meta-analysis of genome-wide association studies of HDL cholesterol response to statins. Journal of Medical Genetics, 2016, 53, 835-845.	1.5	28
490	Determinants of minimal elevation in high-sensitivity cardiac troponin T in the general population. Clinical Biochemistry, 2016, 49, 657-662.	0.8	28
491	Efficacy and safety of rosuvastatin alone and in combination with cholestyramine in patients with severe hypercholesterolemia: A randomized, open-label, multicenter trial. Clinical Therapeutics, 2004, 26, 1855-1864.	1.1	27
492	Segmental Analysis of Carotid Arterial Strain Using Speckle-Tracking. Journal of the American Society of Echocardiography, 2011, 24, 1276-1284.e5.	1.2	27
493	Fibrosis and Inflammatory Markers and Long-Term Risk of Peripheral Artery Disease. Arteriosclerosis, Thrombosis, and Vascular Biology, 2020, 40, 2322-2331.	1.1	27
494	Polygenic Risk Scores for Kidney Function and Their Associations with Circulating Proteome, and Incident Kidney Diseases. Journal of the American Society of Nephrology: JASN, 2021, 32, 3161-3173.	3.0	27
495	Increased prevalence of clonal hematopoiesis of indeterminate potential amongst people living with HIV. Scientific Reports, 2022, 12, 577.	1.6	27
496	Efficacy and safety of an extended-release formulation of fluvastatin for once-daily treatment of primary hypercholesterolemia. American Journal of Cardiology, 2000, 86, 759-763.	0.7	26
497	Long-Term Efficacy and Safety of Rosuvastatin 40 mg in Patients With Severe Hypercholesterolemia. American Journal of Cardiology, 2007, 100, 1387-1396.	0.7	26
498	Automatic quantification of muscle volumes in magnetic resonance imaging scans of the lower extremities. Magnetic Resonance Imaging, 2011, 29, 1065-1075.	1.0	26
499	Serum vitamin D and change in lipid levels over 5Ây: The Atherosclerosis Risk in Communities study. Nutrition, 2017, 38, 85-93.	1.1	26
500	Association of Neutrophils With Platelet Aggregates in Unstable Angina. Circulation, 1996, 94, 1206-1208.	1.6	26
501	Treatment With Icosapent Ethyl to Reduce Ischemic Events in Patients With Prior Percutaneous Coronary Intervention: Insights From REDUCEâ€IT PCI. Journal of the American Heart Association, 2022, 11, e022937.	1.6	26
502	Strategies for implementing lipid-lowering therapy: pharmacy-based approach. American Journal of Cardiology, 2000, 85, 30-35.	0.7	25
503	ACCF/AHA/ACP 2009 Competence and Training Statement: A Curriculum on Prevention of Cardiovascular Disease. Circulation, 2009, 120, e100-26.	1.6	25
504	Improving Adiponectin Levels in Individuals With Diabetes and Obesity: Insights From Look AHEAD. Diabetes Care, 2015, 38, 1544-1550.	4.3	25

#	Article	IF	Citations
505	Galectinâ€3 and Risk of Heart Failure and Death in Blacks and Whites. Journal of the American Heart Association, 2016, 5, .	1.6	25
506	High-Sensitivity Cardiac Troponin T (hs-cTnT) as a Predictor of Incident Diabetes in the Atherosclerosis Risk in Communities Study. Diabetes Care, 2017, 40, 261-269.	4.3	25
507	The use of structured data elements to identify ASCVD patients with statin-associated side effects: Insights from the Department of Veterans Affairs. Journal of Clinical Lipidology, 2019, 13, 797-803.e1.	0.6	25
508	Performance of High-Sensitivity Cardiac Troponin Assays to Reflect Comorbidity Burden and Improve Mortality Risk Stratification in Older Adults With Diabetes. Diabetes Care, 2020, 43, 1200-1208.	4.3	25
509	Comparative Reductions in Investigator-Reported and Adjudicated Ischemic Events in REDUCE-IT. Journal of the American College of Cardiology, 2021, 78, 1525-1537.	1.2	25
510	Marine Ï‰-3 Fatty Acid Intake. Diabetes Care, 2010, 33, 197-199.	4.3	24
511	Chromosome 9p21 Single Nucleotide Polymorphisms Are Not Associated With Recurrent Myocardial Infarction in Patients With Established Coronary Artery Disease. Circulation Journal, 2012, 76, 950-956.	0.7	24
512	Developing and assessing cardiovascular biomarkers. Translational Research, 2012, 159, 265-276.	2.2	24
513	Alteration of Relation of Atherogenic Lipoprotein Cholesterol to Apolipoprotein B by Intensive Statin Therapy in Patients With Acute Coronary Syndrome (from the Limiting UNdertreatment of lipids in ACS) Tj ETQq1 1 0.784314 rgBT /Ove	0.7	24
514	Association of Genome-Wide Variation With Highly Sensitive Cardiac Troponin-T Levels in European Americans and Blacks. Circulation: Cardiovascular Genetics, 2013, 6, 82-88.	5.1	24
515	APOEModulates the Correlation Between Triglycerides, Cholesterol, and CHD Through Pleiotropy, and Gene-by-Gene Interactions. Genetics, 2013, 195, 1397-1405.	1.2	24
516	Systolic and pulse pressure associate with incident knee osteoarthritis: data from the Osteoarthritis Initiative. Clinical Rheumatology, 2017, 36, 2121-2128.	1.0	24
517	Lipoprotein(a) and abdominal aortic aneurysm risk: The Atherosclerosis Risk in Communities study. Atherosclerosis, 2018, 268, 63-67.	0.4	24
518	Associations of High-Sensitivity Troponin and Natriuretic Peptide Levels With Outcomes After Intensive Blood Pressure Lowering. JAMA Cardiology, 2021, 6, 1397.	3.0	24
519	Rare coding variants in 35 genes associate with circulating lipid levelsâ€”A multi-ancestry analysis of 170,000 exomes. American Journal of Human Genetics, 2022, 109, 81-96.	2.6	24
520	Current thinking in lipid lowering. American Journal of Medicine, 1998, 104, 33S-41S.	0.6	23
521	Fluvastatin. Drugs, 2004, 64, 1305-1323.	4.9	23
522	Does Preoperative Statin Therapy Improve Outcomes in Patients Undergoing Isolated Cardiac Valve Surgery?. American Journal of Cardiology, 2008, 102, 1235-1239.	0.7	23

#	Article	IF	Citations
523	A case report of myopathy from consumption of red yeast rice. Journal of Clinical Lipidology, 2008, 2, 60-62.	0.6	23
524	ApoE and the role of very low density lipoproteins in adipose tissue inflammation. Atherosclerosis, 2012, 223, 342-349.	0.4	23
525	Low-Density Lipoprotein Electronegativity Is a Novel Cardiometabolic Risk Factor. PLoS ONE, 2014, 9, e107340.	1.1	23
526	Ticagrelor Use in Acute Myocardial Infarction: Insights From the National Cardiovascular Data Registry. Journal of the American Heart Association, 2018, 7, .	1.6	23
527	Zero Coronary Artery Calcium Score. Circulation, 2020, 142, 917-919.	1.6	23
528	REDUCE-IT INTERIM: accumulation of data across prespecified interim analyses to final results. European Heart Journal - Cardiovascular Pharmacotherapy, 2021, 7, e61-e63.	1.4	23
529	Sex-Related Disparities in Cardiovascular Health Care Among Patients With Premature Atherosclerotic Cardiovascular Disease. JAMA Cardiology, 2021, 6, 782.	3.0	23
530	Proteins Associated with Risk of Kidney Function Decline in the General Population. Journal of the American Society of Nephrology: JASN, 2021, 32, 2291-2302.	3.0	23
531	DCRM Multispecialty Practice Recommendations for the management of diabetes, cardiorenal, and metabolic diseases. Journal of Diabetes and Its Complications, 2022, 36, 108101.	1.2	23
532	Sex and Race Differences in N-Terminal Proâ€“B-type Natriuretic Peptide Concentration and Absolute Risk of Heart Failure in the Community. JAMA Cardiology, 2022, 7, 623.	3.0	23
533	Statins after cardiac transplantation: which statin, what dose, and how low should we go?. Journal of Heart and Lung Transplantation, 2000, 19, 515-517.	0.3	22
534	PLACâ„¢ test for identification of individuals at increased risk for coronary heart disease. Expert Review of Molecular Diagnostics, 2005, 5, 9-14.	1.5	22
535	Effect of ezetimibe/simvastatin versus atorvastatin or rosuvastatin on modifying lipid profiles in patients with diabetes, metabolic syndrome, or neither: Results of two subgroup analyses. Journal of Clinical Lipidology, 2008, 2, 91-105.	0.6	22
536	Screening for kidney disease in vascular patients: SCreening for Occult REnal Disease (SCORED) experience. Nephrology Dialysis Transplantation, 2009, 24, 2452-2457.	0.4	22
537	Baseline Lipoprotein Lipids and Low-Density Lipoprotein Cholesterol Response to Prescription Omega-3 Acid Ethyl Ester Added to Simvastatin Therapy. American Journal of Cardiology, 2010, 105, 1409-1412.	0.7	22
538	Achievement of specified low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol apolipoprotein B, and high-sensitivity C-reactive protein levels with ezetimibe/simvastatin or atorvastatin in metabolic syndrome patients with and without atherosclerotic vascular disease (from the VYMET study). Journal of Clinical Lipidology, 2011, 5, 474-482.	0.6	22
539	Lipoproteinâ€associated phospholipase A2, homocysteine, and Alzheimer's disease. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2015, 1, 464-471.	1.2	22
540	sRAGE, inflammation, and risk of atrial fibrillation: results from the Atherosclerosis Risk in Communities (ARIC) Study. Journal of Diabetes and Its Complications, 2015, 29, 180-185.	1.2	22

#	Article	IF	Citations
541	Eligibility for Statin Therapy According to New Cholesterol Guidelines and Prevalent Use of Medication to Lower Lipid Levels in an Older US Cohort. JAMA Internal Medicine, 2015, 175, 138.	2.6	22
542	Association of Chromosome 9p21 With Subsequent Coronary Heart Disease Events. Circulation Genomic and Precision Medicine, 2019, 12, e002471.	1.6	22
543	Autoimmune Rheumatic Diseases and Premature Atherosclerotic Cardiovascular Disease: An Analysis From the VITAL Registry. American Journal of Medicine, 2020, 133, 1424-1432.e1.	0.6	22
544	High Burden of Subclinical and Cardiovascular Disease Risk in Adults With Metabolically Healthy Obesity: The Atherosclerosis Risk in Communities (ARIC) Study. Diabetes Care, 2021, 44, 1657-1663.	4.3	22
545	Assignment of the gene for intercellular adhesion molecule-1 (Icam-1) to proximal mouse chromosome 9. Genomics, 1991, 9, 547-550.	1.3	21
546	Peripheral Arterial Occlusive Disease: Magnetic Resonance Imaging and the Role of Aggressive Medical Management. World Journal of Surgery, 2007, 31, 695-704.	0.8	21
547	APOE/C1/C4/C2 hepatic control region polymorphism influences plasma apoE and LDL cholesterol levels. Human Molecular Genetics, 2008, 17, 2039-2046.	1.4	21
548	Carotid Atherosclerosis Progression in Familial Hypercholesterolemia Patients. Circulation: Cardiovascular Imaging, 2010, 3, 398-404.	1.3	21
549	A novel mutation in the ABCA1 gene causing an atypical phenotype of Tangier disease. Journal of Clinical Lipidology, 2013, 7, 82-87.	0.6	21
550	Intensive Lifestyle Modification Reduces Lp-PLA2 in Dyslipidemic HIV/HAART Patients. Medicine and Science in Sports and Exercise, 2013, 45, 1043-1050.	0.2	21
551	Comparative associations of diabetes risk factors with five measures of hyperglycemia. BMJ Open Diabetes Research and Care, 2014, 2, e000002.	1.2	21
552	Icosapent Ethyl (Eicosapentaenoic Acid Ethyl Ester): Effects Upon High-Sensitivity C-Reactive Protein and Lipid Parameters in Patients With Metabolic Syndrome. Metabolic Syndrome and Related Disorders, 2015, 13, 239-247.	0.5	21
553	Very High-Risk ASCVD and Eligibility for Nonstatin Therapies Based on the 2018ÂAHA/ACC Cholesterol Guidelines. Journal of the American College of Cardiology, 2019, 74, 712-714.	1.2	21
554	Dalcetrapib Reduces Risk of New-Onset Diabetes in Patients With Coronary Heart Disease. Diabetes Care, 2020, 43, 1077-1084.	4.3	21
555	Determinants of Incident Atherosclerotic Cardiovascular Disease Events Among Those With Absent Coronary Artery Calcium: Multi-Ethnic Study of Atherosclerosis. Circulation, 2022, 145, 259-267.	1.6	21
556	Statins and inflammatory markers. Current Atherosclerosis Reports, 2002, 4, 42-47.	2.0	20
557	Role of nonâ€“high-density lipoprotein cholesterol in prevention of cardiovascular disease: updated evidence from clinical trials. Current Opinion in Cardiology, 2003, 18, 503-509.	0.8	20
558	Peripheral artery disease, biomarkers, and darapladib. American Heart Journal, 2011, 161, 972-978.	1.2	20

#	Article	IF	Citations
559	CD11c Controls Herpes Simplex Virus 1 Responses To Limit Virus Replication during Primary Infection. Journal of Virology, 2011, 85, 9945-9955.	1.5	20
560	Neck Circumference Is Not Associated With Subclinical Atherosclerosis in Retired National Football League Players. Clinical Cardiology, 2014, 37, 402-407.	0.7	20
561	Physical Activity, Obesity, and SubclinicalÂMyocardial Damage. JACC: Heart Failure, 2017, 5, 377-384.	1.9	20
562	Traditional and nontraditional glycemic markers and risk of peripheral artery disease: The Atherosclerosis Risk in Communities (ARIC) study. Atherosclerosis, 2018, 274, 86-93.	0.4	20
563	Replacing Saturated Fat With Unsaturated Fat in Western Diet Reduces Foamy Monocytes and Atherosclerosis in Male Ldlr ^{â€"/â€"} Mice. Arteriosclerosis, Thrombosis, and Vascular Biology, 2020, 40, 72-85.	1.1	20
564	Associations Between Carotid Artery Plaque Burden, Plaque Characteristics, and Cardiovascular Events. JAMA Cardiology, 2021, 6, 79-86.	3.0	20
565	Efficacy and safety of bempedoic acid in patients not receiving statins in phase 3 clinical trials. Journal of Clinical Lipidology, 2022, 16, 286-297.	0.6	20
566	Roles of neutrophil Î²2 integrins in kinetics of bacteremia, extravasation, and tick acquisition of Anaplasma phagocytophila in mice. Blood, 2003, 101, 3257-3264.	0.6	19
567	Variability and persistence of aspirin response in lower extremity peripheral arterial disease patients. Journal of Vascular Surgery, 2011, 53, 668-675.	0.6	19
568	Effect of the Cannabinoid Receptorâ€1 Antagonist Rimonabant on Inflammation in Mice With Dietâ€Induced Obesity. Obesity, 2011, 19, 505-513.	1.5	19
569	Association between traditional cholesterol parameters, lipoprotein particle concentration, novel biomarkers and carotid plaques in retired National Football League players. Atherosclerosis, 2012, 222, 551-556.	0.4	19
570	Changes in prescription patterns before and after reporting of the Ezetimibe and Simvastatin in Hypercholesterolemia Enhances Atherosclerosis Regression trial (ENHANCE) results and expected effectsÂon low-density lipoprotein-cholesterol reduction. Journal of Clinical Lipidology, 2012, 6, 180-191.	0.6	19
571	The effect of various intensities of physical activity and chronic inflammation in men and women by diabetes status in a national sample. Diabetes Research and Clinical Practice, 2012, 97, e6-e8.	1.1	19
572	Lifestyle Modification with Diet and Exercise in Obese Patients with Heart Failure â€" A Pilot Study. Journal of Obesity & Weight Loss Therapy, 2012, 02, 1-8.	0.1	19
573	Modest diet-induced weight loss reduces macrophage cholesterol efflux to plasma of patients with metabolic syndrome. Journal of Clinical Lipidology, 2013, 7, 661-670.	0.6	19
574	Myocardial Injury, Obesity, and the Obesity Paradox. JACC: Heart Failure, 2017, 5, 56-63.	1.9	19
575	Assessing Cardiovascular Risk and Testing in Type 2 Diabetes. Current Cardiology Reports, 2017, 19, 19.	1.3	19
576	PCSK9 inhibitors and foamy monocytes in familial hypercholesterolaemia. Nature Reviews Cardiology, 2017, 14, 385-386.	6.1	19

#	Article	IF	Citations
577	Efficacy and Safety of Alirocumab in High-Risk Patients With Clinical Atherosclerotic Cardiovascular Disease and/or Heterozygous Familial Hypercholesterolemia (from 5 Placebo-Controlled ODYSSEY) Tj ETQq1 1 0.784314 rgBT /Overlo		
578	Facility-Level Variations in Kidney Disease Care among Veterans with Diabetes and CKD. Clinical Journal of the American Society of Nephrology: CJASN, 2018, 13, 1842-1850.	2.2	19
579	ApoB, small-dense LDL-C, Lp(a), LpPLA ₂ activity, and cognitive change. Neurology, 2019, 92, e2580-e2593.	1.5	19
580	Dietary and Pharmacological Fatty Acids and Cardiovascular Health. Journal of Clinical Endocrinology and Metabolism, 2020, 105, 1030-1045.	1.8	19
581	Plasma Dehydroepiandrosterone Sulfate and Cardiovascular Disease Risk in Older Men and Women. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e4304-e4327.	1.8	19
582	Growth Differentiation Factor (GDF)-15 and Cardiometabolic Outcomes among Older Adults: The Atherosclerosis Risk in Communities Study. Clinical Chemistry, 2021, 67, 653-661.	1.5	19
583	Conventional and Novel Lipid Measures and Risk of Peripheral Artery Disease. Arteriosclerosis, Thrombosis, and Vascular Biology, 2021, 41, 1229-1238.	1.1	19
584	Lipoprotein(a) and Subclinical Vascular and Valvular Calcification on Cardiac Computed Tomography: The Atherosclerosis Risk in Communities Study. Journal of the American Heart Association, 2022, 11, .	1.6	19
585	Treatment of hyperlipidemia after heart transplantation and rationale for the heart transplant lipid registry. American Journal of Cardiology, 1996, 78, 532-535.	0.7	18
586	Cardiovascular risk factors associated with immunosuppression in renal transplantation. Transplantation Reviews, 2002, 16, 1-21.	1.2	18
587	Cardiovascular implications of HIV-associated dyslipidemic lipodystrophy. Current Atherosclerosis Reports, 2004, 6, 173-179.	2.0	18
588	Heart positive: Design of a randomized controlled clinical trial of intensive lifestyle intervention, niacin and fenofibrate for HIV lipodystrophy/dyslipidemia. Contemporary Clinical Trials, 2006, 27, 518-530.	0.8	18
589	Effectiveness and Tolerability of Adding Ezetimibe to Niacin-Based Regimens for Treatment of Primary Hyperlipidemia. Endocrine Practice, 2006, 12, 159-164.	1.1	18
590	Developmental Control of Integrin Expression Regulates Th2 Effector Homing. Journal of Immunology, 2008, 180, 4656-4667.	0.4	18
591	Intercellular Adhesion Molecule-1 G241R Polymorphism Predicts Risk of Incident Ischemic Stroke. Stroke, 2010, 41, 1038-1040.	1.0	18
592	Correlates of Repeat Lipid Testing in Patients With Coronary Heart Disease. JAMA Internal Medicine, 2013, 173, 1439.	2.6	18
593	Apolipoproteins do not add prognostic information beyond lipoprotein cholesterol measures among individuals with obesity and insulin resistance syndromes: the ARIC study. European Journal of Preventive Cardiology, 2014, 21, 866-875.	0.8	18
594	Revascularization improves mortality in elderly patients with acute myocardial infarction complicated by cardiogenic shock. International Journal of Cardiology, 2014, 172, 239-241.	0.8	18

#	Article	IF	Citations
595	Plasma Galectin-3 and Sonographic Measures of Carotid Atherosclerosis in the Atherosclerosis Risk in Communities Study. Angiology, 2019, 70, 47-55.	0.8	18
596	Getting to an ImprOved Understanding of Low-Density Lipoprotein-Cholesterol and Dyslipidemia Management (GOULD): Methods and baseline data of a registry of high cardiovascular risk patients in the United States. American Heart Journal, 2020, 219, 70-77.	1.2	18
597	E-cigarette Use and Risk Behaviors among Lesbian, Gay, Bisexual, and Transgender Adults: The Behavioral Risk Factor Surveillance System (BRFSS) Survey. Kansas Journal of Medicine, 2020, 13, 318-321.	0.1	18
598	Obesity: an independent predictor of in-hospital postoperative renal insufficiency among patients undergoing cardiac surgery?. Texas Heart Institute Journal, 2009, 36, 540-5.	0.1	18
599	Baseline characteristics of subjects in the lipoprotein and coronary atherosclerosis study (LCAS) with fluvastatin. American Journal of Cardiology, 1994, 73, D42-D49.	0.7	17
600	Pathophysiology and treatment of lipid perturbation after cardiac transplantation. Current Opinion in Cardiology, 1997, 12, 153-160.	0.8	17
601	Host Resistance of CD18 Knockout Mice against Systemic Infection with Listeria monocytogenes. Infection and Immunity, 2003, 71, 5986-5993.	1.0	17
602	Extra domain A and type III connecting segment of fibronectin in assembly and cleavage. Biochemical and Biophysical Research Communications, 2005, 338, 1640-1647.	1.0	17
603	Low-density lipoprotein and high-density lipoprotein cholesterol levels in relation to genetic polymorphisms and menopausal status: The Atherosclerosis Risk in Communities (ARIC) Study. Atherosclerosis, 2008, 200, 322-328.	0.4	17
604	Association between statins and infections after coronary artery bypass grafting. International Journal of Cardiology, 2013, 168, 117-120.	0.8	17
605	Retinol binding protein 4 and incident diabetes â€“ the Atherosclerosis Risk in Communities Study (ARIC) Tj ETQq1 1 0.784314 rgBT	0.3	17
606	Three-year variability in plasma concentrations of the soluble receptor for advanced glycation end products (sRAGE). Clinical Biochemistry, 2014, 47, 132-134.	0.8	17
607	Case-based educational intervention to assess change in providers' knowledge and attitudes towards the 2013 American College of Cardiology/American Heart Association Cholesterol Management Guideline. Atherosclerosis, 2016, 246, 115-120.	0.4	17
608	Association between high-sensitivity troponin T and cardiovascular risk in individuals with and without metabolic syndrome: The ARIC study. European Journal of Preventive Cardiology, 2017, 24, 628-638.	0.8	17
609	Prospective Study of Endogenous Hormones and Incidence of Venous Thromboembolism: The Atherosclerosis Risk in Communities Study. Thrombosis and Haemostasis, 2018, 118, 1940-1950.	1.8	17
610	Subsequent Event Risk in Individuals With Established Coronary Heart Disease. Circulation Genomic and Precision Medicine, 2019, 12, e002470.	1.6	17
611	Eligibility and Cost for Icosapent Ethyl Based on the REDUCE-IT Trial. Circulation, 2019, 139, 1341-1343.	1.6	17
612	Chromosome Xq23 is associated with lower atherogenic lipid concentrations and favorable cardiometabolic indices. Nature Communications, 2021, 12, 2182.	5.8	17

#	Article	IF	Citations
613	Cardiac Structure and Function Across the Spectrum of Aldosteronism: the Atherosclerosis Risk in Communities Study. Hypertension, 2022, 79, 1984-1993.	1.3	17
614	Hydrogen peroxide induces LFA-1-dependent neutrophil adherence to cardiac myocytes. American Journal of Physiology - Heart and Circulatory Physiology, 2000, 278, H835-H842.	1.5	16
615	Relationship between low-density lipoprotein subclasses and asymptomatic atherosclerosis in subjects from the atherosclerosis risk in communities (ARIC) Study. Biomarkers, 2004, 9, 190-202.	0.9	16
616	Lipoprotein-associated phospholipase A2: Pathogenic mechanisms and clinical utility for predicting cardiovascular events. Current Atherosclerosis Reports, 2006, 8, 374-381.	2.0	16
617	Treatment of Dyslipidemia to Reduce Cardiovascular Risk in Patients with Multiple Risk Factors. Clinical Cornerstone, 2007, 8, S6-S13.	1.0	16
618	â€œRisky Businessâ€• Circulation, 2009, 119, 362-364.	1.6	16
619	Ultrasound in Cardiovascular Risk Prediction: Don't Forget the Plaque!. Journal of the American Heart Association, 2013, 2, e000180.	1.6	16
620	Icosapent ethyl for the treatment of hypertriglyceridemia. Expert Opinion on Pharmacotherapy, 2013, 14, 1409-1416.	0.9	16
621	Troponin T, NT-proBNP, and venous thromboembolism: The Longitudinal Investigation of Thromboembolism Etiology (LITE). Vascular Medicine, 2014, 19, 33-41.	0.8	16
622	Validated context-dependent associations of coronary heart disease risk with genotype variation in the chromosome 9p21 region: the Atherosclerosis Risk in Communities study. Human Genetics, 2014, 133, 1105-1116.	1.8	16
623	Association of High-Sensitivity Cardiac Troponin T and Natriuretic Peptide With Incident ESRD: The Atherosclerosis Risk in Communities (ARIC) Study. American Journal of Kidney Diseases, 2015, 65, 550-558.	2.1	16
624	Lipoprotein associated phospholipase A2 activity, apolipoprotein C3 loss-of-function variants and cardiovascular disease: The Atherosclerosis Risk In Communities Study. Atherosclerosis, 2015, 241, 641-648.	0.4	16
625	Familial Hypercholesterolemia and the 2013 American College of Cardiology/American Heart Association Guidelines: Myths, Oversimplification, and Misinterpretation Versus Facts. American Journal of Cardiology, 2015, 116, 481-484.	0.7	16
626	Alcohol Consumption and Cardiac Biomarkers: The Atherosclerosis Risk in Communities (ARIC) Study. Clinical Chemistry, 2016, 62, 1202-1210.	1.5	16
627	Postprandial lipemia and the risk of coronary heart disease and stroke: the Atherosclerosis Risk in Communities (ARIC) Study. BMJ Open Diabetes Research and Care, 2017, 5, e000335.	1.2	16
628	Weight History and Subclinical Myocardial Damage. Clinical Chemistry, 2018, 64, 201-209.	1.5	16
629	Discovery, fine-mapping, and conditional analyses of genetic variants associated with C-reactive protein in multiethnic populations using the Metabochip in the Population Architecture using Genomics and Epidemiology (PAGE) study. Human Molecular Genetics, 2018, 27, 2940-2953.	1.4	16
630	Association Between Lipid Testing and Statin Adherence in the Veterans Affairs Health System. American Journal of Medicine, 2019, 132, e693-e700.	0.6	16

#	Article	IF	Citations
631	Central and peripheral pulse wave velocity and subclinical myocardial stress and damage in older adults. PLoS ONE, 2019, 14, e0212892.	1.1	16
632	Statin Prescription Rates, Adherence, and Associated Clinical Outcomes Among Women with PAD and ICVD. Cardiovascular Drugs and Therapy, 2020, 34, 745-754.	1.3	16
633	Endothelium-specific depletion of LRP1 improves glucose homeostasis through inducing osteocalcin. Nature Communications, 2021, 12, 5296.	5.8	16
634	Association of Body Mass Index and Waist Circumference with Subclinical Atherosclerosis in Retired NFL Players. Southern Medical Journal, 2014, 107, 633-639.	0.3	16
635	PCSK9-targeted therapies: present and future approaches. Nature Reviews Cardiology, 2021, 18, 805-806.	6.1	16
636	Rationale for Targeting Multiple Lipid Pathways for Optimal Cardiovascular Risk Reduction. American Journal of Cardiology, 2005, 96, 14-19.	0.7	15
637	Long-Term Efficacy of Adding Fenofibric Acid to Moderate-Dose Statin Therapy in Patients with Persistent Elevated Triglycerides. Cardiovascular Drugs and Therapy, 2011, 25, 59-67.	1.3	15
638	Effect of Two Intensive Statin Regimens on Progression of Coronary Disease. Survey of Anesthesiology, 2012, 56, 141-142.	0.1	15
639	Age, abdominal obesity, and baseline high-sensitivity C-reactive protein are associated with low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B responses to ezetimibe/simvastatin and atorvastatin in patients with metabolic syndrome. Journal of Clinical Lipidology, 2013, 7, 292-303.	0.6	15
640	Application of Speckle-Tracking in the Evaluation of Carotid Artery Function in Subjects with Hypertension and Diabetes. Journal of the American Society of Echocardiography, 2013, 26, 901-909.e1.	1.2	15
641	On-treatment analysis of the Improved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE-IT). American Heart Journal, 2016, 182, 89-96.	1.2	15
642	Severe Hypoglycemia and Elevated High-Sensitivity Cardiac Troponin T in Older Adults With Diabetes. Journal of the American College of Cardiology, 2016, 68, 1370-1371.	1.2	15
643	Biomarkers and degree of atherosclerosis are independently associated with incident atherosclerotic cardiovascular disease in a primary prevention cohort: The ARIC study. Atherosclerosis, 2016, 253, 156-163.	0.4	15
644	Galectinâ€3 and venous thromboembolism incidence: the Atherosclerosis Risk in Communities (ARIC) Study. Research and Practice in Thrombosis and Haemostasis, 2017, 1, 223-230.	1.0	15
645	Relation of Isolated Systolic Hypertension and Pulse Pressure to High-Sensitivity Cardiac Troponin-T and N-Terminal pro-B-Type Natriuretic Peptide in Older Adults (from the Atherosclerosis Risk in) Tj ETQq1 1 0.784314 rgBT /Overlock 10	1.7	15
646	Molecular Signature of Multisystem Cardiometabolic Stress and Its Association With Prognosis. JAMA Cardiology, 2020, 5, 1144.	3.0	15
647	Levels and Change in Galectinâ€3 and Association With Cardiovascular Events: The ARIC Study. Journal of the American Heart Association, 2020, 9, e015405.	1.6	15
648	Triglyceride-rich lipoproteins, apolipoprotein C-III, angiopoietin-like protein 3, and cardiovascular events in older adults: Atherosclerosis Risk in Communities (ARIC) study. European Journal of Preventive Cardiology, 2022, 29, e53-e64.	0.8	15

#	Article	IF	Citations
649	Upper Reference Limits for High-Sensitivity Cardiac Troponin T and N-Terminal Fragment of the Prohormone Brain Natriuretic Peptide in Patients With CKD. American Journal of Kidney Diseases, 2022, 79, 383-392.	2.1	15
650	Diabetes Medication Use and Blood Lactate Level among Participants with Type 2 Diabetes: The Atherosclerosis Risk in Communities Carotid MRI Study. PLoS ONE, 2012, 7, e51237.	1.1	15
651	Effect of olezarsen targeting APOC-III on lipoprotein size and particle number measured by NMR in patients with hypertriglyceridemia. Journal of Clinical Lipidology, 2022, 16, 617-625.	0.6	15
652	Achieving greater reductions in cardiovascular risk: lessons from statin therapy on risk measures and risk reduction. American Heart Journal, 2004, 148, S3-S8.	1.2	14
653	Role of Biomarkers in Developing New Therapies for Vascular Disease. World Journal of Surgery, 2007, 31, 676-681.	0.8	14
654	Insights from recent meta-analysis: Role of high-density lipoprotein cholesterol in reducing cardiovascular events and rates of atherosclerotic disease progression. Journal of Clinical Lipidology, 2010, 4, 365-370.	0.6	14
655	Interaction between SNPs in the RXRA and near ANGPTL3 gene region inhibits apoB reduction after statin-fenofibric acid therapy in individuals with mixed dyslipidemia. Journal of Lipid Research, 2012, 53, 2425-2428.	2.0	14
656	Racial Differences in Association of Elevated Interleukin-18 Levels With Type 2 Diabetes: The Atherosclerosis Risk in Communities Study. Diabetes Care, 2012, 35, 1513-1518.	4.3	14
657	Study Design, Rationale, and Baseline Characteristics: Evaluation of Fenofibric Acid on Carotid Intima-Media Thickness in Patients with Type IIb Dyslipidemia with Residual Risk in Addition to Atorvastatin Therapy (FIRST) Trial. Cardiovascular Drugs and Therapy, 2012, 26, 349-358.	1.3	14
658	The 9p21 genetic variant is additive to carotid intima media thickness and plaque in improving coronary heart disease risk prediction in white participants of the Atherosclerosis Risk in Communities (ARIC) Study. Atherosclerosis, 2012, 222, 135-137.	0.4	14
659	Nonâ€“high-density lipoprotein cholesterol calculation and goal awareness among physicians-in-training. Journal of Clinical Lipidology, 2012, 6, 50-57.	0.6	14
660	Calf muscle perfusion as measured with magnetic resonance imaging to assess peripheral arterial disease. Medical and Biological Engineering and Computing, 2016, 54, 1667-1681.	1.6	14
661	Usefulness of Icosapent Ethyl (Eicosapentaenoic Acid Ethyl Ester) in Women to Lower Triglyceride Levels (Results from the MARINE and ANCHOR Trials). American Journal of Cardiology, 2017, 119, 397-403.	0.7	14
662	SES, Heart Failure, and N-terminal Pro-b-type Natriuretic Peptide: The Atherosclerosis Risk in Communities Study. American Journal of Preventive Medicine, 2018, 54, 229-236.	1.6	14
663	Subclinical Cardiovascular Disease and Fall Risk in Older Adults: Results From the Atherosclerosis Risk in Communities Study. Journal of the American Geriatrics Society, 2019, 67, 1795-1802.	1.3	14
664	The Use of Risk-Enhancing Factors to Personalize ASCVD Risk Assessment: Evidence and Recommendations from the 2018 AHA/ACC Multi-Society Cholesterol Guidelines. Current Cardiovascular Risk Reports, 2019, 13, 1.	0.8	14
665	Icosapent Ethyl Effects on Fatty Acid Profiles in Statin-Treated Patients With High Triglycerides: The Randomized, Placebo-controlled ANCHOR Study. Cardiology and Therapy, 2019, 8, 79-90.	1.1	14
666	Combining Biomarkers and Imaging for Shortâ€Term Assessment of Cardiovascular Disease Risk in Apparently Healthy Adults. Journal of the American Heart Association, 2020, 9, e015410.	1.6	14

#	Article	IF	Citations
667	High-Sensitivity Cardiac Troponin I and T for Cardiovascular Risk Stratification in Adults With Diabetes. Diabetes Care, 2020, 43, e144-e146.	4.3	14
668	Shared Decisions: A Qualitative Study on Clinician and Patient Perspectives on Statin Therapy and Statinâ€Associated Side Effects. Journal of the American Heart Association, 2020, 9, e017915.	1.6	14
669	Impact of Lipid Monitoring on Treatment Intensification of Cholesterol Lowering Therapies (from the) Tj ETQq1 1 0.784314 rgBT /Ove	0.7	14
670	Associations of Cardiac, Kidney, and Diabetes Biomarkers With Peripheral Neuropathy among Older Adults in the Atherosclerosis Risk in Communities (ARIC) Study. Clinical Chemistry, 2020, 66, 686-696.	1.5	14
671	Genetic testing in ambulatory cardiology clinics reveals high rate of findings with clinical management implications. Genetics in Medicine, 2021, 23, 2404-2414.	1.1	14
672	Cardiovascular Disease Riskâ€"Based Statin Utilization and Associated Outcomes in a Primary Prevention Cohort: Insights From a Large Health Care Network. Circulation: Cardiovascular Quality and Outcomes, 2021, 14, e007485.	0.9	14
673	Effect of bempedoic acid plus ezetimibe fixed-dose combination vs ezetimibe or placebo on low-density lipoprotein cholesterol in patients with type 2 diabetes and hypercholesterolemia not treated with statins. American Journal of Preventive Cardiology, 2021, 8, 100278.	1.3	14
674	Consistency of Benefit of Icosapent Ethyl by Background Statin Type in REDUCE-IT. Journal of the American College of Cardiology, 2022, 79, 220-222.	1.2	14
675	Ezetimibe/simvastatin compared with atorvastatin or rosuvastatin in lowering to specified levels both LDL-C and each of five other emerging risk factors for coronary heart disease: Nonâ€"HDL-cholesterol, TC/HDL-C, apolipoprotein B, apo-B/apo-A-I, or C-reactive protein. Journal of Clinical Lipidology, 2008, 2, 436-446.	0.6	13
676	Coronary heart disease risk, aspirin use, and apolipoprotein(a) 4399Met allele in the Atherosclerosis Risk in Communities (ARIC) study. Thrombosis and Haemostasis, 2009, 102, 179-180.	1.8	13
677	Differences in responses of platelets to fluid shear stress in patients with peripheral artery disease (PAD) and coronary artery disease (CAD). Platelets, 2009, 20, 199-205.	1.1	13
678	Association of Highâ€Density Lipoproteinâ€Cholesterol Versus Apolipoprotein Aâ€I With Risk of Coronary Heart Disease: The European Prospective Investigation Into Cancerâ€Norfolk Prospective Population Study, the Atherosclerosis Risk in Communities Study, and the Women's Health Study. Journal of the American Heart Association, 2017, 6, .	1.6	13
679	Lipoprotein-associated phospholipase A2 and risk of incident peripheral arterial disease: Findings from The Atherosclerosis Risk in Communities study (ARIC). Atherosclerosis, 2018, 268, 12-18.	0.4	13
680	Premature Atherosclerotic Cardiovascular Disease Risk Among Patients with Inflammatory Bowel Disease. American Journal of Medicine, 2021, 134, 1047-1051.e2.	0.6	13
681	Lipid-Lowering Biotechnological Drugs: from Monoclonal Antibodies to Antisense Therapiesâ€"a Clinical Perspective. Cardiovascular Drugs and Therapy, 2021, 35, 1269-1279.	1.3	13
682	The Challenges of Genome-Wide Interaction Studies: Lessons to Learn from the Analysis of HDL Blood Levels. PLoS ONE, 2014, 9, e109290.	1.1	13
683	Impact of Icosapent Ethyl on Cardiovascular Risk Reduction in Patients With Heart Failure in REDUCEâ€IT. Journal of the American Heart Association, 2022, 11, e024999.	1.6	13
684	Cloning and comparative sequence analysis of the gene encoding canine intercellular adhesion molecule-1 (ICAM-1). Gene, 1995, 156, 291-295.	1.0	12

#	Article	IF	Citations
685	Endothelial lipase and cholesterol metabolism. Current Atherosclerosis Reports, 2004, 6, 126-130.	2.0	12
686	Apolipoprotein E Genotype and Incident Ischemic Stroke. Stroke, 2005, 36, 2484-2486.	1.0	12
687	Real-Time Co-Registration Using Novel Ultrasound Technology: Ex Vivo Validation and In Vivo Applications. Journal of the American Society of Echocardiography, 2011, 24, 720-728.	1.2	12
688	Association Between Preoperative Diuretic Use and Inâ€hospital Outcomes After Cardiac Surgery. Cardiovascular Therapeutics, 2013, 31, 291-297.	1.1	12
689	Inflammation versus Host Defense in Obesity. Cell Metabolism, 2014, 20, 708-709.	7.2	12
690	Lipid-Modifying Efficacy and Tolerability of Anacetrapib Added to Ongoing Statin Therapy in Patients with Hypercholesterolemia or Low High-Density Lipoprotein Cholesterol. American Journal of Cardiology, 2017, 119, 388-396.	0.7	12
691	Relation of Lifestyle Factors and Life's Simple 7 Score to Temporal Reduction in Troponin Levels Measured by a High-Sensitivity Assay (from the Atherosclerosis Risk in Communities Study). American Journal of Cardiology, 2018, 121, 430-436.	0.7	12
692	Lipid Effects of Icosapent Ethyl in Women with Diabetes Mellitus and Persistent High Triglycerides on Statin Treatment: ANCHOR Trial Subanalysis. Journal of Women's Health, 2018, 27, 1170-1176.	1.5	12
693	Applicability and Cost Implications for Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors Based on the ODYSSEY Outcomes Trial. Circulation, 2019, 139, 410-412.	1.6	12
694	How Do We Incorporate Polygenic Risk Scores in Cardiovascular Disease Risk Assessment and Management?. Current Atherosclerosis Reports, 2021, 23, 28.	2.0	12
695	Effectiveness of NPs and PAs in managing diabetes and cardiovascular disease. JAAPA: Official Journal of the American Academy of Physician Assistants, 2018, 31, 39-45.	0.1	12
696	Treating mixed dyslipidemias: Why and how. Clinical Cardiology, 2001, 24, 6-9.	0.7	11
697	Point: High-Sensitivity C-Reactive Protein and Cardiac C-Reactive Protein Assays: Is There a Need to Differentiate?. Clinical Chemistry, 2006, 52, 1254-1256.	1.5	11
698	Intramural coronary lipid injection induces atheromatous lesions expressing proinflammatory chemokines: implications for the development of a porcine model of atherosclerosis. Cardiovascular Revascularization Medicine, 2011, 12, 304-311.	0.3	11
699	LPL gene variants affect apoC-III response to combination therapy of statins and fenofibric acid in a randomized clinical trial of individuals with mixed dyslipidemia. Journal of Lipid Research, 2012, 53, 556-560.	2.0	11
700	Effects of coadministered extended-release niacin/laropiprant and simvastatin on lipoprotein subclasses in patients with dyslipidemia. Journal of Clinical Lipidology, 2012, 6, 235-243.	0.6	11
701	Nonâ€“high-density lipoprotein cholesterol reporting and goal attainment in primary care. Journal of Clinical Lipidology, 2012, 6, 545-552.	0.6	11
702	Relation Between Playing Position and Coronary Artery Calcium Scores in Retired National Football League Players. American Journal of Cardiology, 2014, 114, 1836-1840.	0.7	11

#	Article	IF	Citations
703	Implications of the Eighth Joint National Committee Guidelines for the Management of High Blood Pressure for Aging Adults. Hypertension, 2015, 66, 474-480.	1.3	11
704	A Multiregional, Randomized Evaluation of the Lipid-Modifying Efficacy and Tolerability of Anacetrapib Added to Ongoing Statin Therapy in Patients With Hypercholesterolemia or Low High-Density Lipoprotein Cholesterol. American Journal of Cardiology, 2017, 120, 569-576.	0.7	11
705	Cardiovascular Disease Prevention: Training Opportunities, the Challenges, and Future Directions. Current Atherosclerosis Reports, 2018, 20, 35.	2.0	11
706	Reply. Journal of the American College of Cardiology, 2019, 74, 1849-1850.	1.2	11
707	Physical Activity and Incident Heart Failure in Highâ€Risk Subgroups: The ARIC Study. Journal of the American Heart Association, 2020, 9, e014885.	1.6	11
708	Highâ€Sensitivity Cardiac Troponin I for Risk Stratification in Older Adults. Journal of the American Geriatrics Society, 2021, 69, 986-994.	1.3	11
709	Social Determinants of Health and Comorbidities Among Individuals with Atherosclerotic Cardiovascular Disease: The Behavioral Risk Factor Surveillance System Survey. Population Health Management, 2022, 25, 39-45.	0.8	11
710	Association of Low-Density Lipoprotein Testing After an Atherosclerotic Cardiovascular Event with Subsequent Statin Adherence and Intensification. American Journal of Medicine, 2022, 135, 603-606.	0.6	11
711	Cost-effectiveness of Icosapent Ethyl for High-risk Patients With Hypertriglyceridemia Despite Statin Treatment. JAMA Network Open, 2022, 5, e2148172.	2.8	11
712	The Editor's Roundtable: Lipid Management Beyond Statinsâ€”Reducing Residual Cardiovascular Risk. American Journal of Cardiology, 2008, 102, 559-567.	0.7	10
713	The transcription factor 7-like 2 (TCF7L2) polymorphism may be associated with focal arteriolar narrowing in Caucasians with hypertension or without diabetes: the ARIC Study. BMC Endocrine Disorders, 2010, 10, 9.	0.9	10
714	Analysis of Multiple Association Studies Provides Evidence of an Expression QTL Hub in Gene-Gene Interaction Network Affecting HDL Cholesterol Levels. PLoS ONE, 2014, 9, e92469.	1.1	10
715	Rare LPL gene variants attenuate triglyceride reduction and HDL cholesterol increase in response to fenofibric acid therapy in individuals with mixed dyslipidemia. Atherosclerosis, 2014, 234, 249-253.	0.4	10
716	Influence of metabolic syndrome factors and insulin resistance on the efficacy of ezetimibe/simvastatin and atorvastatin in patients with metabolic syndrome and atherosclerotic coronary heart disease risk. Lipids in Health and Disease, 2015, 14, 103.	1.2	10
717	A common variant in the CLDN7/ELP5 locus predicts adiponectin change with lifestyle intervention and improved fitness in obese individuals with diabetes. Physiological Genomics, 2015, 47, 215-224.	1.0	10
718	Implications for Ezetimibe Therapy Use Based on IMPROVE-IT Criteria. American Journal of Medicine, 2015, 128, 1253-1256.	0.6	10
719	Postprandial effects on arterial stiffness parameters in healthy young adults. Vascular Medicine, 2015, 20, 501-508.	0.8	10
720	Improving Outcomes After Myocardial Infarction in the US Population. Journal of the American Heart Association, 2018, 7, .	1.6	10

#	Article	IF	Citations
721	Usefulness of Lipoprotein-Associated Phospholipase A2 Activity and C-Reactive Protein in Identifying High-Risk Smokers for Atherosclerotic Cardiovascular Disease (from the Atherosclerosis Risk in) Tj ETQq1 1 0.784314 rgBT /Overlock	1.7	10
722	Case reports of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibition nonresponse. Journal of Clinical Lipidology, 2018, 12, 1141-1145.	0.6	10
723	Low-Density Lipoprotein Cholesterol. Circulation, 2018, 138, 2326-2329.	1.6	10
724	Relationship of extracellular volume assessed on cardiac magnetic resonance and serum cardiac troponins and natriuretic peptides with heart failure outcomes. Scientific Reports, 2019, 9, 20168.	1.6	10
725	Deficiency of Stat1 in CD11c+ Cells Alters Adipose Tissue Inflammation and Improves Metabolic Dysfunctions in Mice Fed a High-Fat Diet. Diabetes, 2021, 70, 720-732.	0.3	10
726	Has the â€˜strengthâ€™ of fish oil therapy been â€˜reducedâ€™? Reconciling the results of REDUCE-IT and STRENGTH. European Heart Journal - Cardiovascular Pharmacotherapy, 2021, 7, e7-e8.	1.4	10
727	Loss of bone morphogenetic protein-binding endothelial regulator causes insulin resistance. Nature Communications, 2021, 12, 1927.	5.8	10
728	Racial Disparities in Modifiable Risk Factors and Statin Usage in Black Patients With Familial Hypercholesterolemia. Journal of the American Heart Association, 2021, 10, e020890.	1.6	10
729	Impact of adventitial neovascularisation on atherosclerotic plaque composition and vascular remodelling in a porcine model of coronary atherosclerosis. EuroIntervention, 2010, 5, 981-988.	1.4	10
730	Cardiovascular risk and complications associated with COVID-19. American Journal of Cardiovascular Disease, 2020, 10, 479-489.	0.5	10
731	Heart Failure Risk Associated With Severity of Modifiable Heart Failure Risk Factors: The ARIC Study. Journal of the American Heart Association, 2022, 11, e021583.	1.6	10
732	Phagocytes in Ischemia Injury. Annals of the New York Academy of Sciences, 1997, 832, 243-265.	1.8	9
733	Low-Density Lipoprotein Cholesterol Reduction and Goal Achievement With Ezetimibe/Simvastatin Versus Atorvastatin or Rosuvastatin in Patients With Diabetes, Metabolic Syndrome, or Neither Disease, Stratified by National Cholesterol Education Program Risk Category. Metabolic Syndrome and Related Disorders, 2009, 7, 601-610.	0.5	9
734	Distribution of calcification in carotid endarterectomy tissues: Comparison of micro-computed tomography imaging with histology. Vascular Medicine, 2014, 19, 343-350.	0.8	9
735	Fiber Intake and Plasminogen Activator Inhibitor-1 in Type 2 Diabetes: Look AHEAD (Action for Health in) Tj ETQq1 1 0.784314 rgBT /Overlock 114, 1800-1810.e2.	0.4	9
736	25â€Hydroxyvitamin D Levels and Markers of Subclinical Myocardial Damage and Wall Stress: The Atherosclerosis Risk in Communities Study. Journal of the American Heart Association, 2016, 5, .	1.6	9
737	Looking Back at Look AHEAD Through the Lens of Recent Diabetes Outcome Trials. Circulation, 2017, 135, 720-723.	1.6	9
738	Sedentary Behavior and Subclinical Cardiac Injury. Circulation, 2017, 136, 1451-1453.	1.6	9

#	Article	IF	Citations
739	Prevention of â€œFailureâ€. Circulation, 2018, 137, 106-108.	1.6	9
740	Patient-specific flow descriptors and normalised wall index in peripheral artery disease: a preliminary study. Computer Methods in Biomechanics and Biomedical Engineering: Imaging and Visualization, 2018, 6, 119-127.	1.3	9
741	Spotlight from the American Society for Preventive Cardiology on Key Features of the 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guidelines on the Management of Blood Cholesterol. American Journal of Cardiovascular Drugs, 2020, 20, 1-9.	1.0	9
742	New Approaches for the Prevention and Treatment of Cardiovascular Disease: Focus on Lipoproteins and Inflammation. Annual Review of Medicine, 2021, 72, 431-446.	5.0	9
743	Racial and geographic disparities in influenza vaccination in the U.S. among individuals with atherosclerotic cardiovascular disease: Renewed importance in the setting of COVID-19. American Journal of Preventive Cardiology, 2021, 5, 100150.	1.3	9
744	Association Between Omega-3 Fatty Acid Treatment and Atrial Fibrillation in Cardiovascular Outcome Trials: A Systematic Review and Meta-Analysis. Cardiovascular Drugs and Therapy, 2021, 35, 793-800.	1.3	9
745	What Do US Physicians and Patients Think About Lipidâ€Lowering Therapy and Goals of Treatment? Results From the GOULD Registry. Journal of the American Heart Association, 2021, 10, e020893.	1.6	9
746	Technology-Assisted Self-Selection of Candidates for Nonprescription StatinÂTherapy. Journal of the American College of Cardiology, 2021, 78, 1114-1123.	1.2	9
747	Fluvastatin Reduces Cardiac Mortality in Patients with Coronary Heart Disease. Cardiovascular Drugs and Therapy, 2004, 18, 67-75.	1.3	8
748	Inflammatory Protein Levels and Depression Screening After Coronary Stenting Predict Major Adverse Coronary Events. Biological Research for Nursing, 2009, 11, 163-173.	1.0	8
749	Statin-Induced Diabetes: Will It Change Clinical Practice?. Diabetes Care, 2009, 32, 1941-1943.	4.3	8
750	Icosapent Ethyl (eicosapentaenoic acid ethyl ester): Effects on Apolipoprotein C-III in Patients from the MARINE and ANCHOR Studies. Journal of Clinical Lipidology, 2014, 8, 313-314.	0.6	8
751	Association between lipoprotein associated phospholipase A2 mass and subclinical coronary and carotid atherosclerosis in Retired National Football League players. Atherosclerosis, 2014, 236, 251-256.	0.4	8
752	Defective Association of the Platelet Glycoprotein Ibâ€“IX Complex with the Glycosphingolipid-Enriched Membrane Domain Inhibits Murine Thrombus and Atheroma Formation. Journal of Immunology, 2016, 197, 288-295.	0.4	8
753	Cancer Survivorship and Subclinical Myocardial Damage. American Journal of Epidemiology, 2019, 188, 2188-2195.	1.6	8
754	Sleep apnea and galectin-3: possible sex-specific relationship. Sleep and Breathing, 2019, 23, 1107-1114.	0.9	8
755	Soluble Angiotensin-Converting Enzyme 2, Cardiac Biomarkers, Structure, and Function, and Cardiovascular Events (from the Atherosclerosis Risk in Communities Study). American Journal of Cardiology, 2021, 146, 15-21.	0.7	8
756	Mentored implementation to initiate a diabetes program in an underserved community: a pilot study. BMJ Open Diabetes Research and Care, 2021, 9, e002320.	1.2	8

#	Article	IF	Citations
757	Poststatin Lipid Therapeutics: A Review. Methodist DeBakey Cardiovascular Journal, 2021, 15, 32.	0.5	8
758	Obesity, Galectinâ€3, and Incident Heart Failure: The ARIC Study. Journal of the American Heart Association, 2022, 11, e023238.	1.6	8
759	Guideline-Concordant Statin Therapy UseÂin Secondary Prevention. Journal of the American College of Cardiology, 2022, 79, 1814-1817.	1.2	8
760	Role of selective cholesterol absorption inhibition in the management of dyslipidemia. Current Atherosclerosis Reports, 2004, 6, 52-59.	2.0	7
761	Management of metabolic syndrome: statins. Endocrinology and Metabolism Clinics of North America, 2004, 33, 509-523.	1.2	7
762	Utility of statin therapy using high-sensitivity C-reactive protein as an indicator of coronary heart disease risk. Current Atherosclerosis Reports, 2005, 7, 22-28.	2.0	7
763	How to identify patients with vulnerable plaques. Diabetes, Obesity and Metabolism, 2008, 10, 824-833.	2.2	7
764	The Editorâ€™s Roundtable: Atherosclerosis Regression. American Journal of Cardiology, 2008, 101, 967-974.	0.7	7
765	Rare APOA5 promoter variants associated with paradoxical HDL cholesterol decrease in response to fenofibric acid therapy. Journal of Lipid Research, 2013, 54, 1980-1987.	2.0	7
766	Genetic Testing in Hyperlipidemia. Cardiology Clinics, 2015, 33, 267-275.	0.9	7
767	Highâ€Sensitive Troponin T, Natriuretic Peptide, and Cognitive Change. Journal of the American Geriatrics Society, 2019, 67, 2353-2361.	1.3	7
768	CD11c participates in triggering acute graftâ€versusâ€host disease during bone marrow transplantation. Immunology, 2021, 164, 148-160.	2.0	7
769	Greater than expected reduction in low-density lipoprotein-cholesterol (LDL-C) with bempedoic acid in a patient with heterozygous familial hypercholesterolemia (HeFH). Journal of Clinical Lipidology, 2021, 15, 649-652.	0.6	7
770	Proteomics and Risk of Atrial Fibrillation in Older Adults (From the Atherosclerosis Risk in) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 222 Td (	0.7	7
771	Diabetes, GDF-15 and incident heart failure: the atherosclerosis risk in communities study. Diabetologia, 2022, , 1.	2.9	7
772	Molecular markers for atherosclerosis. European Journal of Cardiovascular Prevention and Rehabilitation, 1997, 4, 353-356.	1.5	6
773	Management of persons with high risk of coronary heart disease but low serum low-density lipoprotein cholesterol. American Journal of Cardiology, 2003, 91, 1134-1136.	0.7	6
774	Variation in the checkpoint kinase 2 gene is associated with type 2 diabetes in multiple populations. Acta Diabetologica, 2010, 47, 199-207.	1.2	6

#	Article	IF	Citations
775	Simultaneous bilateral magnetic resonance imaging of the femoral arteries in peripheral arterial disease patients. Journal of Magnetic Resonance Imaging, 2011, 34, 150-156.	1.9	6
776	Nutrition and metabolism - sphingolipids and branched chain amino acids. Current Opinion in Lipidology, 2011, 22, 503-504.	1.2	6
777	Single Nucleotide Polymorphisms in Cholesteryl Ester Transfer Protein Gene and Recurrent Coronary Heart Disease or Mortality in Patients With Established Atherosclerosis. American Journal of Cardiology, 2013, 112, 1287-1292.	0.7	6
778	A dataset to assess providers×3 knowledge and attitudes towards the 2013 American College of Cardiology/American Heart Association Cholesterol Management Guideline. Data in Brief, 2016, 7, 595-598.	0.5	6
779	Magnetic Resonance Venous Volume Measurements in Peripheral Artery Disease (from ELIMIT). American Journal of Cardiology, 2016, 118, 1399-1404.	0.7	6
780	Lifestyle Intervention for Weight Loss and Cardiometabolic Changes in the Setting of Glucokinase Regulatory Protein Inhibition. Circulation: Cardiovascular Genetics, 2016, 9, 71-78.	5.1	6
781	A simplified pathway to proprotein convertase subtilisin/kexin type 9 inhibitor prior authorization approval: A lipid clinic experience. Journal of Clinical Lipidology, 2017, 11, 596-599.	0.6	6
782	Association of lipoprotein-associated phospholipase A2 and risk of incident atrial fibrillation: Findings from 3 cohorts. American Heart Journal, 2018, 197, 62-69.	1.2	6
783	Cardiac Biomarkers and Subsequent Risk of Hospitalization With Bleeding in the Community: Atherosclerosis Risk in Communities Study. Journal of the American Heart Association, 2020, 9, e013560.	1.6	6
784	Facility-Level Variation in Reported Statin-Associated Side Effects Among Patients with Atherosclerotic Cardiovascular Diseaseâ€"Perspective from the Veterans Affair Healthcare System. Cardiovascular Drugs and Therapy, 2021, , 1.	1.3	6
785	High-sensitivity cardiac troponin T and the risk of heart failure in postmenopausal women of the ARIC Study. Menopause, 2021, 28, 284-291.	0.8	6
786	Cholesterol, lipids, and statins. Texas Heart Institute Journal, 2005, 32, 378-9.	0.1	6
787	Matrix metalloproteinase-1 and tissue inhibitors do not predict incident coronary artery disease in the atherosclerosis risk in communities (ARIC) study. Texas Heart Institute Journal, 2008, 35, 388-94.	0.1	6
788	Coronary artery disease in the young in the US population-based cohort. American Journal of Cardiovascular Disease, 2020, 10, 189-194.	0.5	6
789	Use of denaturing HPLC to provide efficient detection of mutations causing familial hypercholesterolemia. Clinical Chemistry, 2002, 48, 1913-8.	1.5	6
790	Soluble adhesion molecules and coronary heart disease. Lancet, The, 2002, 359, 525.	6.3	5
791	Increasing Prevalence of Obesity and Clustered Cardiometabolic Risk: Can Treatment of the Underlying Cause Reverse the Trends?. Critical Pathways in Cardiology, 2007, 6, 41-45.	0.2	5
792	Validity of self-report of lipid medication use: The Atherosclerosis Risk in Communities (ARIC) Study. Atherosclerosis, 2015, 242, 625-629.	0.4	5

#	Article	IF	Citations
793	The impact of multiple single day blood pressure readings on cardiovascular risk estimation: The Atherosclerosis Risk in Communities study. European Journal of Preventive Cardiology, 2016, 23, 1529-1536.	0.8	5
794	Icosapent ethyl reduces atherogenic markers in high-risk statin-treated patients with stage 3 chronic kidney disease and high triglycerides. Postgraduate Medicine, 2019, 131, 390-396.	0.9	5
795	Association of high-density lipoprotein particle concentration with cardiovascular risk following acute coronary syndrome: A case-cohort analysis of the dal-Outcomes trial. American Heart Journal, 2020, 221, 60-66.	1.2	5
796	Association of Longitudinal Changes in Cardiac Biomarkers With Atrial and Ventricular Arrhythmias (from the Atherosclerosis Risk in Communities [ARIC] Study). American Journal of Cardiology, 2021, 158, 45-52.	0.7	5
797	Prevalence and Determinants of Difficulty in Accessing Medical Care in U.S. Adults. American Journal of Preventive Medicine, 2021, 61, 492-500.	1.6	5
798	Identification of Functional Genetic Determinants of Cardiac Troponin T and I in a Multiethnic Population and Causal Associations With Atrial Fibrillation. Circulation Genomic and Precision Medicine, 2021, 14, CIRCGEN121003460.	1.6	5
799	NT-pro B-type natriuretic peptide, early menopause, and incident heart failure in postmenopausal women of the ARIC study. Menopause, 2022, 29, 309-316.	0.8	5
800	A Headâ€toâ€Head Comparison of a Free Fatty Acid Formulation of Omegaâ€3 Pentaenoic Acids Versus Icosapent Ethyl in Adults With Hypertriglyceridemia: The ENHANCEâ€IT Study. Journal of the American Heart Association, 2022, 11, e024176.	1.6	5
801	Reducing atherothrombotic events in high-risk patients: Recent data on therapy with statins and fatty acids. Current Atherosclerosis Reports, 1999, 1, 6-8.	2.0	4
802	Fat, Fit, and Leading the Charge. Arteriosclerosis, Thrombosis, and Vascular Biology, 2005, 25, 2013-2015.	1.1	4
803	Newer risk markers and surrogate endpoints in atherosclerosis management. Clinical Cardiology, 2001, 24, 13-17.	0.7	4
804	Therapy and clinical trials: HDL-cholesterol and niacin therapy â€“ past, present, and future. Current Opinion in Lipidology, 2010, 21, 165-166.	1.2	4
805	Coronary Artery Bypass Graft Surgery Remains the Standard of Care for Patients With Diabetes. Seminars in Thoracic and Cardiovascular Surgery, 2013, 25, 97-99.	0.4	4
806	Treatment With Dalcetrapib Modifies the Relationship Between High-Density Lipoprotein Cholesterol and C-Reactive Protein. Journal of the American College of Cardiology, 2016, 68, 2488-2490.	1.2	4
807	Genetic Testing in Hyperlipidemia. Endocrinology and Metabolism Clinics of North America, 2016, 45, 129-140.	1.2	4
808	Lipoprotein(a) and Risk for Stroke and Myocardial Infarction. Journal of the American College of Cardiology, 2019, 74, 67-69.	1.2	4
809	Premorbid levels of high-sensitivity cardiac troponin T and natriuretic peptide and prognosis after incident myocardial infarction. American Heart Journal, 2019, 216, 62-73.	1.2	4
810	Associations of High-Sensitivity Cardiac Troponin and Natriuretic Peptide With Subsequent Risk of Infection in Persons Without Cardiovascular Disease: The Atherosclerosis Risk in Communities Study. American Journal of Epidemiology, 2019, 188, 2146-2155.	1.6	4

#	Article	IF	Citations
811	Monocyte phenotyping and management of lipoprotein X syndrome. Journal of Clinical Lipidology, 2020, 14, 850-858.	0.6	4
812	Androgens In Men Study (AIMS): protocol for meta-analyses of individual participant data investigating associations of androgens with health outcomes in men. BMJ Open, 2020, 10, e034777.	0.8	4
813	Real-world data, theoretical application of guidelines, cost, and access: how do we optimize non-statin therapy for LDL-C/non-HDL-C/ApoB?. European Heart Journal, 2020, 41, 3910-3912.	1.0	4
814	Relation of Magnetic Resonance Imaging Based Arterial Signal Enhancement to Markers of Peripheral Artery Disease. American Journal of Cardiology, 2021, 140, 140-147.	0.7	4
815	Health care costs associated with primary care physicians versus nurse practitioners and physician assistants. Journal of the American Association of Nurse Practitioners, 2021, 33, 967-974.	0.5	4
816	High-Sensitivity Cardiac Troponin, Natriuretic Peptide, and Long-Term Risk of Acute Kidney Injury: The Atherosclerosis Risk in Communities (ARIC) Study. Clinical Chemistry, 2021, 67, 298-307.	1.5	4
817	Association of patient, provider and facility related characteristics with statin associated side effects and statin use: Insight from the Veteran's Affairs healthcare system. Journal of Clinical Lipidology, 2021, 15, 832-839.	0.6	4
818	Leveraging structured and unstructured electronic health record data to detect reasons for suboptimal statin therapy use in patients with atherosclerotic cardiovascular disease. American Journal of Preventive Cardiology, 2022, 9, 100300.	1.3	4
819	Abstract 10627: Benefits of Icosapent Ethyl in Patients with Prior Peripheral Artery Disease: REDUCE-IT PAD. Circulation, 2021, 144, .	1.6	4
820	APOL1 Kidney Risk Variants and Proteomics. Clinical Journal of the American Society of Nephrology: CJASN, 2022, 17, 684-692.	2.2	4
821	Abstract 17499: ETC-1002 Incrementally Lowers Low Density Lipoprotein-cholesterol in Patients With Hypercholesterolemia Receiving Stable Statin Therapy. Circulation, 2015, 132, .	1.6	4
822	Estimated cardiovascular benefits of bempedoic acid in patients with established cardiovascular disease. Atherosclerosis Plus, 2022, 49, 20-27.	0.3	4
823	Poloxamer 407 Induces Hypertriglyceridemia but Decreases Atherosclerosis in Ldlrâ^'/â^' Mice. Cells, 2022, 11, 1795.	1.8	4
824	Adhesion molecules in cardiovascular disease. Expert Opinion on Therapeutic Targets, 1999, 3, 263-277.	1.0	3
825	The Evolving Role of High-Density Lipoprotein in Reducing Cardiovascular Risk. Preventive Cardiology, 2001, 4, 65-72.	1.1	3
826	Advances in Lipid Testing and Management in Patients with Diabetes Mellitus. Endocrine Practice, 2009, 15, 641-652.	1.1	3
827	Effects of combination therapy with rosuvastatin and fenofibric acid in patients with mixed dyslipidemia and high-sensitivity C-reactive protein (â‰¥2 mg/L). Journal of Clinical Lipidology, 2011, 5, 401-407.	0.6	3
828	Clinical use of genetic typing in human lipid disordersâ€. Journal of Clinical Lipidology, 2012, 6, 199-207.	0.6	3

#	Article	IF	Citations
829	Effects of Icosapent Ethyl on Lipoprotein Particle Concentration and the Fatty Acid Desaturation Index in Statin-treated Patients With Persistent High Triglycerides (the ANCHOR Study). Journal of Clinical Lipidology, 2013, 7, 270-271.	0.6	3
830	ETC-1002 Lowers LDL-Cholesterol and is Well Tolerated in Hypercholesterolemic Patients Across Four Phase 2a Studies. Journal of Clinical Lipidology, 2014, 8, 339-340.	0.6	3
831	From Plaque Burden to Plaque Composition. JACC: Cardiovascular Imaging, 2017, 10, 250-252.	2.3	3
832	Association of Elevated Triglycerides and Atherogenic Lipoproteins with Incident Cardiovascular Diseases: Insights from Genetic Data in the Atherosclerosis Risk in Communities Study. Journal of Clinical Lipidology, 2017, 11, 788.	0.6	3
833	Pediatric Familial Hypercholesterolemia: Children and Adolescents Enrolled in the CAscade SCreening for Awareness. Journal of Clinical Lipidology, 2017, 11, 812-813.	0.6	3
834	Diagnostic Performance of 1,5-Anhydroglucitol Compared to 2-H Glucose in the Atherosclerosis Risk in Communities Study. Clinical Chemistry, 2018, 64, 1536-1537.	1.5	3
835	Response by Jia et al to Letter Regarding Article, â€œHigh-Sensitivity Troponin I and Incident Coronary Events, Stroke, Heart Failure Hospitalization, and Mortality in the ARIC Studyâ€• Circulation, 2019, 140, e772-e773.	1.6	3
836	Associations of 1,5-Anhydroglucitol and 2-Hour Glucose with Major Clinical Outcomes in the Atherosclerosis Risk in Communities (ARIC) Study. journal of applied laboratory medicine, The, 2020, 5, 1296-1306.	0.6	3
837	JCL roundtable: Omega-3 fatty acids and cardiovascular outcomes. Journal of Clinical Lipidology, 2020, 14, 4-15.	0.6	3
838	Facility-Level Variation in Cardiac Stress Test Use Among Patients With Diabetes: Findings From the Veterans Affairs National Database. Diabetes Care, 2020, 43, e58-e60.	4.3	3
839	Significant Facility-Level Variation in Utilization of and Adherence with Secondary Prevention Therapies Among Patients with Premature Atherosclerotic Cardiovascular Disease: Insights from the VITAL (Veterans wIth premaTure AtheroscLerosis) Registry7. Cardiovascular Drugs and Therapy, 2021, , 1.	1.3	3
840	Prevention: The past, present, and future of medicine and society. Journal of Clinical Lipidology, 2021, 15, 245-247.	0.6	3
841	Glycated Hemoglobin to Detect Subclinical Atherosclerosis in People Without Diabetes. Journal of the American College of Cardiology, 2021, 77, 2792-2795.	1.2	3
842	Mid- to Late-Life Inflammation and Risk of Cardiac Dysfunction, HFpEF and HFrEF in Late Life. Journal of Cardiac Failure, 2021, 27, 1382-1392.	0.7	3
843	Association between circulating Galectin-3 and arterial stiffness in older adults. Vasa - European Journal of Vascular Medicine, 2021, 50, 439-445.	0.6	3
844	Abstract P018: Calibration of Analytes Over Twenty-Five Years in the Atherosclerosis Risk in Communities Study. Circulation, 2014, 129, .	1.6	3
845	LDL-C goal attainment with ezetimibe plus simvastatin coadministration vs atorvastatin or simvastatin monotherapy in patients at high risk of CHD. MedGenMed: Medscape General Medicine, 2005, 7, 3.	0.2	3
846	Galectin-3 and the incidence of abdominal aortic aneurysm: the atherosclerosis risk in communities (ARIC) study. American Journal of Cardiovascular Disease, 2017, 7, 114-121.	0.5	3

#	Article	IF	Citations
847	Associations of Highâ€Sensitivity Troponin and Natriuretic Peptide Levels With Serious Adverse Events in SPRINT. Journal of the American Heart Association, 2022, 11, e023314.	1.6	3
848	Midlife determinants of healthy cardiovascular aging: The Atherosclerosis Risk in Communities (ARIC) study. Atherosclerosis, 2022, 350, 82-89.	0.4	3
849	Growth Differentiation Factor 15 and the Subsequent Risk of Atrial Fibrillation: The Atherosclerosis Risk in Communities Study. Clinical Chemistry, 2022, 68, 1084-1093.	1.5	3
850	Lowering LDL cholesterol in clinical practice: time for change?. Lancet, The, 2022, 400, 341-343.	6.3	3
851	Application of Recent Definitions of the Metabolic Syndrome to Survey Data From the National Cholesterol Education Program Evaluation Project Utilizing Novel E-Technology (NEPTUNE II). Journal of the Cardiometabolic Syndrome, 2006, 1, 295-300.	1.7	2
852	An Annual, Prospective, International Study of Outpatients With Cardiovascular Disease or Risk Factors. Critical Pathways in Cardiology, 2007, 6, 72-75.	0.2	2
853	Efficacy and tolerability of multidrug therapy for hypertriglyceridemia. Journal of Clinical Lipidology, 2009, 3, 341-344.	0.6	2
854	METEOR Trial Reports on the Effect of Rosuvastatin on Progression of Carotid Intima-Media Thickness in Low-Risk Individuals with Subclinical Atherosclerosis. Physician and Sportsmedicine, 2010, 38, 180-182.	1.0	2
855	The Editor's Roundtable: JUPITER Follow-Up. American Journal of Cardiology, 2011, 107, 1549-1557.	0.7	2
856	Lipoprotein-associated phospholipase A2 and venous thromboembolism: A prospective study. Thrombosis Research, 2013, 132, 44-46.	0.8	2
857	The Editor's Roundtable: Hypertriglyceridemia. American Journal of Cardiology, 2013, 112, 1133-1141.	0.7	2
858	Severity of hypoxia modulates effect of CPAP on myocardial stress as measured by highly sensitive troponin T. Respiratory Research, 2015, 16, 126.	1.4	2
859	Plaque Volume of Carotid Endarterectomy Specimens Measured by 3D Ultrasound Technology. JACC: Cardiovascular Imaging, 2016, 9, 1118-1119.	2.3	2
860	Aldosterone Does Not Predict Cardiovascular Events Following Acute Coronary Syndrome in Patients Initially Without Heart Failure. Journal of the American Heart Association, 2017, 6, .	1.6	2
861	Association of Body Mass Index With Risk Factor Optimization and Guideline-Directed Medical Therapy in US Veterans With Cardiovascular Disease. Circulation: Cardiovascular Quality and Outcomes, 2019, 12, e004817.	0.9	2
862	C-reactive protein levels and plaque regression with evolocumab: Insights from GLAGOV. American Journal of Preventive Cardiology, 2020, 3, 100091.	1.3	2
863	Acute Tubular Injury in a Patient on a Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor. JACC: Case Reports, 2020, 2, 1042-1045.	0.3	2
864	Abstract 57: Reduction in Ischemic Stroke With Icosapent Ethyl - Insights From REDUCE-IT. Stroke, 2021, 52, .	1.0	2

#	Article	IF	Citations
865	Lipid Monitoring After Initiation of Lipid-Lowering Therapies: Return of Performance Measures?. Current Cardiology Reports, 2021, 23, 116.	1.3	2
866	Abstract 52: Efficacy and Safety of Mipomersen in Patients with Familial Hypercholesterolemia and Inadequately Controlled LDL-C Levels. Arteriosclerosis, Thrombosis, and Vascular Biology, 2016, 36, .	1.1	2
867	JCL Roundtable. Making prevention a priority. Journal of Clinical Lipidology, 2021, 15, 530-537.	0.6	2
868	Longitudinal Changes in Cardiac Troponin and Risk of Heart Failure Among Black Adults. Journal of Cardiac Failure, 2023, 29, 6-15.	0.7	2
869	Inflammation and lipid-lowering treatment. Current Cardiology Reports, 1999, 1, 251-255.	1.3	1
870	Introduction. American Journal of Cardiology, 2000, 85, 1-2.	0.7	1
871	ASCOT-LLA and the primary prevention of coronary artery disease in hypertensive patients. Current Atherosclerosis Reports, 2004, 6, 353-358.	2.0	1
872	Changes in Prescription Patterns for Ezetimibe/Simvastatin, Ezetimibe and Statin, and Statin Therapies and Expected Effects on LDL-C Reduction. Journal of Clinical Lipidology, 2010, 4, 219-220.	0.6	1
873	Lipid Target Attainment by Switching Statin Monotherapy to Fenofibric Acid + Statin in Patients with Mixed Dyslipidemia and at High-/Highest-Risk for Coronary Heart Disease. Journal of Clinical Lipidology, 2011, 5, 202-203.	0.6	1
874	Update on therapies targeting HDL. Current Opinion in Lipidology, 2011, 22, 514-516.	1.2	1
875	Response to Letter From Watanabe and Aizawa Regarding Article, â€œBlood Lipid Levels, Lipid-Lowering Medications, and the Incidence of Atrial Fibrillation: The Atherosclerosis Risk in Communities (ARIC) Study,â€•by Lopez et al. Circulation: Arrhythmia and Electrophysiology, 2012, 5, .	2.1	1
876	The Effect of Two Doses of AMR101 on Fasting Serum Triglycerides and Other Lipid Parameters in Statin-Treated Patients with Persistent High Triglycerides (â‰¥200 and <500 mg/dL): The ANCHOR Studyâ€. Journal of Clinical Lipidology, 2012, 6, 279-280.	0.6	1
877	ASSOCIATIONS OF LIPOPROTEIN(A) LEVELS WITH INCIDENT ATRIAL FIBRILLATION AND STROKE AMONG WHITES AND BLACKS: THE ATHEROSCLEROSIS RISK IN COMMUNITIES (ARIC) STUDY. Journal of the American College of Cardiology, 2017, 69, 485.	1.2	1
878	ASSOCIATION OF REMNANT-LIKE PARTICLE CHOLESTEROL AND LOW-DENSITY LIPOPROTEIN TRIGLYCERIDE WITH INCIDENCE OF CARDIOVASCULAR EVENTS: THE ARIC STUDY. Journal of the American College of Cardiology, 2017, 69, 1721.	1.2	1
879	Are All Benefits and Harms Equal?. Journal of the American College of Cardiology, 2018, 72, 819-820.	1.2	1
880	Statin use in carnitine palmitoyltransferase II deficiency. Journal of Clinical Lipidology, 2019, 13, 550-553.	0.6	1
881	Understanding by General Providers of the Echocardiogram Report. American Journal of Cardiology, 2019, 124, 296-302.	0.7	1
882	APOL1 Risk Alleles, Cardiac Markers, and Risk of ESKD in African Americans: The Atherosclerosis Risk in Communities Study. Kidney Medicine, 2020, 2, 502-504.	1.0	1

#	Article	IF	Citations
883	Largeâ€scale plasma proteomic analysis identifies proteins and biological pathways associated with incident dementia. Alzheimer's and Dementia, 2020, 16, e038307.	0.4	1
884	Letter to the Editor: Temporal Trends in E-Cigarette and Cigarette Use Among US Adults by US State: Behavioral Risk Factor Surveillance System, 2016 to 2018. Population Health Management, 2021, 24, 414-415.	0.8	1
885	Eligibility for Low-Dose Rivaroxaban Based on the COMPASS Trial: Insights from the Veterans Affairs Healthcare System. Cardiovascular Drugs and Therapy, 2021, 35, 533-538.	1.3	1
886	Sixâ€year changes in Nâ€terminal proâ€brain natriuretic peptide and changes in weight and risk of obesity. Obesity, 2021, 29, 1215-1222.	1.5	1
887	Statins and Your Memory. Journal of the American College of Cardiology, 2021, 77, 3157-3159.	1.2	1
888	A Metabolic Model for the Hypolipidemic and Antiatherogenic Effects of N-3 Fatty Acids: Effect of Omacor on Plasma Lipids. Medical Science Symposia Series, 1996, , 675-680.	0.0	1
889	Abstract 138: Contemporary Patterns of Use of Antiplatelet Agents in Patients With Acute Myocardial Infarction: Insight From the National Cardiovascular Data Registry (NCDR). Circulation: Cardiovascular Quality and Outcomes, 2016, 9, .	0.9	1
890	Abstract 4985: Are All Patients Considered â€œLow Riskâ€•for Coronary Heart Disease Really Low Risk? An Analysis from the Atherosclerosis Risk in Communities (ARIC) Study. Circulation, 2008, 118, .	1.6	1
891	Abstract 020: NT-proBNP, hs-Troponin T and Incident Venous Thromboembolism: The Atherosclerosis Risk in Communities (ARIC) Study. Circulation, 2013, 127, .	1.6	1
892	Abstract P021: NT-proBNP Predicts Incident Heart Failure Among Individuals in All BMI Categories. Circulation, 2014, 129, .	1.6	1
893	Abstract 12169: LDL-C Levels and Treatment Patterns Among Adults With Heterozygous Familial Hypercholesterolemia in the United States: Data From the CASCADE-FH Registry. Circulation, 2015, 132, .	1.6	1
894	Transatlantic guidelines on dyslipidemia and cardiovascular risk: key differences across the pond. Current Opinion in Endocrinology, Diabetes and Obesity, 2021, 28, 114-121.	1.2	1
895	The Fifth-Generation Cardiac Troponin T and Cardiovascular Disease in the Community. Journal of the American College of Cardiology, 2021, 78, 2019-2021.	1.2	1
896	Management of hyperlipidaemia among statin-intolerant patients after acute coronary syndrome: where do we stand in 2020?. European Journal of Preventive Cardiology, 2021, 28, 30-32.	0.8	1
897	Exercise and Mortality in HeartÂDiseaseÂCohorts. Journal of the American College of Cardiology, 2022, 79, 1701-1703.	1.2	1
898	Development and assessment of antiatherosclerotic therapies beyond low-density lipoprotein cholesterol and blood pressure. Current Atherosclerosis Reports, 2000, 2, 281-283.	2.0	0
899	Lipoprotein-associated phospholipase A2: Risk marker or target of therapy?. Current Cardiovascular Risk Reports, 2007, 1, 66-71.	0.8	0
900	Response to Letters Regarding Article, â€œEffect of Rosuvastatin Therapy on Coronary Artery Stenoses Assessed by Quantitative Coronary Angiography: A Study to Evaluate the Effect of Rosuvastatin on Intravascular Ultrasoundâ€“Derived Coronary Atheroma Burdenâ€• Circulation, 2008, 118, .	1.6	0

#	Article	IF	Citations
901	Newer Markers for Population Screening: Focus on Lipoprotein-Related Markers. , 0, , 181-203.		0
902	Inflammation, Adipose Tissue, and T Cells: What Is the â€œStraight Skinnyâ€•on Lean Versus Fat Mice?. Circulation Research, 2009, 105, e3-4; author reply e5.	2.0	0
903	Barriers to Non-HDL-Cholesterol Goal Attainment: Exploring the Gaps in Knowledge, Attitude, and Practices of Providers*. Journal of Clinical Lipidology, 2011, 5, 211-213.	0.6	0
904	Statin Therapy Alters the Relationship Between Apolipoprotein B and Both LDL-C and Non-HDL-C in High-Risk Patients: Effect of Race/Ethnic Backgroundâ€. Journal of Clinical Lipidology, 2012, 6, 272-273.	0.6	0
905	Age, Abdominal Obesity, and Baseline High-Sensitivity C-Reactive Protein Are Associated with Low-Density Lipoprotein Cholesterol, nonâ€“High-Density Lipoprotein Cholesterol, and ApoB Responses to Lipid-Lowering Therapy in Patients with Metabolic Syndrome and Moderately High/High Coronary Heart Disease Riskâ€. Journal of Clinical Lipidology, 2012, 6, 290-291.	0.6	0
906	Response to Zhou et al. â€œLetter to the Editor: The effects of various intensities of physical activity and chronic inflammation in men and women by diabetes status in a national sampleâ€• Diabetes Research and Clinical Practice, 2013, 99, e20.	1.1	0
907	ETC-1002 Lowers LDL-Cholesterol and Beneficially Modulates Other Cardio-Metabolic Risk Factors in Hypercholesterolemic Subjectsâ€. Journal of Clinical Lipidology, 2013, 7, 283.	0.6	0
908	Authors' Reply. American Journal of Cardiology, 2013, 111, 455-456.	0.7	0
909	Reply: The Association between Obstructive Sleep Apnea Severity and N-Terminal Proâ€“B-Type Natriuretic Peptide Levels in Women. American Journal of Respiratory and Critical Care Medicine, 2014, 189, 869-870.	2.5	0
910	Reply. Journal of the American College of Cardiology, 2014, 64, 2434-2435.	1.2	0
911	Decrease the Incentives to Order Lipid Panelsâ€”Reply. JAMA Internal Medicine, 2014, 174, 473.	2.6	0
912	ETC-1002 Reduces Blood Pressure in Hypercholesterolemic Patients with Mildly Elevated Blood Pressure. Journal of Clinical Lipidology, 2014, 8, 350.	0.6	0
913	High Sensitivity Troponin T (Hs-TnT) Predicts Outcomes in Patients Admitted with Acute Decompensated Heart. Journal of Cardiac Failure, 2014, 20, S110.	0.7	0
914	Association Between Low Density Lipoprotein Cholesterol or Low Density Lipoprotein Particle Concentration and Metabolic Syndrome and High Sensitivity C-Reactive Protein in Retired National Football League Players*. Journal of Clinical Lipidology, 2014, 8, 357-358.	0.6	0
915	Lipoprotein Associated Phospholipase A2 Mass is Not Associated with Subclinical Coronary and Carotid Atherosclerosis in the Retired National Football League Players*. Journal of Clinical Lipidology, 2014, 8, 345-346.	0.6	0
916	Association of Small Dense Low-Density Lipoprotein Cholesterol and Lipoprotein-Associated Phospholipase A2 with Carotid Plaque Characteristics in the Atherosclerosis Risk in Communities Study*. Journal of Clinical Lipidology, 2014, 8, 319-321.	0.6	0
917	The World and Lipidology as It Relates to Cardiology. Cardiology Clinics, 2015, 33, xiii-xiv.	0.9	0
918	Diagnosing Familial Hypercholesterolemia (FH) in the United States: Results from the CASCADE FH Patient Registry*â€. Journal of Clinical Lipidology, 2015, 9, 451-452.	0.6	0

#	Article	IF	Citations
919	The Promise of Proprotein Convertase Subtilisin/Kexin 9 Inhibitors for the Treatment of Familial Hypercholesterolemia. Current Atherosclerosis Reports, 2015, 17, 508.	2.0	0
920	Medical Management of Serum Lipids and Coronary Heart Disease. Cardiovascular Medicine, 2015, , 39-55.	0.0	0
921	P2-415: Association of Baseline Lipids with 20-Year Cognitive Change: The ARIC Neurocognitive Study. , 2016, 12, P804-P804.		0
922	Effects of Eicosapentaenoic Acid Plus Docosapentaenoic Acid and Eicosapentaenoic Acid Alone on Fasting and Postprandial Lipids. Journal of Clinical Lipidology, 2016, 10, 700.	0.6	0
923	Lipoprotein(a) and Heart Failure. JACC: Heart Failure, 2016, 4, 88-89.	1.9	0
924	Lipoprotein (a) levels and Risk of Cardiovascular Disease Events in Diabetes Mellitus and Prediabetes: The Atherosclerosis Risk in Communities Study. Journal of Clinical Lipidology, 2017, 11, 779-780.	0.6	0
925	DEVELOPMENT AND VALIDATION OF PREDICTION MODELS WITH NON-TRADITIONAL MARKERS FOR 10-YEAR RISK OF ISCHEMIC LEG AMPUTATION AMONG PERSONS WITH DIABETES: THE ATHEROSCLEROSIS RISK IN COMMUNITIES (ARIC) STUDY. Journal of the American College of Cardiology, 2017, 69, 2028.	1.2	0
926	Low Density Lipoprotein Triglyceride and Incident Cardiovascular: Insights from the Atherosclerosis Risk in Communities Study*. Journal of Clinical Lipidology, 2018, 12, 527-528.	0.6	0
927	Do Biomarkers Improve Short-term Risk Prediction of Global Cardiovascular Events in Older Adults? Insights from the Atherosclerosis Risk in Communities Study*. Journal of Clinical Lipidology, 2018, 12, 525-526.	0.6	0
928	INTENSITY OF LIPID LOWERING THERAPY AMONG PATIENTS WITH POLYVASCULAR DISEASE: INSIGHTS FROM THE GOULD REGISTRY. Journal of the American College of Cardiology, 2019, 73, 241.	1.2	0
929	SEX AND RACE DIFFERENCES IN CIRCULATING LEVELS OF NATRIURETIC PEPTIDE CONCENTRATIONS AND THE ASSOCIATION WITH INCIDENT HEART FAILURE IN THE COMMUNITY: THE ATHEROSCLEROSIS RISK IN COMMUNITIES STUDY. Journal of the American College of Cardiology, 2019, 73, 911.	1.2	0
930	LIPID-LOWERING THERAPY IN DIFFERENT REGIONS OF THE UNITED STATES: INSIGHTS FROM GETTING TO AN IMPROVED UNDERSTANDING OF LOW-DENSITY LIPOPROTEIN CHOLESTEROL AND DYSLIPIDEMIA MANAGEMENT (GOULD): A REGISTRY OF HIGH CARDIOVASCULAR RISK PATIENTS IN THE UNITED STATES. Journal of the American College of Cardiology, 2019, 73, 1834.	1.2	0
931	Seven Metrics That Will Determine Your Cardiovascular Success or Failure. JACC: Heart Failure, 2019, 7, 648-650.	1.9	0
932	Homozygous Familial Hypercholesterolemia in the United States: Data from the CASCADE-FH Registryâ€. Journal of Clinical Lipidology, 2019, 13, e39.	0.6	0
933	Genetic Testing for Hypertriglyceridemia - Pilot Data from a Single Center Lipid Clinic. Journal of Clinical Lipidology, 2019, 13, e17-e18.	0.6	0
934	Letter by Wu and Ballantyne Regarding Article, â€œProtein Kinase CÎ¸ via Activating Transcription Factor 2â€“Mediated CD36 Expression and Foam Cell Formation of Ly6C ^{hi} Cells Contributes to Atherosclerosisâ€• Circulation, 2019, 139, 2077-2078.	1.6	0
935	Future Directions in the Use of Biomarkers for Prevention of Cardiovascular Disease. , 2019, , 171-177.		0
936	Use of Lipid-Lowering Therapies in Patients with CKD and ASCVD: A 1-Year Update From GOULDâˆ—. Journal of Clinical Lipidology, 2020, 14, 603-604.	0.6	0

#	Article	IF	Citations
937	Physician Characteristics and Attitudes towards Lipid-Lowering Treatment and Variability in Implementation of Guidelines: Insights from the Getting to an ImprOved Understanding of Low-Density Lipoprotein-Cholesterol and Dyslipidemia Management (GOULD) Reg. Journal of Clinical Lipidology, 2020, 14, 607-608.	0.6	0
938	Genetic Testing for Hypertriglyceridemia--Experience From a Single Center Lipid Clinicâ^—. Journal of Clinical Lipidology, 2020, 14, 608-610.	0.6	0
939	Abstract 903: Circulating inflammatory proteins associated with mortality from causes other than the index cancer in older adult cancer survivors in the atherosclerosis risk in communities study. , 2021, , .		0
940	Unanswered questions about the use of statins. , 2003, , 228-240.		0
941	Gender-Dependent Up-Regulation of the VWF-Cleaving metalloprotease ADAMTS-13 in Mice with Obesity and Hypercholesterolemia.. Blood, 2004, 104, 3500-3500.	0.6	0
942	Intraluminal crawling of neutrophils to emigration sites: a molecularly distinct process from adhesion in the recruitment cascade. Journal of Cell Biology, 2006, 175, i13-i13.	2.3	0
943	Cardiac Rehabilitation: Statins and the Rationale for Implementation of Lipid-Lowering Therapy. , 2007, , 141-156.		0
944	The Î± x Î² 2 integrin CD11c is a potent costimulator of CD8 T cell responses. FASEB Journal, 2008, 22, 855.10.	0.2	0
945	Emerging Assays. , 2009, , 178-183.		0
946	Monocyte integrin CD11c/CD18 is a functional biomarker for risk of cardiovascular disease. FASEB Journal, 2009, 23, 593.7.	0.2	0
947	Monocyte CD11c/CD18 expression is upregulated postprandially and mediates firm arrest on VCAMâ€1. FASEB Journal, 2009, 23, 640.5.	0.2	0
948	Rust and Rupture: Atherosclerosis. , 2011, , 89-97.		0
949	Genetic Determinants of Plasma Von Willebrand Factor Antigen Levels: A Target Gene SNP and Haplotype Analysis of the ARIC Cohort. Blood, 2010, 116, 4310-4310.	0.6	0
950	Abstract P162: Has LDL Cholesterol (LDL-C) and Non-HDL Cholesterol (Non-HDL-C) Goal Attainment Improved 7 Years After Adult Treatment Panel III (ATP III) Guidelines Were Published?. Circulation: Cardiovascular Quality and Outcomes, 2011, 4, .	0.9	0
951	Abstract P43: Frequency and Predictors of Low-Density Lipoprotein Cholesterol Control and Appropriate Response to Elevated LDL-C Levels in Patients with Cardiovascular Disease. Circulation: Cardiovascular Quality and Outcomes, 2011, 4, .	0.9	0
952	Abstract P002: Evidence For Smoking Dependent Genetic Effects on C-reactive Protein Levels in a Multi-ethnic Cohort Setting: The Care Consortium.. Circulation, 2012, 125, .	1.6	0
953	Abstract 051: Trans-ethnic Metabochip Genotyping of Established Lipid Loci Identifies Low Frequency Susceptibility Variants and Additional Independent Signals in Known Loci. Circulation, 2012, 125, .	1.6	0
954	Abstract MP074: High-sensitivity C-reactive Protein and Family History in the Prediction of Risk for Coronary Heart Disease: The Atherosclerosis Risk in Communities Study. Circulation, 2012, 125, .	1.6	0

#	Article	IF	Citations
955	Abstract P009: The Association of Liver Enzymes with Subclinical Myocardial Damage. Circulation, 2012, 125, .	1.6	0
956	Abstract P220: The Effect of Diet-Induced Weight Loss on HDL Functionality in Individuals with Metabolic Syndrome: Investigating Alteration of the Initial Step in Reverse Cholesterol Transport as a Function of Plasma Lipoprotein Composition. Circulation, 2012, 125, .	1.6	0
957	Abstract 303: Pre-operative Angiotensin Converting Enzyme Inhibitor use and outcomes in patients undergoing Isolated Coronary Artery Bypass Grafting. Circulation: Cardiovascular Quality and Outcomes, 2012, 5, .	0.9	0
958	Abstract 304: The Outcomes of Pre-Procedural Angiotensin Converting Enzyme Inhibitor Therapy in patients undergoing Percutaneous Coronary Intervention. Circulation: Cardiovascular Quality and Outcomes, 2012, 5, .	0.9	0
959	Abstract 453: Ceruloplasmin and Cardiovascular Disease in the Atherosclerosis Risk in Communities (ARIC) Study. Arteriosclerosis, Thrombosis, and Vascular Biology, 2012, 32, .	1.1	0
960	Abstract 166: Small Dense LDL Cholesterol Is Associated with Risk for Coronary Heart Disease: The Atherosclerosis Risk in Communities (ARIC) Study. Arteriosclerosis, Thrombosis, and Vascular Biology, 2012, 32, .	1.1	0
961	Abstract 79: Troponin T, NT-proBNP, and Incidence of Stroke: The Atherosclerosis Risk in Communities (ARIC) Study. Stroke, 2013, 44, .	1.0	0
962	Abstract MP26: Highly Sensitive Cardiac Troponin T is Associated with Cognitive Function and Incidence of Dementia. Circulation, 2013, 127, .	1.6	0
963	Abstract MP27: Cardiovascular Biomarkers and MRI-defined Small Vessel Disease of the Brain in the Atherosclerosis Risk in Communities (ARIC) Study. Circulation, 2013, 127, .	1.6	0
964	Abstract MP11: Elevated High Sensitivity C-Reactive Protein as a Risk Marker of the Attenuated Relationship Between Serum Cholesterol and Coronary Heart Disease at Older Age - Atherosclerosis Risk in Communities Study. Circulation, 2013, 127, .	1.6	0
965	Abstract 18: The Effect of Lipid Modification on Peripheral Arterial Disease after Endovascular Intervention Trial (ELIMIT). Arteriosclerosis, Thrombosis, and Vascular Biology, 2013, 33, .	1.1	0
966	Integration of Biomarkers with Plaque Imaging. Contemporary Cardiology, 2014, , 203-214.	0.0	0
967	Abstract MP13: N-Terminal Pro-Brain Natriuretic Peptide (NT-proBNP) and Risk of Hypertension in the Atherosclerosis Risk in Communities (ARIC) Study. Circulation, 2014, 129, .	1.6	0
968	Abstract 16: Diabetes, Pre-diabetes, and Progression of Subclinical Myocardial Damage. Circulation, 2014, 129, .	1.6	0
969	Abstract P010: Cardiac Risk Factors and 6-Year Change in high-sensitivity Cardiac Troponin-T.. Circulation, 2014, 129, .	1.6	0
970	Abstract MP87: Circulating sRAGE Levels And The Risk Of Heart Failure. Circulation, 2014, 129, .	1.6	0
971	Abstract 25: Six-year Change in C-reactive Protein Levels and Risk of Incident Diabetes, Cardiovascular Events and Mortality. Circulation, 2014, 129, .	1.6	0
972	Pathophysiology of Atherosclerosis. Developments in Cardiovascular Medicine, 1998, , 3-58.	0.1	0

#	Article	IF	Citations
973	Dyslipidemia, Diabetes, and Cell Adhesion Molecules. Medical Science Symposia Series, 1998, , 191-198.	0.0	0
974	Abstract 15: Frequency and Predictors of Inappropriate Aspirin Prescribing for Primary Prevention of Cardiovascular Disease: Insights from the NCDRÂ® PINNACLE Registry.. Circulation: Cardiovascular Quality and Outcomes, 2014, 7, .	0.9	0
975	Abstract 19771: Persistent Thrombocytopenia after Myocardial Infarction is Associated with Increased Short- and Long-Term Mortality. Circulation, 2014, 130, .	1.6	0
976	Abstract 19852: The Relationship Between Obesity and Heart Failure is Stronger than Those for Other CVD Subtypes and Not Explained by Traditional Risk Factors. Circulation, 2014, 130, .	1.6	0
977	Abstract 12777: High Sensitivity Troponin T is Associated With Increased Heart Failure Risk in Metabolic Syndrome in the Atherosclerosis Risk in Communities (ARIC) Study. Circulation, 2014, 130, .	1.6	0
978	Abstract 16803: Icosapent Ethyl (Eicosapentaenoic Acid Ethyl Ester): Effects on Remnant-Like Particle Cholesterol From the MARINE and ANCHOR Studies. Circulation, 2014, 130, .	1.6	0
979	Abstract 12693: Influence of Resting Heart Rate and Changes in Resting Heart Rate on Cardiovascular Outcomes From the Atherosclerosis Risk in Communities Study. Circulation, 2014, 130, .	1.6	0
980	Abstract P244: Combined Measures of Total and Abdominal Adiposity and the Likelihood of Subclinical Myocardial Damage. Circulation, 2015, 131, .	1.6	0
981	Abstract MP47: The Association of Socioeconomic Status with Subclinical Myocardial Damage. Circulation, 2015, 131, .	1.6	0
982	Abstract 11: Compliance With Risk Factor Optimization and Medical Therapy in Patients With Peripheral Vascular Disease (Peripheral Artery and Ischemic Cerebrovascular Disease) Compared to Ischemic Heart Disease.. Circulation: Cardiovascular Quality and Outcomes, 2015, 8, .	0.9	0
983	Abstract 12446: Frequency and Practice Level Variation in Statin Use Among Patients With Diabetes: Insights From the NCDRÂ® PINNACLE Registry. Circulation, 2015, 132, .	1.6	0
984	Abstract 18914: Comparison of Statin Eligibility Using the Pooled Cohort Equations, ATP-III Framingham and Reynolds Risk Scores Among Adults Who Experienced ASCVD Events: The Atherosclerosis Risk in Communities Study. Circulation, 2015, 132, .	1.6	0
985	Abstract 253: The Association of Socioeconomic Status With Elevation of N-terminal Pro-b-type Natriuretic Peptide. Circulation: Cardiovascular Quality and Outcomes, 2016, 9, .	0.9	0
986	Abstract 14: Statin Use Before and After the 2013 American College of Cardiology/American Heart Association Cholesterol Management Guideline. Circulation: Cardiovascular Quality and Outcomes, 2016, 9, .	0.9	0
987	Abstract 664: Effects of Eicosapentaenoic Acid Plus Docosapentaenoic Acid and Eicosapentaenoic Acid Alone on Fasting and Postprandial Monocyte Phenotypes. Arteriosclerosis, Thrombosis, and Vascular Biology, 2016, 36, .	1.1	0
988	Abstract 623: Effect of High-intensity Statin Therapy on High-density Lipoprotein (HDL) Subfractions and Regression of Coronary Atheroma: The SATURN Trial. Arteriosclerosis, Thrombosis, and Vascular Biology, 2016, 36, .	1.1	0
989	Abstract P249: Hemostatic Factors and Long-Term Risk of Peripheral Arterial Disease: The Atherosclerosis Risk in Communities (ARIC) Study. Circulation, 2017, 135, .	1.6	0
990	Abstract P248: Glycemic Markers and Risk of Peripheral Artery Disease: The Atherosclerosis Risk in Communities (ARIC) Study. Circulation, 2017, 135, .	1.6	0

#	Article	IF	Citations
991	Abstract MP012: Plasma Galectin-3 Levels and Subsequent Risk of Incident Chronic Kidney Disease. Circulation, 2017, 135, .	1.6	0
992	Abstract P034: Comparison of the Prognostic Value of 1,5-anhydroglucitol (1,5-AG) and the Oral Glucose Tolerance Test (OGTT) in the Atherosclerosis Risk in Communities (ARIC) Study. Circulation, 2017, 135, .	1.6	0
993	Abstract 593: High-Monounsaturated Fat Mediterranean-Type Diet Reduces Foamy Monocyte Formation and Atherosclerosis in Ldlr-/- Mice on High-Cholesterol Diet. Arteriosclerosis, Thrombosis, and Vascular Biology, 2017, 37, .	1.1	0
994	Abstract 193: Remnant-Like Particle Cholesterol, Low-Density Lipoprotein Triglyceride and Incident Cardiovascular Disease in the Atherosclerosis Risk in Communities Study: Can Genetic Variants Provide New Insights on Triglycerides and Atherogenic Lipoproteins?. Arteriosclerosis, Thrombosis, and Vascular Biology, 2017, 37, .	1.1	0
995	Abstract P168: The Association of Longitudinal Changes in Metabolic Syndrome With Incident Heart Failure: The Atherosclerosis Risk in Communities (ARIC) Study. Circulation, 2018, 137, .	1.6	0
996	Abstract P048: Segment-Specific Pulse Wave Velocity and Subclinical Cardiac Overload and Damage in Older Adults: The Atherosclerosis Risk in Communities (ARIC) Study. Circulation, 2018, 137, .	1.6	0
997	Abstract MP17: Galectin-3 and Subsequent Risk of Lower-extremity Peripheral Artery Disease: The Atherosclerosis Risk in Communities (ARIC) Study. Circulation, 2018, 137, .	1.6	0
998	Abstract 598: Monounsaturated Fat Reduces Foamy Monocyte Formation and Atherosclerosis Development in Ldlr ^{-/-} Mice Compared to Western High Saturated Fat Diet. Arteriosclerosis, Thrombosis, and Vascular Biology, 2018, 38, .	1.1	0
999	Abstract 562: Foamy Monocytes in Hypertriglyceridemia. Arteriosclerosis, Thrombosis, and Vascular Biology, 2018, 38, .	1.1	0
1000	Abstract 17187: The Association of Longitudinal Patterns of Metabolic Syndrome With Elevated hs-cTnT: The Atherosclerosis Risk in Communities (ARIC) Study. Circulation, 2018, 138, .	1.6	0
1001	Abstract P413: Association Between High Sensitivity Troponin T and N-Terminal Pro B-Type Natriuretic Peptide and Fall Risk in Older Adult Participants of the Atherosclerosis Risk in Communities Study (ARIC). Circulation, 2019, 139, .	1.6	0
1002	Abstract P021: Cardiac Biomarkers, Electrolytes, and Anemia with Arrhythmias over Two Weeks in Chronic Kidney Disease: The Atherosclerosis Risk in Communities (ARIC) Study. Circulation, 2019, 139, .	1.6	0
1003	Abstract MP44: Association of High-Sensitivity Troponin With Peripheral Neuropathy in the Atherosclerosis Risk in Communities (ARIC) Study. Circulation, 2019, 139, .	1.6	0
1004	Abstract MP47: Diabetes, Prediabetes, and Short-Term Cardiovascular Risk and Death in Older Adults. Circulation, 2019, 139, .	1.6	0
1005	Abstract P036: Association Between Circulating Galectin-3 and Arterial Stiffness in the Atherosclerosis Risk in Communities Study. Circulation, 2019, 139, .	1.6	0
1006	Abstract P194: Proteomic Analysis of Cardiac Troponin I And T in Older Adults Without Cardiovascular Disease. Circulation, 2020, 141, .	1.6	0
1007	Abstract MP33: Association of Cardiac Troponin T and Troponin I With Peripheral Neuropathy in Older Adults: The Atherosclerosis Risk in Communities (ARIC) Study. Circulation, 2020, 141, .	1.6	0
1008	PRECISION MEDICINE FOR CARDIOVASCULAR DISEASE PREVENTION: WHERE DO WE STAND IN 2019 WITH A FOCUS ON INFLAMMATION AND LIPIDS?. Transactions of the American Clinical and Climatological Association, 2020, 131, 42-47.	0.9	0

#	Article	IF	Citations
1009	Abstract 15265: Trace or Mild Valvular Heart Disease With Cardiac Remodeling, Damage, and Overload in Older Adults: The Atherosclerosis Risk in Communities (ARIC) Study. Circulation, 2020, 142, .	1.6	0
1010	Use of lipid-lowering therapies in patients with CKD and ASCVD: A 1-year update from GOULD. Journal of Clinical Lipidology, 2021, 15, e1.	0.6	0
1011	An Open-label, Crossover Study Comparing EPA+DPA-Free Fatty Acids and EPA-Ethyl Esters in Adults with Elevated Triglycerides: ENHANCE-IT. Journal of Clinical Lipidology, 2022, 16, e14.	0.6	0
1012	Strategies for Optimizing Lipid Management. Postgraduate Medicine, 2010, 122, 13-20.	0.9	0
1013	Abstract 9794: Factors Associated with Enhanced Low-Density Lipoprotein Cholesterol Lowering with Bempedoic Acid Among Patients Enrolled in Phase 3 Studies. Circulation, 2021, 144, .	1.6	0
1014	Abstract 9797: Efficacy and Safety of Bempedoic Acid in Patients with Metabolic Syndrome. Circulation, 2021, 144, .	1.6	0
1015	Abstract 138: Deficiency of CD11a Reduces CD8+ T-Cell Activation and Proliferation in Adipose Tissue of Obese Mice. Arteriosclerosis, Thrombosis, and Vascular Biology, 2012, 32, .	1.1	0
1016	Abstract 155: Contribution of Foamy Monocytes to Nascent Atherosclerosis. Arteriosclerosis, Thrombosis, and Vascular Biology, 2013, 33, .	1.1	0
1017	Abstract 265: Plasma Lactate and Incident Hypertension in the Atherosclerosis Risk in Communities (ARIC) Study. Hypertension, 2013, 62, .	1.3	0
1018	Abstract 66: Small Dense LDL Cholesterol Predicts Incident Diabetes Mellitus: The Atherosclerosis Risk in Communities Study. Arteriosclerosis, Thrombosis, and Vascular Biology, 2014, 34, .	1.1	0
1019	Abstract 276: Postprandial Effects on Monocyte Phenotype in Obese Humans With Metabolic Syndrome. Arteriosclerosis, Thrombosis, and Vascular Biology, 2015, 35, .	1.1	0
1020	Abstract 148: Stat2 Deficiency Does Not Protect From Atherosclerosis in Ldlr Knockout Mice Fed a Western Diet. Arteriosclerosis, Thrombosis, and Vascular Biology, 2015, 35, .	1.1	0
1021	Abstract 311: Comparative Effectiveness of Outpatient Cardiovascular Disease Care Delivery Between Physician and Non-Physician Primary Care Providers: Implications for Care Under the Affordable Care Act. Circulation: Cardiovascular Quality and Outcomes, 2015, 8, .	0.9	0
1022	Abstract 19227: Weight History Influences the Likelihood of Subclinical Myocardial Injury. Circulation, 2015, 132, .	1.6	0
1023	Abstract 16992: Changes in Physical Activity and the Risk of Incident Heart Failure: The Atherosclerosis Risk in Communities (ARIC) Study. Circulation, 2015, 132, .	1.6	0
1024	Abstract P097: Shortness of Breath, Edema, and Fatigue and the Risk of Hospitalized Heart Failure (HF). The Atherosclerosis Risk in Communities (ARIC) Study. Circulation, 2016, 133, .	1.6	0
1025	Abstract MP018: Performance of 1,5-anhydroglucitol Compared to the Oral Glucose Tolerance Test and Fasting Glucose for Identification of Diabetes in the Community. Circulation, 2017, 135, .	1.6	0
1026	Abstract MP007: Higher Plasma Galectin-3 is Associated With Increased Incidence of Atrial Fibrillation: The Atherosclerosis Risk in Communities (ARIC) Study. Circulation, 2017, 135, .	1.6	0

#	Article	IF	Citations
1027	Abstract MP011: Cardiac Markers and Risk for Hospitalization with Infection: The Atherosclerosis Risk in Communities (ARIC) Study. Circulation, 2017, 135, .	1.6	0
1028	Plasma Lipids, Lipoproteins, and Apolipoproteins and Incident Ischemic Stroke:. Circulation, 2001, 103, 1363-1363.	1.6	0